|
Frontage Holdings Corporation is a global pharmaceutical development organization that provides integrated laboratory and clinical services for drug discovery and development. The company operates as a full-service contract research organization (CRO) and contract development and manufacturing organization (CDMO), offering a comprehensive portfolio of services including drug discovery, drug metabolism and pharmacokinetics (DMPK), safety and toxicology, bioanalytical testing, and chemistry, manufacturing, and controls (CMC). Frontage supports clients in advancing drug candidates from lead optimization through first-in-human studies and IND submissions, serving pharmaceutical, biotechnology, and agrochemical companies. Its CMC capabilities cover API synthesis, formulation, and clinical trial material manufacturing for new chemical entities, 505(b)(2), and ANDA products, including biologics and cell and gene therapies. The company serves markets in North America, Europe, and Asia Pacific, with sites in the United States, China, and other regions. Frontage Laboratories, Inc. is a principal subsidiary, and the group has acquired entities such as Nucro-Technics Inc. and Accelera S.r.l. to expand its bioanalytical and testing capabilities. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Diagnostics & Research | Homepage frontagelab.com |
| Sector Healthcare | IR page frontagelab.com/investor-relations | |
|
Tags
drug discovery, drug development, contract research organization, contract development and manufacturing organization, pharmacokinetics, toxicology, bioanalytical testing, chemistry manufacturing and controls, clinical trial services, agrochemical testing, biologics, cell and gene therapy, Frontage Laboratories Inc., Nucro-Technics Inc., Nucro-Technics Holdings, Accelera S.r.l.
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 4.21B |
| Market cap (USD) | $ 536.529M |
| P/E | 78.11 |
| PEG | — |
| P/BV | 1.50 |
| P/S | 1.93 |
| P/OCF | 10.56 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.03% |
| Returns | |
|---|---|
| ROE | 2.0% |
| ROI | 1.7% |
| ROIC | 1.7% |
| Profit margin | 2.6% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -35.9% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 26.8% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -43.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
At the request of Frontage Holdings Corporation (the “Company”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited will be halted with effect from 9:00 a.m. on October 22, 2026 pending the release of an announcement pursuant to the Code on Takeovers and Mergers which contains inside information of the Company. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, October 22, 2026
As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.
- For identification purpose only
News
/ Frontage Laboratories Is Pleased to Welcome Dr. Yuxiang (Richard) Huang, PhD, as Vice President, BGCT and Genomics Services

October 19, 2026
Frontage Laboratories Is Pleased to Welcome Dr. Yuxiang (Richard) Huang, PhD, as Vice President, BGCT and Genomics Services
EXTON, Pa., October 19, 2026 – Frontage Laboratories, Inc. (“Frontage”), a leading global CRO/CDMO, is pleased to welcome Dr. Yuxiang Huang, as Vice President, BGCT and Genomics Services. Dr. Huang brings more than 20 years of biotechnology, advanced therapeutics, genomics, and process development experience to the role. He has extensive expertise in cell and gene therapies, recombinant antibodies, CMC strategy, and GMP manufacturing readiness. In his previous roles, he has managed multi-million-dollar development budgets and supported more than 15 technology transfers alongside more than 10 IND/BLA programs.
Under a matrix reporting structure, Dr. Huang will report to Dr. Tony Liu, SVP and Head of US CDMO supporting BGCT services, while reporting to Dr. John Lin, Co-CEO, in supporting Genomics Services.
Prior to joining Frontage, Dr. Huang served as an independent CMC consultant, advising biotechnology organizations on manufacturing strategy, CDMO selection, technology transfer, and clinical supply planning. Previously, he was Executive Director and Head of Cell and Viral Vector Process Development at Minaris Advanced Therapies and held Senior Director and Executive Director roles at WuXi Advanced Therapies. In these positions, he directed large-scale, multidisciplinary teams of up to 38 scientists and engineers to scale up and transfer development processes into GMP manufacturing environments. His teams successfully transferred more than 15 programs across modalities including CAR-T, TIL, HSC, MSC, NK, lentiviral vectors, and AAV.
Earlier in his career, Dr. Huang led sequencing activities supporting TCR-T discovery at Gilead Sciences’ Kite Pharma, where he managed whole-genome, whole-exome, RNA, and single-cell sequencing workflows. During nearly nine years at Illumina, he held progressive scientific and team leadership roles supporting HiSeq X, NovaSeq, and iSeq technologies, contributing directly to sequencing platform innovation and manufacturing process improvements.
Dr. Huang is recognized for his scientific depth, collaborative leadership style, and ability to translate complex client needs into coordinated development plans. His unique combination of genomics innovation and advanced therapeutics development experience will further strengthen Frontage’s BGCT and Genomics Services capabilities and support the delivery of high-quality scientific services to clients.
Dr. Huang earned his PhD in Biochemistry from the University of Hong Kong. He also holds a Master of Science in Biochemistry and a Bachelor of Science in Microbiology from Sichuan University. He is an author of peer-reviewed scientific publications and a contributor to patented sequencing and flowcell technologies.
Frontage anticipates that Dr. Huang’s leadership and vision will greatly benefit its global clients.
About Frontage
Founded in 2001, Frontage Laboratories, Inc. is a global CRO/CDMO headquartered in Pennsylvania with numerous facilities across North America, Europe, and China. The company provides comprehensive, science-driven drug development solutions spanning discovery, safety, manufacturing, and clinical trials to support various regulatory submissions.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
URL
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
Notifications
FINANCIAL HIGHLIGHTS Six months ended June 30, 2026 2025 US$ million US$ million
Change
Revenue
148.2
126.6
17.1%
Gross Profit Gross Profit Margin
37.9 25.6%
35.3 27.9%
7.4%
EBITDA EBITDA Margin
31.7 21.4%
27.0 21.4%
17.4%
Adjusted EBITDA(1) Adjusted EBITDA Margin
34.5 23.3%
28.1 22.2%
22.8%
Net Profit Net Profit Margin
6.8 4.6%
2.9 2.3%
134.5%
Adjusted Net Profit(2) Adjusted Net Profit Margin
13.4 9.1%
7.7 6.1%
74.0%
US$
US$
– Basic – Diluted
0.0033 0.0033
0.0014 0.0014
135.7% 135.7%
Adjusted Earnings per share – Basic – Diluted
0.0066 0.0066
0.0038 0.0038
73.7% 73.7%
Earnings per share
The Board has resolved not to declare an interim dividend for the six months ended June 30, 2026.
1
(1)
Calculation of adjusted EBITDA is modified and calculated as EBITDA for the Reporting Period, excluding the share-based compensation expenses, gain or loss arising from financial assets measured as fair value through profit or loss, losses from restructuring and resource integration initiatives and expenses in relation to mergers and acquisitions to better reflect the Company’s current business and operations.
(2)
Calculation of adjusted net profit is modified and calculated as net profit for the Reporting Period, excluding the share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, gain or loss arising from financial assets measured as fair value through profit or loss, losses from restructuring and resource integration initiatives and expenses in relation to mergers and acquisitions to better reflect the Company’s current business and operations.
Non-IFRS Measures To supplement the Group’s consolidated financial statements which are presented in accordance with the IFRSs, the Company has provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic and diluted earnings per share (excluding the share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, gain or loss arising from financial assets measured as fair value through profit or loss, losses from restructuring and resource integration initiatives and expenses in relation to mergers and acquisitions to better reflect the Company’s current business and operations) as additional financial measures, which are not required by, or presented in accordance with, the IFRSs. The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, nonrecurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’ s business. However, the presentation of these non-IFRSs financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. The adjusted results should not be viewed on a stand-alone basis or as a substitute for results under IFRSs. The Board of the Company is pleased to announce the unaudited condensed consolidated interim results of the Group for the Reporting Period together with comparative figures for the corresponding period in 2025 as set out below:
2
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the six months ended June 30, 2026
NOTES
Revenue Cost of services
Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) 148,190 (110,295)
126,578 (91,267)
37,895 1,834 (2,103) (3,043)
35,311 1,360 662 (2,173)
7
1,112 13 (3,959) (18,912) 111 (3,488)
(763) (53) (4,283) (20,824) 85 (4,215)
8 9
9,460 (2,672)
5,107 (2,184)
6,788
2,923
Other comprehensive income Items that may be reclassified subsequently to profit or loss: Exchange differences arising from translation of foreign operations
913
3,131
Total comprehensive income for the period
7,701
6,054
3
Gross profit Other income Other gains and losses, net Research and development expenses Reversal of impairment/(impairment losses) recognized on – trade receivables – unbilled revenue Selling and marketing expenses Administrative expenses Share of profit of associates Finance costs Profit before tax Income tax expense Profit for the period
3
5 6
NOTES
Profit/(loss) for the period attributable to: Owners of the Company Non-controlling interests
Total comprehensive income for the period attributable to: Owners of the Company Non-controlling interests
Earnings per share – Basic (US$)
Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) 6,755 33
2,927 (4)
6,788
2,923
7,628 73
6,054 –
7,701
6,054
0.0033
0.0014
0.0033
0.0014
10
– Diluted (US$)
4
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION As at June 30, 2026 As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
119,137 39,622 196,584 29,857 9,817 11,484
123,331 45,253 187,658 23,205 7,184 10,598
5,528 813
4,813 816
412,842
402,858
8,984 85,054 33,236 2,263 2,836 704 34,555
2,979 72,206 20,125 2,845 3,017 695 36,299
167,632
138,166
25,540 37,732 48,065 787 210 6,748
18,596 27,795 47,497 887 210 8,511
119,082
103,496
Net Current Assets
48,550
34,670
Total Assets less Current Liabilities
461,392
437,528
NOTES
Non-current Assets Property, plant and equipment Right-of-use assets Goodwill Intangible assets Interests in associates Deferred tax assets Financial assets at fair value through profit or loss (“FVTPL”) Other long-term deposits
Current Assets Inventories Trade and other receivables and prepayment Unbilled revenue Structured deposits Tax recoverable Restricted bank deposits Cash and cash equivalents
12 13 14 14
Current Liabilities Trade and other payables Advances from customers Bank borrowings Income tax payable Amounts due to shareholders Lease liabilities
15 16 17
5
As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
47,924 2,010 17,082 38,150
28,181 1,936 15,939 43,426
105,166
89,482
356,226
348,046
20 (313) 355,186
20 (313) 347,079
Equity attributable to owners of the Company Non-controlling interests
354,893 1,333
346,786 1,260
Total Equity
356,226
348,046
NOTES
Non-current Liabilities Bank borrowings Deferred government grant Deferred tax liabilities Lease liabilities
17
Net Assets Capital and Reserves Share capital Treasury shares Reserves
18 19
6
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS For the six months ended June 30, 2026 1.
GENERAL INFORMATION Frontage Holdings Corporation (the “Company” or “Frontage”) was incorporated in the Cayman Islands as an exempted company with limited liability on April 16, 2018 under the Company Law of the Cayman Islands, and its shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since May 30, 2019. The immediate holding company of the Company is Hongkong Tigermed Co., Limited (“Hongkong Tigermed”), a company incorporated under the laws of Hong Kong with limited liability. The ultimate holding company of the Company is Hangzhou Tigermed Consulting Co., Ltd. ( “Hangzhou Tigermed”), a company established in Hangzhou, the PRC and whose shares have been listed on the ChiNext market of the Shenzhen Stock Exchange and the Main Board of The Stock Exchange. The Company is a holding company. The principal activities of the Company and its subsidiaries (collectively the “Group”) are to provide laboratory and related services to pharmaceutical and agrochemical companies as well as bioequivalence clinical and chemical services. The registered office of the Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111 Cayman Islands. The principal places of business in the United States of America (the “USA”) and Hong Kong are 700 Pennsylvania Drive, Exton, PA 19341, USA and Room 1920, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, respectively. The functional currency of the Company and the operating subsidiaries incorporated in the USA is US dollars (“US$”). The functional currency of the PRC operating subsidiaries is Renminbi (“RMB”). The functional currency of the operating subsidiary incorporated in Canada is Canadian dollars (“CAD”). The functional currency of the operating subsidiary incorporated in Europe is Euro (“EUR”). The reporting currency used for the presentation of the condensed consolidated financial statements is US$, which is the same as the functional currency of the Company.
BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES INFORMATION (a)
Basis of preparation of the financial statements The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” (“IAS 34”) issued by the International Accounting Standards Board as well as with the applicable disclosure requirements of Appendix D2 to the Rules Governing the Listing of Securities on The Stock Exchange. The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments which are measured at fair value. Other than additional accounting policies resulting from application of amendments to IFRS Accounting Standards ( “ IFRSs ” ), the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended June 30, 2026 are the same as those presented in the Group’s annual financial statements for the year ended December 31, 2025.
(b)
Application of amendments to IFRSs – effective for annual period beginning on or after January 1, 2026 In the current interim period, the Group has applied the following amendments to IFRSs issued by the International Accounting Standard Board, for the first time, which are mandatory effective for the annual period beginning on or after January 1, 2026 for the preparation of the Group’s condensed consolidated financial statements: Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7 Amendments to IFRS 9 and IFRS 7
Annual Improvements to IFRS Accounting Standards – Volume 11 Amendments to the Classification and Measurement of Financial Instruments Contracts Referencing Nature-dependent Electricity
Amendments to IFRS 9 and IFRS 7
7
The application of the amendments to IFRS in the current period has had no material impact on the Group’s financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements. 3.
REVENUE The Group’s revenue streams are categorized as follows: –
Drug Discovery Unit, consisting of medicinal chemistry, pharmacology, and efficacy & absorption, distribution, metabolism, and excretion (“ADME”) screening;
–
Drug Development Unit, comprising drug metabolism and pharmacokinetics (“DMPK”), Safety and Toxicology, early phase clinical services, as well as a suite of bioequivalence and related services such as pharmacology, medical writing and regulatory support;
–
Pharmaceutical Product Development Unit, encompassing intermediate and active pharmaceutical ingredient ( “ API ” ) synthesis, process and formulation development, and clinical trial material manufacturing;
–
Laboratory Testing Unit is to offer extensive laboratory testing support to clients worldwide involved in drug development. Their services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, chemistry, manufacturing and controls (“CMC”) Analytical Testing, and Central Laboratory services.
An analysis of the Group’s revenue is as follows: Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Drug discovery Drug development Pharmaceutical product development Laboratory testing
12,027 46,756 4,551 84,856
13,180 41,732 4,790 66,876
148,190
126,578
All revenue of the Group listed above are recognized over time as the Group’s performance does not create an asset with an alternative future use since the Group cannot redirect the asset for use on another customer, and the contract terms specify the Group has an enforceable right to payment for performance completed to date. 4.
SEGMENT INFORMATION Operating segments are determined based on the Group’s internal reports which are submitted to chief executive officer, being the chief operating decision maker (“CODM”) of the Group, for the purpose of performance assessment and resources allocation. This is also the basis upon which the Group is organized and managed. The Group’s consolidated revenue and results are primarily attributable to the markets in the USA, Canada and Europe (together as “North America and Europe”) and the PRC and all of the Group’s consolidated assets and liabilities are either located in North America and Europe or the PRC. No segment assets and liabilities are presented as they were not regularly provided to the CODM for the purpose of performance assessment and resources allocation.
8
The following are the Group’s reportable segments under IFRS 8 “Operating Segments”: –
North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe;
–
PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC.
Segment revenues and results The following is an analysis of the Group’s revenue by reportable segments from continuing operations.
For the six months ended June 30, 2026 (Unaudited) North America and Europe US$ ’000
PRC US$ ’000
Total US$ ’000
5,088 36,080 3,153 61,976
6,939 10,676 1,398 22,880
12,027 46,756 4,551 84,856
106,297
41,893
148,190
Cost of services Other income Other gains and losses, net Research and development expenses Reversal of impairment recognized on trade and other receivables and unbilled revenue Selling and marketing expenses Administrative expenses Share of profit of associates Finance costs
(77,325) 80 389 –
(32,970) 1,754 (2,492) (3,043)
(110,295) 1,834 (2,103) (3,043)
994 (2,812) (14,398) – (2,550)
131 (1,147) (4,514) 111 (938)
1,125 (3,959) (18,912) 111 (3,488)
Segment profit/(loss)
10,675
(1,215)
Revenue – Drug discovery – Drug development – Pharmaceutical product development – Laboratory testing
9,460
Profit before tax
9
For the six months ended June 30, 2025 (Unaudited)
Revenue – Drug discovery – Drug development – Pharmaceutical product development – Laboratory testing
Cost of services Other income Other gains and losses, net Research and development expenses Impairment losses recognized on trade and other receivables and unbilled revenue Selling and marketing expenses Administrative expenses Share of profit of associates Finance costs Segment profit/(loss)
North America and Europe US$ ’000
PRC US$ ’000
Total US$ ’000
6,760 33,139 2,949 55,737
6,420 8,593 1,841 11,139
13,180 41,732 4,790 66,876
98,585
27,993
126,578
(68,653) 424 568 –
(22,614) 936 94 (2,173)
(91,267) 1,360 662 (2,173)
(701) (3,105) (16,938) – (3,407)
(115) (1,178) (3,886) 85 (808)
(816) (4,283) (20,824) 85 (4,215)
6,773
(1,666)
Profit before tax
5,107
The material accounting policies of reportable segments are the same as the Group’s accounting policies. Geographical information The Group’s operations and non-current assets are located in North America and Europe and the PRC. An analysis of the Group’s revenue from external customers, analyzed by the customer’s respective country/ region of operation, is presented below: Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Revenue from external customers – USA and Canada – PRC – Rest of the world
10
101,592 35,627 10,971
99,649 21,485 5,444
148,190
126,578
Information about the Group’s non-current assets by geographical location of the assets are presented below:
Non-current assets excluding financial assets and deferred tax assets – North America and Europe – PRC
6/30/2026 US$ ’000 (Unaudited)
12/31/2025 US$ ’000 (Audited)
303,324 91,693
313,015 73,616
395,017
386,631
OTHER INCOME Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Interest income Government grants related to income Income from rendering technical support service
26 1,173 635
189 757 414
1,834
1,360
OTHER GAINS AND LOSSES, NET Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) (Losses)/gains on disposal of property, plant and equipment Gains on Lease termination Fair value change on financial assets measured at FVTPL Net foreign exchange gain Others
(3,576) 918 555 74 (74)
3 – – 693 (34)
(2,103)
662
FINANCE COSTS Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Interest expense on lease liabilities Interest expense on bank borrowings
11
1,286 2,202
1,588 2,627
3,488
4,215
PROFIT BEFORE TAX Profit before tax has been arrived at after charging: Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Staff costs (including directors’ emoluments): – Salaries and other benefits – Retirement benefit scheme contributions – Share-based payment expense
Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortization of intangible assets 9.
59,371 4,613 290
52,857 3,985 1,112
64,274
57,954
10,743 3,921 4,075
9,063 4,804 3,847
INCOME TAX EXPENSE Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Current tax: – PRC Enterprise Income Tax (“EIT”) – U.S. Federal Tax – U.S. State Tax – Canada Corporate Tax
287 2,360 645 371
303 2,814 795 417
3,663
4,329
Deferred tax: – Current period
(991)
(2,145)
Total income tax expense
2,672
2,184
The Company and U.S. subsidiaries are subject to U.S. Federal and State Income taxes, with the combined income tax rate being 26.27% for the six months ended June 30, 2026 (the six months ended June 30, 2025: 27.05%). BRI Biopharmaceutical Research, Inc. ( “ BRI ” ), a wholly owned subsidiary of the Group and as a non-Canadian-controlled private corporation (“CCPC”) and engaged in active business in British Columbia, Canada, has been subject a flat tax rate of 27%. Nucro-Technics, Inc. (“Nucro”), a wholly owned subsidiary of the Group, as a non-CCPC and engaged in active business in Ontario, Canada, has been subject an effective corporate tax rate of 26.5%. Under the law of the PRC on Enterprise Income Tax (the “EIT Law”) and Implementation Regulation of the EIT Law, the EIT rate of the PRC subsidiaries is 25% unless subject to tax exemption set out below. Frontage Laboratories (Shanghai) Co., Ltd. (“Frontage Shanghai”), a wholly owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in November 2023 and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2023 to the end of 2025 and in the process of renew the High and New Technology Enterprise status in 2026.
12
Acme Biopharma Co. (Shanghai) Ltd. (“Acme Shanghai”), a wholly owned subsidiary of the Group in the PRC, was accredited as an “Advanced Technology Enterprise” in December 2025, and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2025 to the end of 2027. Wuhan Heyan Biomedical Technology Co., Ltd. (“Heyan Biotech”), a 70% owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in October 2023 and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2023 to the end of 2025 and in the process of renew the High and New Technology Enterprise status in 2026. Suzhou Frontage New Drug Development Co., Ltd., a wholly owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in December 2023 and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2023 to the end of 2025 and in the process of renew the High and New Technology Enterprise status in 2026. Acme Biopharma (Wuhan) Co., Ltd., a wholly owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in December 2025 and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2025 to the end of 2027. Teddy Clinical Research Laboratory (Shanghai) Ltd., a wholly owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in December 2024 and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2024 to the end of 2026. Teddy Clinical Research Laboratory (Wuxi) Ltd., a wholly owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise ” in November 2025 and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2025 to the end of 2027. The group entities incorporated in Hong Kong are subject to Hong Kong profits tax at a rate of 16.5% on the estimated assessable profits for the six months ended June 30, 2026 and 2025. On March 21, 2018, the Hong Kong Legislative Council passed the Inland Revenue (Amendment) (No. 7) Bill 2017 (the “Bill”) which introduces the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazette on the following day. Under the two-tiered profits tax rates regime, the first HK$2,000,000 of profits of qualifying corporations will be taxed at 8.25%, and profits above HK$2,000,000 will be taxed at 16.5%. The two-tiered profits tax rates regime is applicable to the Group’s Hong Kong subsidiaries with estimated assessable profits for its annual reporting periods ending on or after April 1, 2018. The group entities incorporated in the Cayman Islands are not subject to income or capital gains tax under the law of the Cayman Islands. No provision for Italy income tax has been made as the Group did not generate any assessable profits in Italy during the six months ended June 30, 2026 and 2025.
13
EARNINGS PER SHARE The calculation of the basic and diluted earnings per share attribute to owners of the Company is based on the following data: Six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 (Unaudited) (Unaudited) Earnings: Earnings for the purpose of calculating basic and diluted earnings per share
6,755
2,927
Number of Shares: Six months ended 6/30/2026 6/30/2025 (Unaudited) (Unaudited) Weighted average number of ordinary shares for the purpose of calculating basic earnings per share Effect of dilutive potential ordinary shares: Share options Share awards Weighted average number of ordinary shares for the purpose of calculating diluted earnings per share
2,029,748,194
2,026,369,855
3,387,312 –
101,510 1,361,117
2,033,135,506
2,027,832,482
Note: (i) 11.
The weighted average number of ordinary shares shown above has been adjusted for treasury shares as set out in Note 19.
DIVIDENDS No dividends were paid, declared or proposed during the current interim period. The directors of the Company have determined that no dividend will be paid in respect of the current interim period (six months ended June 30, 2025: nil).
14
TRADE AND OTHER RECEIVABLES AND PREPAYMENTS As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
71,992 4,395 (4,551)
65,882 2,053 (5,402)
71,836
62,533
2,291 1 (50)
1,996 – (37)
2,242
1,959
Notes receivables – third parties
566
102
Prepayments – third parties – related parties
8,545 48
6,018 287
8,593
6,305
1,817
1,307
85,054
72,206
Trade receivables – third parties – related parties Less: loss allowance for trade receivables
Other receivables – third parties – related parties Less: loss allowance for other receivables
Value-added tax recoverable
The Group allows a credit period ranging from 30 to 90 days to its customers. The following is an age analysis of trade receivables (net of loss allowance), presented based on the invoice dates, at the end of the reporting period:
Within 90 days 91 to 180 days 181 days to 1 year Over 1 year
15
As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
62,804 3,052 2,690 3,290
53,727 3,436 2,975 2,395
71,836
62,533
UNBILLED REVENUE
Unbilled revenue – third parties – related parties Less: loss allowance for unbilled revenue
As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
29,707 4,606 (1,077)
17,286 3,662 (823)
33,236
20,125
Generally, significant payment terms are disclosed within the contents of a given contract and are in the form of either milestone payment terms representing a percentage of the total budgeted contract price or corresponding directly with the value to the customer of the Group’s performance. Revenues recognized in excess of billings are recognized as contract assets and disclosed in the condensed consolidated statement of financial position as unbilled revenue. 14.
RESTRICTED BANK DEPOSITS/CASH AND CASH EQUIVALENTS At the end of each reporting period, cash and cash equivalents of the Group comprised of bank balances and cash held. The bank deposits carry interest at market rates which ranged from 0.02% to 2.8% per annum as at June 30, 2026 (December 31, 2025: from 0.02% to 3.5% per annum). According to the lease agreement for the property at Secaucus, NJ, a cash deposit of US$300,000 was required as a guarantee over the property. As at June 30, 2026, the cash deposits of US$399,000 (December 31, 2025: US$392,000) were required by Pennsylvania department of environmental protection, Bureau of radiation protection and the state of Ohio Bureau of radiation protection in the USA for radiology license in the USA, and the amount were restricted. As at June 30, 2026, the remaining amount in the collateral account were US$399,000 (December 31 2025: US$392,000), which had been included in restricted bank deposits. As at June 30, 2026, certain bank deposits with balances of approximately RMB40,000 (equivalent to approximately US$6,000) (December 31, 2025: RMB24,000 (equivalent to approximately US$3,000)) were pledged to secure bank facilities granted to the Group.
16
TRADE AND OTHER PAYABLES As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
13,214 927
8,389 971
14,141
9,360
Notes payables – third parties
467
838
Other payables – third parties
2,909
1,997
Salary and bonus payables Other taxes payable
6,615 1,408
5,813 588
25,540
18,596
Trade payables – third parties – related parties
Payment terms with suppliers are mainly on credit ranging from 30 to 90 days from the invoice date. The following is an age analysis of trade payables, presented based on invoice date, at the end of each reporting period:
Within 90 days 91 days to 1 year
As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
13,031 1,110
9,360 –
14,141
9,360
As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
36,001 1,731
26,371 1,424
37,732
27,795
ADVANCES FROM CUSTOMERS
Advances from customers – third parties – related parties
Amounts received in accordance with contracted payment schedules but in excess of revenues earned are recognized as contract liabilities and disclosed in the condensed consolidated statement of financial position as advances from customers. Changes in advances from customers primarily relate to the Group’s performance of services under the related contracts.
17
BANK BORROWINGS Bank Loans As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
95,989
75,678
6/30/2026 US$ ’000 (Unaudited)
12/31/2025 US$ ’000 (Audited)
Within one year More than one year, but not exceeding two years More than two years, but not exceeding five years More than five years
48,065 8,705 8,239 30,980
47,497 19,522 8,659 –
Less: Amount shown under current liabilities
95,989 (48,065)
75,678 (47,497)
Amount shown under non-current liabilities
47,924
28,181
2.30%-5.82%
2.65%-6.09%
Secured and unguaranteed bank loans
Loan interest of rate per annum in the range of 18.
SHARE CAPITAL Number of shares
Amount US$
Ordinary shares of US$0.00001 each Authorized: As at January 1, 2025, December 31, 2025, January 1, 2026 and June 30, 2026
5,000,000,000
50,000
Number of shares
Amount US$
Show in the financial statements as US$ ’000
Issued and fully paid: As at January 1, 2025 (Unaudited), December 31, 2025 (Audited) and January 1, 2026 (Unaudited) Exercise of share options
2,035,724,910 6,350,000
20,359 64
20 –
As at June 30, 2026 (Unaudited)
2,042,074,910
20,423
20
18
TREASURY SHARES As at June 30, 2026 Number of Cost of shares acquisition US$ ’000 (Unaudited) (Unaudited)
As at December 31, 2025 Number of Cost of shares acquisition US$ ’000 (Audited) (Audited)
Balance brought forward Vesting of share awards
7,996,438 –
313 –
12,084,002 (4,087,564)
313 –
Balance carried forward
7,996,438
313
7,996,438
313
Note: The Company acquired its own shares in the open market which are held as treasury shares. 20.
CAPITAL COMMITMENTS The Group has capital commitments under non-cancellable contracts as follows:
Purchase of property, plant and equipment Acquisition of subsidiaries
19
As at 6/30/2026 US$ ’000 (Unaudited)
As at 12/31/2025 US$ ’000 (Audited)
634 –
429 38,413
634
38,842
MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS REVIEW Overview Frontage is a globally integrated, science-driven CRO delivering high-quality research and development services to the pharmaceutical, biotechnology, chemical, and life sciences industries. With a commitment to scientific excellence and customer-centric solutions, Frontage offers comprehensive services from drug discovery to clinical trials. Our services are designed to help biopharmaceutical companies accelerate their product development and achieve their goals with efficiency and precision. Additionally, we support academic institutions and start-up companies in discovering and developing new therapeutics for human health. In March 2026, the Group completed the acquisition of Teddy Lab, a leading central laboratory in China, further strengthening its laboratory capabilities across pathology, flow cytometry, and molecular biology, while expanding its service experience in next-generation modalities such as cell and gene therapy, vaccines, and radiopharmaceuticals. With the addition of Teddy Lab, Frontage now operates 25 sites worldwide. Headquartered in Exton, Pennsylvania, Frontage operates across key global markets, including North America (U.S. and Canada), China, and Europe (Italy), positioning the Group to capitalize on growth opportunities globally. The Group is committed to expanding its expertise and capabilities to become a leading global CRO offering exceptional service to clients and fulfilling career opportunities for its employees. The Group’s diverse client base includes small, mid-sized, and large biopharmaceutical companies, biotechnology companies, CROs, agricultural and industrial chemical companies, life science companies, contract manufacturing companies, and diagnostic and other commercial entities, as well as hospitals, academic institutions, and government agencies. The Group’s customer base is geographically diverse with well-established relationships in North America, China, Europe, India, Japan, South Korea, and Australia. The Group also continued to invest in Artificial Intelligence ( “ AI ” )-assisted workflows and laboratory automation across its global platform, implementing AI-assisted report generation for in vitro ADME studies and deploying advanced laboratory automation infrastructure to improve efficiency, consistency, and turnaround time. Overall, the Group’s revenue increased by 17.1% from approximately US$126.6 million for the six months ended June 30, 2025 to approximately US$148.2 million for the six months ended June 30, 2026. The Group’s contract future revenue, which represents future service revenues from work not yet completed or performed under all signed contracts or customer’s purchase orders in effect at that time, achieved approximately US$543.2 million as at June 30, 2026, representing an increase of 34.2% compared to approximately US$404.7 million as at June 30, 2025.
20
ENHANCED CAPABILITIES AND EXPERTISE North America and Europe During the first half of 2026, Frontage’s two core business divisions, Global Drug Discovery & Development Services and Global Laboratory Services, continued to advance their technical capabilities and service capacity across North America and Europe. Advancements in AI-assisted workflows, laboratory automation, expanded manufacturing platforms, and new analytical technologies enhanced operational efficiency and strengthened the Group ’ s readiness for an increasingly AI-enabled future. •
Global Drug Discovery & Development Services During the Reporting Period, the Global Drug Discovery & Development Services division continued to expand and innovate across the full research and development spectrum from preclinical to clinical development. The Safety and Toxicology group enhanced its biomarker and bioanalysis capabilities with the addition of the Meso Scale Discovery (“MSD”) platform, broadening the scope of integrated safety assessment services. The CMC-Product Development & Manufacturing team added technical capabilities to support aseptic filling of IV bags for infusion, roller compaction for processing poor-flow and water-sensitive active pharmaceutical ingredients, and bilayer tablet manufacturing. These advancements expand the formulation and manufacturing options available to clients and reinforce the Group’s commitment to addressing increasingly complex development requirements. The Global Drug Discovery & Development Services continued its digital transformation through the implementation of AI-assisted workflows, enhancing operational efficiency, consistency, quality, and turnaround times while upholding rigorous scientific standards. During the Reporting Period, we expanded the sterile manufacturing platform, increasing sterile bulk solution compounding capabilities to 400 liters per batch and expanding the sterile vial filling operation to accommodate batch sizes of up to 10,000 vials, increasing fill-finish throughput for larger clinical studies and multi-site patient supply requirements. We further strengthened laboratory capabilities by adding advanced analytical technologies and upgrading laboratory infrastructure. These upgrades increased analytical capacity and throughput, expanded scientific capabilities, and improved the Group’s ability to support a broad range of regulated and discovery programs with high-quality analytical services.
•
Global Laboratory Services During the Reporting Period, the Global Laboratory Services division continued to enhance its technical capabilities and service capacity across bioanalysis, biomarker services, biologics, central lab, and genomics. The Bioanalytical Services team expanded its support for complex therapeutic modalities and regulatory bioanalytical programs, successfully supporting a wide range of studies including pharmacokinetic, toxicokinetic, bioequivalence, drug-drug interaction, and biomarker programs across small molecules, peptides, oligonucleotides, antibody-drug conjugate (ADC)-related analytes, and targeted protein degrader compounds. 21
A strategic initiative during the Reporting Period was the launch of CLIA-based Laboratory Developed Test (LDT) capability development, broadening Frontage’ s service offerings beyond traditional PK/TK bioanalysis into clinical biomarker testing and precision medicine applications. By integrating LC-MS/MS technologies with CLIA laboratory operations, the Group is positioned to provide comprehensive solutions spanning drug development and clinical biomarker testing. The Biomarker Services team launched the NULISA proteomics platform, including ultra-sensitive discovery assays such as the CNS 120-panel and Inflammation 250-panel, achieving certified service provider status. The team also expanded its cytokine testing portfolio to support full-spectrum testing from discovery through clinical application with multiplex and ultra-sensitive assays, and established a comprehensive biomarker organizational model integrating soluble, IVD, LC-MS, tissue, and genomic biomarker offerings. The Biologics team completed a major laboratory automation expansion, including the buildout of Hamilton infrastructure with multiple Hamilton STAR systems and STARlet deployment. Automated workflows for ADC, PK, and ADA sample preparation, quality control, normalization, and buffer additions were implemented, with dedicated laboratory automation leadership established to drive operational efficiency improvements. The Central Laboratory team expanded with the opening of a new kitting and biobanking laboratory at 75 East Uwchlan Avenue in Exton, Pennsylvania, enhancing specimen management and storage operations. The team expanded its global partner network, launched a client portal providing real-time sample information access, and formalized rapid protocol-amendment workflows. In Europe, the Central Laboratory expanded its activities with the implementation of a PBMC processing laboratory and the addition of ultralow freezer sample storage capabilities. In addition to the service expansions and enhancements, the first half of 2026 demonstrated continued strong performance in quality and regulatory compliance across operations in North America and Europe. The Exton facility successfully completed a Pennsylvania Department of Environmental Protection radiation inspection with no observations and achieved AAALAC reaccreditation. China During the first half of 2026, the Group’s operations in China continued to advance across multiple service lines while actively pursuing strategic acquisitions and capability expansions. The Group completed the acquisition of Teddy Lab, a leading central laboratory in China, further enlarging Frontage’s market presence in Asia and strengthening laboratory capabilities across analytical platforms including pathology, flow cytometry, and molecular biology, while enabling the accumulation of extensive laboratory service experience in next-generation modalities such as cell and gene therapy, vaccines, and radiopharmaceuticals.
22
•
Global Drug Discovery & Development Services During the Reporting Period, new services were developed at the Preclinical Services facility in Suzhou, China, including tests for developmental and reproductive toxicity (DART), juvenile toxicology, genotoxicity (comet assay), and tissue cross-reactivity. The Preclinical Services team supported multiple projects with cynomolgus monkey animal models for in vivo CAR-T studies, with these capabilities meeting the needs of global pharmaceutical clients. The Chemistry team further advanced two key technology platforms, High-Throughput Experimentation (HTE) and Continuous Flow, with hundreds of challenging reactions optimized during the period. The Group offers robust continuous-flow process development, scale-up, heat and mass transfer optimization, and safe handling of hazardous reactions including nitration, diazotization, hydrogenation, and oxidation, with standardized workflows from process design to technology transfer delivering safer, more efficient, and greener solutions. During the Reporting Period, Global Drug Discovery & Development Services implemented a range of operational and laboratory enhancements to improve efficiency, optimize facility utilization, and strengthen scientific capabilities. These initiatives increased operational capacity, enhanced laboratory productivity, and expanded bioanalytical capabilities, where facility and laboratory enhancements increased animal housing capacity by approximately 11% and bioanalytical capacity by approximately 30%. The pharmaceutical intermediate R&D and technical service operations achieved ISO 9001:2015 certification, demonstrating the Group ’ s commitment to maintaining a robust quality management system aligned with international standards. During the Reporting Period, the Group also obtained several recognized certifications, including National High-Tech Enterprise, China Advanced Service Enterprise, and Technology-Based SME certifications.
•
Global Laboratory Services During the Reporting Period, the Global Laboratory Services in China was strengthened through the completion of the Teddy Lab acquisition. The integration of Teddy Lab ’ s established client relationships, experienced scientific team, and diversified testing platforms complements Frontage ’s existing bioanalytical and biomarker service offerings in China, creating a more comprehensive laboratory services platform capable of supporting the full spectrum of clinical development programs. During the Reporting Period, the Global Laboratory Services in China continued to build on the integrated bioanalytical platform established in 2025, which combines small molecule and large molecule analysis within a unified workflow. The platform was further refined to support an expanding range of therapeutic modalities, with optimized workflows deployed for emerging drug formats, accelerating timelines for pharmacokinetic, immunogenicity, and biomarker studies and enabling more efficient cross-modality project execution. The real-time quality control dashboard introduced in 2025 to track assay performance metrics and turnaround times was further enhanced during the Reporting Period with expanded data visualization. The dashboard has been integrated into routine laboratory operations, supporting proactive identification of performance deviations, and continuous process improvement.
23
These continued advancements in platform integration, quality systems, and biomarker technologies position the Global Laboratory Services division in China to deliver increasingly comprehensive and efficient analytical solutions to pharmaceutical and biotechnology clients across domestic and international markets. THE GROUP’S FACILITIES As of June 30, 2026, the Group had 13 facilities in North America and Europe, consisting of: •
four (4) facilities in Exton, PA, USA;
•
two (2) facilities in Hayward, CA, USA;
•
one (1) facility in Secaucus, NJ, USA;
•
one (1) facility in Concord, OH, USA;
•
one (1) facility in Deerfield, FL, USA;
•
one (1) facility in Chicago, IL, USA;
•
one (1) facility in Vancouver, Canada;
•
one (1) facility in Toronto, Canada; and
•
one (1) facility in Milan, Italy.
In addition, as of June 30, 2026, the Group had 12 facilities in China, consisting of: •
four (4) facilities in Shanghai;
•
three (3) facilities in Suzhou, Jiangsu Province;
•
one (1) facility in Wuxi, Jiangsu Province;
•
one (1) facility in Hangzhou, Zhejiang Province;
•
one (1) facility in Zhengzhou, Henan Province; and
•
two (2) facilities in Wuhan, Hubei Province.
24
FINANCIAL REVIEW Revenue The revenue of the Group increased by 17.1% from approximately US$126.6 million for the six months ended June 30, 2025 to approximately US$148.2 million for the six months ended June 30, 2026. Revenue from operations in North America and Europe increased by 7.8% from approximately US$98.6 million for the six months ended June 30, 2025 to approximately US$106.3 million for the six months ended June 30, 2026. Excluding the impact of currency translation, the revenue from operations in China increased by 43.6% from approximately RMB200.9 million (equivalent to approximately US$28.0 million) for the six months ended June 30, 2025 to approximately RMB288.4 million (equivalent to approximately US$41.9 million) for the six months ended June 30, 2026. The increase in revenue from operations in North America and Europe was mainly attributable to the strong demand for laboratory testing services and improvement of capacity utilization and marketing efforts made by the Group. The growth of revenue from operations in China was mainly attributable to the acquisition of Teddy Lab and improvement of capacity utilization and marketing efforts made by the Group. The following table sets forth a breakdown of our revenue by type of service during the Reporting Period: For the six months ended 6/30/2026 6/30/2025 US$ ’000 US$ ’000 Drug discovery Drug development Pharmaceutical product development Laboratory testing
12,027 46,756 4,551 84,856
13,180 41,732 4,790 66,876
148,190
126,578
An analysis of the Group’s revenue from external customers, analyzed by the customer ’s respective country/region of operation, is presented below:
Revenue
For the six months ended June 30, 2026 2025 US$ ’000 % US$ ’000
– USA and Canada – China – Rest of the world(Note)
101,592 35,627 10,971
68.6 24.0 7.4
99,649 21,485 5,444
78.7 17.0 4.3
Total
148,190
100.0
126,578
100.0
Note: Rest of the world primarily includes Europe, India, Japan, South Korea and Australia.
25
%
Top 5 customers’ revenue increased by 32.4% from approximately US$18.8 million for the six months ended June 30, 2025 to approximately US$24.9 million for the six months ended June 30, 2026, accounting for 16.8% of total revenue for the six months ended June 30, 2026 as compared to 14.8% for the six months ended June 30, 2025. Top 10 customers’ revenue increased by 22.9% from approximately US$27.5 million for the six months ended June 30, 2025 to approximately US$33.8 million for the six months ended June 30, 2026, accounting for 22.8% of total revenue for the six months ended June 30, 2026, as compared to 21.7% for the six months ended June 30, 2025. Cost of Services The cost of services of the Group increased by 20.8% from approximately US$91.3 million for the six months ended June 30, 2025 to approximately US$110.3 million for the six months ended June 30, 2026. The increase in the cost of services was in line with the increased revenue, plus the impact of the acquisition of Teddy Lab. The cost of services of the Group consists of direct labor costs, cost of raw materials and overhead. Direct labor costs primarily consist of salaries, bonuses and social security costs for the employees in the Group’s business units. Cost of raw materials primarily consists of costs incurred for the purchase of raw materials used in rendering of our services. Overheads primarily consist of depreciation charges of the facilities and equipment used in rendering the Group’s services, utilities and maintenance. Gross Profit and Gross Profit Margin The gross profit of the Group increased by 7.4% from approximately US$35.3 million for the six months ended June 30, 2025 to approximately US$37.9 million for the six months ended June 30, 2026. The Group’s gross profit margin decreased from approximately 27.9% for the six months ended June 30, 2025 to approximately 25.6% for the six months ended June 30, 2026. In particular, gross profit margin in North America and Europe decreased from approximately 30.4% for the six months ended June 30, 2025 to approximately 27.3% for the six months ended June 30, 2026, which was primarily due to a shift in revenue mix toward lower-margin programs and higher input costs, partially offset by operational efficiency improvements. Gross profit margin in China increased from approximately 19.2% for the six months ended June 30, 2025, to approximately 21.3% for the six months ended June 30, 2026, which was mainly contributed by the acquisition of Teddy Lab which has a higher gross profit. Other Gains and Losses, Net The Group’s net other gains and losses changed from approximately US$0.7 million of gains for the six months ended June 30, 2025 to approximately US$2.1 million of losses for the six months ended June 30, 2026, primarily due to the losses from restructuring and resource integration initiatives, the Group closed a facility in China as part of its efforts to improve operational efficiency.
26
Selling and Marketing Expenses Selling and marketing expenses of the Group decreased by 7.0% from approximately US$4.3 million for the six months ended June 30, 2025 to approximately US$4.0 million for the six months ended June 30, 2026, as a result of cost driven by the improvement in efficiency. Administrative Expenses The Group’s administrative expenses decreased by 9.1% from approximately US$20.8 million for the six months ended June 30, 2025 to approximately US$18.9 million for the six months ended June 30, 2026. Excluding share-based compensation expense and amortization of intangible assets acquired from mergers and acquisitions and expenses in relation to mergers and acquisitions, the Group’s administrative expenses decreased by 10.0% from approximately US$16.0 million for the six months ended June 30, 2025 to approximately US$14.4 million for the six months ended June 30, 2026, primarily due to the decrease of labor cost and improvement of efficiency. Research and Development Expenses Our research and development activities mainly focused on (i) developing technologies and methodologies to continue to enhance our services; and (ii) improving the quality and efficiency of our services. The Group’s research and development expenses increased by 36.4% from approximately US$2.2 million for the six months ended June 30, 2025 to approximately US$3.0 million for the six months ended June 30, 2026, primarily due to the acquisition of Teddy Lab. Finance Costs The Group’s finance costs decreased by 16.7% from approximately US$4.2 million for the six months ended June 30, 2025 to approximately US$3.5 million for the six months ended June 30, 2026, primarily due to the repayment of bank borrowings with higher interest rate in North America. Income Tax Expense The income tax expense of the Group increased from approximately US$2.2 million for the six months ended June 30, 2025 to approximately US$2.7 million for the six months ended June 30, 2026, primarily due to an increase in pretax income. Net Profit and Net Profit Margin The Group’s net profit increased from approximately US$2.9 million for the six months ended June 30, 2025 to approximately US$6.8 million for the six months ended June 30, 2026. The Group’s net profit margin of increased from approximately 2.3% for the six months ended June 30, 2025 to approximately 4.6% for the six months ended June 30, 2026. The higher net profit and net profit margin compared to the six months ended June 30, 2025 was mainly attributable to the operational efficiency improvements.
27
Adjusted Net Profit The following table presents a reconciliation of adjusted net profit to the net profit for the periods, the most directly comparable IFRS measure, for each of the periods indicated: For the six months ended June 30, 2026 2025 US$ ’000 US$ ’000 Net Profit
6,788
2,923
290
1,112
3,858
3,703
(555) 2,691 364
– – –
Adjusted Net Profit
13,436
7,738
Adjusted Net Profit Margin
9.1%
6.1%
Add: Share-based compensation expense Amortization of acquired intangible assets from mergers and acquisitions Gain arising from financial assets measured as fair value through profit or loss Losses from restructuring and resource integration initiatives Expenses in relation to mergers and acquisitions
The adjusted net profit of the Group increased by 74.0% from approximately US$7.7 million for the six months ended June 30, 2025 to approximately US$13.4 million for the six months ended June 30, 2026. The adjusted net profit margin of the Group for the six months ended June 30, 2026 was 9.1%, compared to 6.1% for the six months ended June 30, 2025. The higher adjusted net profit and adjusted net profit margin of the Group for the six months ended June 30, 2026 was primarily due to a higher net profit and net profit margin as discussed above. EBITDA The EBITDA1 of the Group increased by 17.4% from approximately US$27.0 million for the six months ended June 30, 2025 to approximately US$31.7 million for the six months ended June 30, 2026. The EBITDA margin of the Group for the six months ended June 30, 2026 was 21.4%, compared to 21.4% for the six months ended June 30, 2025. The increase of EBITDA is in line with the net profit which had been discussed above.
1
EBITDA represents net profit before (i) interest expenses; (ii) income tax expenses; and (iii) amortization and depreciation.
28
Adjusted EBITDA The adjusted EBITDA2 of the Group increased by 22.8% from approximately US$28.1 million for the six months ended June 30, 2025 to approximately US$34.5 million for the six months ended June 30, 2026. The adjusted EBITDA margin of the Group increased from 22.2% for the six months ended June 30, 2025 to 23.3% for the six months ended June 30, 2026. The increase of adjusted EBITDA is in line with the EBITDA which had been discussed above. Basic and Diluted Earnings Per Share The basic earnings per share for the six months ended June 30, 2026 amounted to US$0.0033, representing an increase of 135.7% as compared with that of US$0.0014 for the six months ended June 30, 2025. The Group recorded diluted earnings per share of US$0.0033 for the six months ended June 30, 2026, as compared to diluted earnings per share of US$0.0014 for the six months ended June 30, 2025. The adjusted basic earnings per share for the six months ended June 30, 2026 amounted to US$0.0066, representing an increase of 73.7% as compared with that of US$0.0038 for the six months ended June 30, 2025. The adjusted diluted earnings per share of the Group for the six months ended June 30, 2026 amounted to US$0.0066 when compared with that of US$0.0038 for the six months ended June 30, 2025. The increase in both the adjusted basic and the adjusted diluted earnings per share was primarily due to the increase in the adjusted net profit as discussed in the above. Non-IFRS Measures To supplement the Group’s consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, and adjusted basic and diluted earnings per share (excluding the share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, gain or loss arising from financial assets measured as fair value through profit or loss, losses from restructuring and resource integration initiatives and expenses in relation to mergers and acquisitions) as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. The adjusted results should not be viewed on a stand-alone basis or as a substitute for results under IFRS.
2
Calculation of adjusted EBITDA is modified and calculated as EBITDA for the Reporting Period, excluding the share-based compensation expenses, gain or loss arising from financial assets measured as fair value through profit or loss, losses from restructuring and resource integration initiatives and expenses in relation to mergers and acquisitions to better reflect the Company’s current business and operations.
29
Right-of-Use Assets The Group recorded approximately US$39.6 million right-of-use assets as at June 30, 2026, which decreased by 12.6% from approximately US$45.3 million as at December 31, 2025. The decrease was mainly due to the depreciation charges of existing leases. Intangible Assets The Group recorded approximately US$29.9 million intangible assets as at June 30, 2026, which increased by 28.9% from approximately US$23.2 million as at December 31, 2025. The increase was mainly due to the acquisition of Teddy Lab. Trade and Other Receivables and Prepayment The trade and other receivables and prepayment of the Group increased by 17.9% from approximately US$72.2 million as at December 31, 2025 to approximately US$85.1 million as at June 30, 2026. The increase was mainly due to the Group’s business development and the acquisition of Teddy Lab. Unbilled Revenue The Group’s unbilled revenue increased by 65.2% from approximately US$20.1 million as at December 31, 2025 to approximately US$33.2 million as at June 30, 2026. The increase was mainly due to the Group’s business development and the acquisition of Teddy Lab. Trade and Other Payables The trade and other payables of the Group increased by 37.1% from approximately US$18.6 million as at December 31, 2025 to approximately US$25.5 million as at June 30, 2026, primarily due to the Group’s business development and the acquisition of Teddy Lab. Advances from Customers The advances from customers of the Group increased by 35.6% from approximately US$27.8 million as at December 31, 2025 to approximately US$37.7 million as at June 30, 2026. The increase was mainly due to the Group’s business development and the acquisition of Teddy Lab. Liquidity and Capital Resources The Group’s bank balances and cash amounted to approximately US$34.6 million in total as at June 30, 2026, as compared to approximately US$36.3 million as at December 31, 2025, as a result of payments for purchase of property, plant and equipment and repayment of bank borrowings and the acquisition of Teddy Lab, plus cash inflow from operating activities. The cash and cash equivalents held by the Company are composed of RMB, HK$, CAD, EUR and US$. Currently, the Group follows a set of funding and treasury policies to manage its capital resources and prevent risks involved.
30
The following table sets forth a condensed summary of the Group’s consolidated statements of cash flows for the periods indicated and analysis of balances of cash and cash equivalents for the periods indicated: For the six months ended June 30, 2026 2025 US$ ’000 US$ ’000 Net cash generated from operating activities Net cash used in investing activities Net cash generated from/(used in) financing activities
25,660 (39,972) 11,766
18,764 (3,551) (25,200)
Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the period Effect of exchange rate changes
(2,546) 36,299 802
(9,987) 44,091 (442)
Cash and cash equivalents at the end of the period
34,555
33,662
Capital Expenditures Our principal capital expenditures relate primarily to purchases of property, plant and equipment, and intangible assets relation to the expansion and enhancement of our facilities and purchases of equipment and intangible assets used in providing our services. Approximately US$6.2 million of capital expenditures were incurred for the six months ended June 30, 2026, which was increased by 67.6% when compared to approximately US$3.7 million for the six months ended June 30, 2025, primarily due to the increased expenditures for enhancement of facilities. Indebtedness Borrowings The Group had total bank borrowings of US$96.0 million as at June 30, 2026 compared to US$75.7 million as at December 31, 2025. On June 30, 2026, the effective interest rate of the Group’s bank borrowings ranged from 2.30% to 5.82%. US$ borrowings amounted to US$34.4 million and RMB borrowings amounted to RMB419.8 million (equivalent to US$61.6 million). Lease Liabilities The Group leased some of our equipment and facilities under lease agreements with lease terms of three to twenty-five years and right-of-use assets agreements. The Group recorded approximately US$44.9 million lease liabilities as at June 30, 2026, compared to approximately US$51.9 million as at December 31, 2025 due to the payments for existing leases. Contingent Liabilities and Guarantees As at June 30, 2026, the Group did not have any material contingent liabilities or guarantees.
31
Currency Risk The functional currency of the Company and the operating subsidiaries incorporated in the USA is US$. The functional currency of the PRC operating subsidiaries is RMB. The functional currency of the operating subsidiary incorporated in Canada is CAD. The functional currency of the operating subsidiary incorporated in Europe is EUR. Particularly, the PRC operating subsidiaries have foreign currency sales and purchases, which expose the Group to foreign currency risk. The PRC operating subsidiaries are mainly exposed to foreign currencies of US$ and Euro. The Group does not use any derivative contracts to hedge against its exposure to currency risk. The Group seeks to limit its exposure to foreign currency risk by closely monitoring and minimizing its net foreign currency position. Gearing Ratio The gearing ratio is calculated using interest-bearing borrowings less cash and cash equivalents and structured deposits divided by total equity and multiplied by 100%. The gearing ratios were 29.2% and 25.4% as at June 30, 2026 and December 31, 2025, respectively. The increase is primarily due to the addition of bank borrowings for the acquisition of Teddy Lab. Employees and Remuneration Policies As at June 30, 2026, the Group had a total of 1,800 employees, of whom 829 were located in North America and Europe and 971 were located in China; 1,505 were scientific and technical support staff and 295 were sales, general and administrative staff. Approximately 83% of employees hold a bachelor’s degree or above, and we have 608 employees that hold an advanced degree (a master ’s level degree or higher such as Ph.D, M.D. or other doctorate level degrees). The staff costs, including Directors’ emoluments but excluding any contributions to retirement benefit scheme contributions and share-based compensation expenses, were approximately US$64.3 million for the six months ended June 30, 2026, as compared to approximately US$52.9 million for the six months ended June 30, 2025. The remuneration packages of employees generally include salary and bonus elements. In general, the Group determines the remuneration packages based on the qualifications, position and performance of its employees. The Group also makes contributions to pension schemes, social insurance funds, including basic pension insurance, medical insurance, unemployment insurance, childbirth insurance, work-related injury insurance funds, and housing reserve fund as applicable to the countries where the Group operates. As at the date of this announcement, the Group has adopted the Pre-IPO Share Incentive Plans, the 2018 Share Incentive Plan and the 2021 Share Award Scheme to provide incentives or rewards to eligible participants for their contribution or potential contribution to the Group. In addition, the Group has training systems, including orientation and on-the-job training for all staff, to accelerate the learning progress and improve the knowledge and skill levels of its workforce. The Group also has a training program for senior management that focuses on management skills, conflict resolution and effective communication skills and sessions on how to recruit and retain talent. The orientation process covers corporate culture and policies, work ethics, introduction to the drugs development process, quality management and occupational safety. The periodic on-the-job training covers certain technical aspects of the Group’s services, environmental, health and safety management systems and mandatory training required by applicable laws and regulations. 32
EVENTS AFTER THE REPORTING PERIOD The Board is not aware of any significant events affecting the Group, which have occurred subsequent to June 30, 2026 and up to the date of this announcement. PROSPECTS The global CRO services market is estimated at approximately US$99.87 billion in 2026 and is projected to reach US$199.28 billion by 2034, growing at a CAGR of 9.0%.3 As the industry evolves, clients increasingly seek comprehensive CROs which can navigate complex regulatory pathways across multiple jurisdictions, deliver specialized laboratory and bioanalytical services, support advanced therapeutic modalities, and manage manufacturing processes with precision and quality. Frontage is well-positioned to meet this demand through its comprehensive, integrated “one-stop-shop” solutions across North America, Europe, and China, supported by decades of experience in biopharmaceutical development. The Group is focused on expanding its capabilities in high-growth service areas and advancing its integrated drug development platform. Across the broader organization, the Group is accelerating its adoption of AI and automation technologies to improve operational efficiency, data quality, and turnaround times. Frontage will continue to pursue growth through ongoing capability development, strategic acquisitions, expanded collaborations with industrial groups, scientific organizations, and the strengthening of global partnerships. MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES In October 2025, Frontage Shanghai, a wholly-owned subsidiary of the Company, entered into a Share Transfer Agreement with Hangzhou Tigermed and Jiaxing Xinge to acquire 45,169,326 shares representing 100% of the entire issued share capital of Teddy Lab at the total consideration of RMB270 million upon completion of a repurchase and capital reduction by the Teddy Lab (the “Acquisition”). The Acquisition constitutes (i) a major transaction under Chapter 14 of the Listing Rules as the highest applicable percentage ratio exceeds 25% but is less than 100%; and (ii) a connected transaction under Chapter 14A of the Listing Rules as Hangzhou Tigermed is the controlling shareholder of the Company and the highest applicable percentage ratio exceeds 5%, and was subject to the reporting, disclosure and shareholder approval requirements under the Listing Rules. For details, please refer to the announcement of the Company dated October 10, 2025 and the circular of the Company dated December 15, 2025.
3
33
The Acquisition was completed on March 3, 2026. Immediately following the completion of Acquisition, Teddy Lab has become a wholly-owned subsidiary of Frontage Shanghai. INTERIM DIVIDEND The Board has resolved not to declare an interim dividend for the six months ended June 30, 2026 (six months ended June 30, 2025: Nil). PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company’s listed securities (whether on the Stock Exchange or otherwise) during the six months ended June 30, 2026 (including sale of treasury shares (as defined under the Listing Rules)). As at June 30, 2026, the Company did not hold any treasury shares (as defined under the Listing Rules). MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS The Company has adopted the Model Code as its code of conduct regarding securities transactions by the Directors. Having made specific enquiries with all the Directors, all the Directors confirmed that they had complied with the required standard of dealings as set out in the Model Code during the six months ended June 30, 2026. CORPORATE GOVERNANCE CODE During the six months ended June 30, 2026, the Company has followed the principles and complied with the code provisions set out in the CG Code. REVIEW OF INTERIM RESULTS BY THE AUDIT AND RISK MANAGEMENT COMMITTEE The Audit and Risk Management Committee has reviewed together with the Company ’ s management, the accounting principles and policies, internal controls, risk management and financial reporting adopted by the Group, the unaudited condensed consolidated financial statements, interim results announcement and interim report of the Group for the Reporting Period. The Audit and Risk Management Committee is satisfied that the unaudited condensed consolidated financial statements, interim results announcement and interim report of the Group for the Reporting Period were prepared in accordance with the applicable accounting standards and fairly present the Group’s financial position and results for the Reporting Period and that adequate disclosures had been made in accordance with the requirements of the Listing Rules. PUBLICATION OF THE 2026 INTERIM RESULTS ANNOUNCEMENT AND 2026 INTERIM REPORT This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.frontagelab.com). The interim report of the Company for the Reporting Period containing all the information required under the Listing Rules will be published on the aforesaid websites of the Stock Exchange and the Company and will be dispatched to the Shareholders upon request of the Shareholders.
34
DEFINITIONS “2008 Share Incentive Plan”
the pre-IPO share incentive plan approved by Frontage Labs in 2008 and assumed by the Company on April 17, 2018
“2015 Share Incentive Plan”
the pre-IPO share incentive plan approved by Frontage Labs in 2015 and assumed by the Company on April 17, 2018
“2017 Tax Act” or “Transition Tax”
The Tax Cuts and Jobs Act was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes reduce tax rates and modify policies, credits and deductions for businesses. The 2017 Tax Act also transitions the U.S. international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which could result in subjecting certain earnings of Frontage Shanghai to U.S. taxation. These changes are effective beginning in 2018. The 2017 Tax Act also includes a tax on the mandatory deemed repatriation of accumulated previously untaxed foreign earnings of Frontage Shanghai (the “Transition Tax”)
“2018 Share Incentive Plan”
the post-IPO share incentive plan adopted by the Company on May 11, 2019
“2021 Share Award Scheme”
the “ 2021 Share Award Scheme ” constituted by the rules adopted on January 22, 2021, in its present form or as amended from time to time in accordance with the provisions therein
“AAALAC”
Association for Assessment and Accreditation of Laboratory Animal Care
“Audit and Risk Management Committee”
the audit and risk management committee of the Board
“Award Participants”
the selected participants who were awarded the Awarded Shares under the 2021 Share Award Scheme
“Awarded Shares”
the 22,950,500 Shares granted by the Company to the Award Participants pursuant to the terms of the 2021 Share Award Scheme
“Board of Directors” or “Board”
the board of directors of the Company from time to time
“CAD”
Canadian Dollars, the lawful currency of Canada
35
“CG Code”
the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
“CLIA”
Clinical Laboratory Improvement Amendments
“CMC”
stands for Chemistry, Manufacturing and Controls. The Group ’ s portfolio of CMC services spans from drug discovery to the post-approval phase, including lead compound quantification and analytical testing for the discovery phase, formulation development, Good Laboratory Practice toxicology batch studies, release and product testing, stability testing, Clinical Trial Materials and Good Manufacturing Practice manufacturing, extractability and leachability studies and commercial product release following approval of an application
“CODM”
the chief operating decision maker of the Group
“Company”
Frontage Holdings Corporation (方達控股公司), a company incorporated under the laws of the Cayman Islands with limited liability on April 16, 2018
“Connected Award Participants”
the Award Participants who are connected with the Company or connected persons of the Company
“Controlling Shareholder(s)”
has the meaning given to it under the Listing Rules and unless the context requires otherwise, refers to Hangzhou Tigermed and Hongkong Tigermed
“CRO”
Contract research organization
“Director(s)”
the director(s) of the Company from time to time
“DMPK”
Drug Metabolism and Pharmacokinetics, refers to studies designed to determine the absorption and distribution of an administered drug, the rate at which a drug takes effect, the duration a drug maintains its effects and what happens to the drug after being metabolized by the body
“EIT”
PRC Enterprise Income Tax
“EIT Law”
Enterprise Income Tax Law of the PRC
“Frontage Labs”
Frontage Laboratories, Inc., a company incorporated under the laws of Pennsylvania, United States on April 21, 2004 and the wholly-owned subsidiary of the Company
36
“Frontage Shanghai”
Frontage Laboratories (Shanghai) Co., Ltd. (方達醫藥技 術(上海)有限公司), a company established in the PRC on August 2, 2005 and a subsidiary of the Company
“Frontage Suzhou”
Frontage Laboratories (Suzhou) Co, Ltd., a company established in the PRC on January 7, 2014, and a subsidiary of the Company
“Group”, “We”, “Our” or “Us”
the Company and its subsidiaries
“Hangzhou Tigermed”
Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格醫藥 科技股份有限公司), a company established in the PRC on December 15, 2004 with its shares being listed on ChiNext market of the Shenzhen Stock Exchange with stock code 300347 and on the Main Board of the Hong Kong Stock Exchange with stock code 3347, which is one of the controlling shareholders of the Company
“HK$” or “HKD”
Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”
the Hong Kong Special Administrative Region of the PRC
“Hongkong Tigermed”
Hongkong Tigermed Co., Limited (香港泰格醫藥科技有 限公司), a company incorporated under the laws of Hong Kong with limited liability on September 14, 2011 and which is a wholly-owned subsidiary of Hangzhou Tigermed and one of the controlling shareholders of the Company
“IFRSs”
International Financial Reporting Standards
“IPO”
initial public offering
“IVD”
In Vitro Diagnostics
“Jiaxing Xinge”
Jiaxing Xinge Medical Consulting Co., Ltd. (嘉興欣格醫 藥科技有限公司), a company established in the PRC with limited liability and a wholly owned subsidiary of Hangzhou Tigermed
“LC-MS/MS”
Liquid Chromatography–Tandem Mass Spectrometry
“Listing”
the listing of the Shares on the Main Board of the Stock Exchange
“Listing Date”
May 30, 2019, being on the date the Shares were listed on the Main Board
“Listing Rules”
the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
37
“Model Code”
the Model Code for Securities Transactions by Directors of Listed Issues contained in Appendix C3 to the Listing Rules
“Non-connected Award Participants” the Award Participants who are not connected with the Company or connected persons of the Company “NULISA”
Nucleic acid Linked Immuno-Sandwich Assay
“PBMC”
Peripheral Blood Mononuclear Cell
“PRC” or “China”
the People ’ s Republic of China, but for the purposes of this announcement only, except where the context requires, references to the PRC or China exclude Hong Kong, Macau and Taiwan
“Pre-IPO Share Incentive Plans”
the 2008 Share Incentive Plan and the 2015 Share Incentive Plan
“Prospectus”
the prospectus of the Company dated May 17, 2019
“Reporting Period”
the six months ended June 30, 2026
“RMB”
Renminbi, the lawful currency of the PRC
“Share(s)”
ordinary shares(s) with nominal value USD0.00001 each in the issued share capital of the Company
“Shareholder(s)”
holder(s) of Shares
“STAR”
Sequential Transfer and Aliquoting Robot
“Stock Exchange” or “Hong Kong Stock Exchange”
The Stock Exchange of Hong Kong Limited
“Teddy Lab”
Teddy Clinical Research Laboratory (Shanghai) Ltd. (上 海觀合醫藥科技股份有限公司), a joint stock company established in the PRC with limited liability
“US$” or “USD”
United States Dollars, the lawful currency of the U.S.
“USA”, the “United States” or the “U.S.”
the United States of America
%
per cent
38
In this announcement, the terms “associate ”, “connected person ”, “controlling shareholder ” and “subsidiary ” shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, August 28, 2026
As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive Directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive Directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors.
- For identification purpose only
39
News
/ Frontage China Becomes First Certified Service Provider in Asia Pacific & Greater China for Alamar Biosciences, Strengthening Global Biomarker Detection Capabilities

July 21, 2026
Frontage China Becomes First Certified Service Provider in Asia Pacific & Greater China for Alamar Biosciences, Strengthening Global Biomarker Detection Capabilities
EXTON, Pa., July 21, 2026 –
Frontage China has officially been granted the Certified Service Provider (CSP) designation by Alamar Biosciences, becoming the first laboratory in the Asia-Pacific region and Greater China to receive this official accreditation. The certification integrates Frontage into Alamar Biosciences’ global network of authorized service providers. Leveraging the ARGO™ HT System and the NULISA™ ultra-sensitive protein detection platform, Frontage will deliver high-quality, high-sensitivity protein biomarker testing services in strict accordance with Alamar’s official standards, further enhancing its bioanalytical and translational medicine capabilities.
The Alamar Biosciences Certified Service Provider (CSP) program is an official accreditation framework that recognizes laboratories possessing the technical expertise, quality systems, and operational capacity to perform NULISA™ platform testing to Alamar’s specifications. Previously, the official CSP network was primarily concentrated in Europe and the Americas. Frontage China’s attainment of CSP status not only fills a critical gap in the Asia-Pacific and Greater China regions but also provides regional biopharmaceutical innovators with more accessible, efficient, and internationally compliant testing solutions for drug development.
With this achievement, both Frontage US and Frontage China now hold Alamar Biosciences CSP credentials. Operating under Frontage’s “One World, One System” global unified quality framework, clients can access official-certified testing services that adhere to consistent standards across both China and the U.S., tailored to project requirements. This enables the generation of high-quality, comparable data to support global multi-center clinical trials and cross-regional drug development programs, while ensuring seamless project execution and data consistency across regions.
Earning the Alamar Biosciences CSP designation marks a significant milestone in Frontage’s ongoing commitment to expanding its global bioanalytical capabilities and underscores its international competitiveness in high-sensitivity protein biomarker detection. As a core pillar of Frontage’s business, the bioanalytical platform has evolved over 25 years into a globally integrated network spanning the U.S., China, and Europe, offering comprehensive analytical solutions for small molecules, large molecules, biomarkers, and cell and gene therapy (CGT) products, all while meeting stringent international regulatory requirements.
Powered by cutting-edge technology platforms, extensive project experience, and a
globally harmonized quality management system, Frontage has become a trusted, long-term partner for numerous innovative drug developers and top 30 multinational pharmaceutical companies worldwide. Looking ahead, Frontage will continue to introduce advanced international technologies, broaden the frontiers of its bioanalytical capabilities, and elevate its global service offerings to provide clients with more comprehensive, efficient, and internationally aligned integrated R&D support.
“Alamar Biosciences welcomes Frontage China to our global Certified Service Provider network,” said a spokesperson from Alamar. “With Frontage’s robust quality systems, expert technical teams, and extensive bioanalytical track record, this certification will significantly improve access to NULISA™ platform testing services for clients in the Asia-Pacific region, delivering more efficient and reliable technical support for global innovative drug development.”
About Frontage
Frontage Laboratories, Inc. is a US-based global Contract Research, Development, and Manufacturing Organization (CRO/CDMO) offering fully integrated, science-driven solutions across the drug development journey. Founded in 2001 and headquartered in Pennsylvania, with 28 facilities across the U.S., Canada, Europe and China, Frontage provides seamless end-to-end capabilities – from drug discovery, API synthesis, DMPK, and safety & toxicology to formulation development and manufacturing, CMC analytical, clinical trials, bioanalytical and central lab services. With deep scientific expertise and strong operational execution, Frontage supports innovative, generic, and consumer health companies of all sizes in achieving IND, NDA, ANDA, BLA, and 505(b)(2) submissions – helping turn bold ideas into real-world therapies.
SOURCE Frontage Laboratories, Inc.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
Notifications
News
/ Frontage Laboratories Is Pleased to Welcome Dr. Peter Boldingh, PharmD., as Senior Vice President, Clinical Services

July 20, 2026
Frontage Laboratories Is Pleased to Welcome Dr. Peter Boldingh, PharmD., as Senior Vice President, Clinical Services
EXTON, Pa., July 20, 2026 – Frontage Laboratories, Inc. (“Frontage”), a leading global CRO/CDMO, is pleased to welcome Dr. Peter Boldingh (“Pete”), as Senior Vice President, Clinical Services, bringing more than 25 years of clinical research, clinical operations, and healthcare leadership experience. He has extensive expertise in early-phase clinical development, having led the successful execution of hundreds of Phase I clinical studies supporting pharmaceutical, biotechnology, and generic drug development programs. Pete reports directly to Dr. Abdul Mutlib, Chief Strategy and Scientific Officer.
Prior to joining Frontage, Pete served as Vice President of Clinical Operations at Axis Clinicals, where he was responsible for the strategic leadership and operational oversight of early-phase clinical research activities. His responsibilities included study feasibility, protocol review and development, volunteer recruitment and screening, study conduct, pharmacy operations, sponsor engagement, quality management, and regulatory compliance. He also played a key role in expanding organizational capabilities, including the implementation of specialized clinical research technologies and services.
Earlier in his career, Pete held progressive leadership roles in clinical operations, pharmacy services, and clinical research. He has served as a Principal Investigator and Sub-Investigator on approximately 800 clinical studies spanning Phase I through Phase IV research and has extensive experience supporting sponsors through complex clinical development programs.
Pete is recognized for his operational excellence, collaborative leadership style, and ability to build high-performing teams that deliver quality, compliance, and executional efficiency. His deep understanding of early clinical development, combined with his pharmacy and clinical research expertise, will further strengthen Frontage’s clinical services capabilities and support the company’s continued global growth strategy.
Pete received his Doctor of Pharmacy (PharmD) degree and Bachelor of Science in Pharmaceutical Sciences from North Dakota State University. His extensive experience spanning clinical research, pharmacy leadership, and early-phase clinical operations provides a strong foundation for advancing Frontage’s commitment to delivering high-quality, innovative drug development solutions to clients worldwide.
Frontage is proud to welcome Dr. Peter Boldingh and looks forward to the scientific leadership and strategic vision he will contribute to our global client base.
About Frontage
Frontage Laboratories, Inc. is a US-based global Contract Research, Development, and Manufacturing Organization (CRO/CDMO) offering fully integrated, science-driven solutions across the drug development journey. Founded in 2001 and headquartered in Pennsylvania, with 28 facilities across the U.S., Canada, Europe and China, Frontage provides seamless end-to-end capabilities – from drug discovery, API synthesis, DMPK, and safety & toxicology to formulation development and manufacturing, CMC analytical, clinical trials, bioanalytical and central lab services. With deep scientific expertise and strong operational execution, Frontage supports innovative, generic, and consumer health companies of all sizes in achieving IND, NDA, ANDA, BLA, and 505(b)(2) submissions – helping turn bold ideas into real-world therapies.
SOURCE Frontage Laboratories, Inc.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
X/Twitter
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
News
/ Frontage Laboratories Is Pleased to Welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services

June 29, 2026
Frontage Laboratories Is Pleased to Welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services
EXTON, Pa., June 29, 2026 – Frontage Laboratories, Inc. (“Frontage”), a leading global CRO/CDMO, is pleased to welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services. Dr. Prakash is internationally recognized for his scientific leadership in drug metabolism and pharmacokinetics (DMPK), clinical pharmacology, biotransformation, bioanalysis, and translational ADME sciences. Over his 40‑year career, he has made significant contributions to the mechanistic understanding of drug disposition, metabolic pathways, and exposure–response relationships that underpin modern drug development.
In this advisory role, Dr. Prakash will support the advancement of Frontage’s Clinical Services organization by providing strategic guidance on:
- Clinical pharmacology study design (SAD/MAD, Food Effect, rBA, DDI) and quantitative decision‑making
- Human ADME and mass‑balance programs, including metabolite profiling and characterization
- PBPK modeling and simulation strategies to inform dose selection and predict clinical outcomes
- Drug–drug interaction risk assessment, including transporter and enzyme‑mediated pathways
- Regulatory submissions, with emphasis on IND, NDA, and MAA clinical pharmacology packages
Dr. Prakash previously held several academic appointments at Vanderbilt and University of Maryland and senior scientific leadership roles at Agios Pharmaceuticals, Biogen, and Pfizer. His work has supported numerous successful regulatory (IND and NDA) submissions and the approval of multiple marketed therapies across oncology, neurology, rare diseases, and metabolic disorders.
With nearly 300 peer‑reviewed publications, presentations, book chapters, and patents, and service as Editor‑in‑Chief of Current Drug Metabolism and Drug Metabolism Letters, Dr. Prakash has played a central role in shaping contemporary DMPK and clinical pharmacology practice.
“Dr. Prakash is a true luminary in DMPK and clinical pharmacology with an exceptional track record of scientific leadership and regulatory impact,” said Dr. Abdul Mutlib, PhD, Chief Strategy and Scientific Officer. “His deep expertise and industry insights will be invaluable as we continue to expand our clinical services and deliver best-in-class support to our biopharmaceutical partners worldwide.”
Frontage is honored to welcome Dr. Prakash and looks forward to the scientific depth and strategic insight he will bring to our global client base.
About Frontage
Frontage Laboratories, Inc. is a US-based global Contract Research, Development, and Manufacturing Organization (CRO/CDMO) offering fully integrated, science-driven solutions across the drug development journey. Founded in 2001 and headquartered in Pennsylvania, with 28 facilities across the U.S., Canada, Europe and China, Frontage provides seamless end-to-end capabilities – from drug discovery, API synthesis, DMPK, and safety & toxicology to formulation development and manufacturing, CMC analytical, clinical trials, bioanalytical and central lab services. With deep scientific expertise and strong operational execution, Frontage supports innovative, generic, and consumer health companies of all sizes in achieving IND, NDA, ANDA, BLA, and 505(b)(2) submissions – helping turn bold ideas into real-world therapies.
SOURCE Frontage Laboratories, Inc.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
Name
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
POLL RESULTS OF THE AGM The Board is pleased to announce that all the resolutions proposed at the AGM held on June 2, 2026 were duly passed by way of poll. POLL RESULTS OF THE AGM The board (the “Board”) of directors (the “Directors”) of Frontage Holdings Corporation (the “Company ”) is pleased to announce the voting results of the annual general meeting of the Company (the “AGM”) held on Tuesday, June 2, 2026. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the circular of the Company dated April 28, 2026 (the “Circular”). All the resolutions proposed at the AGM were taken by poll. The Company ’s branch share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. As at the date of the AGM, the total number of issued Shares was 2,038,024,910 Shares (including 3,536,000 Shares which have been repurchased and were yet to be cancelled), and holders of 2,034,488,910 Shares were entitled to attend and vote for or against all the resolutions proposed at the AGM. The Company does not have any treasury shares (as defined under the Listing Rules). There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules and no Shareholders were required to abstain from voting at the AGM under the Listing Rules. No Shareholders had indicated in the Circular that they intended to vote against or to abstain from voting on any resolutions at the AGM.
1
The poll results in respect of the respective resolutions proposed at the AGM are as follows: Number of Votes (%)
Ordinary Resolutions
For
Against
To receive and adopt the audited consolidated financial statements of the Company and the reports of the Directors and auditor of the Company for the year ended December 31, 2025.
513,597,038 (100.00%)
0 (0.00%)
2(a).
To re-elect Dr. Song Li as an Executive Director.
513,581,038 (99.99%)
16,000 (0.01%)
2(b).
To re-elect Mr. Yifan Li as an Independent Nonexecutive Director.
513,581,038 (99.99%)
16,000 (0.01%)
2(c).
To re-elect Mr. Erh Fei Liu as an Independent Non-executive Director.
513,597,038 (100.00%)
0 (0.00%)
2(d).
To authorize the Board to fix the respective Directors’ remuneration.
513,597,038 (100.00%)
0 (0.00%)
To re-appoint BDO Limited as the Company’ s auditor and to authorize the Board to fix their remuneration.
510,681,038 (99.43%)
2,916,000 (0.57%)
To grant a general and unconditional mandate to the Directors to repurchase Shares not exceeding 10% of the total number of Shares (excluding any treasury shares) as at the date of passing of this resolution.
513,597,038 (100.00%)
0 (0.00%)
To grant a general and unconditional mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of Shares (excluding any treasury shares) as at the date of passing of this resolution.
510,681,038 (99.43%)
2,916,000 (0.57%)
Conditional upon resolutions 4 and 5 being passed, to extend the general mandate granted to the Directors to issue, allot and deal with additional Shares by the aggregate number of Shares repurchased by the Company.
510,681,038 (99.43%)
2,916,000 (0.57%)
To grant the Board an authorization to grant awards pursuant to the post-IPO share incentive plan adopted by the Company on May 11, 2019 in respect of a maximum number of 85,823,591 Shares and to authorize the Board to allot, issue and deal with Shares in respect of which awards are granted.
510,665,038 (99.43%)
2,932,000 (0.57%)
The full text of the resolutions numbered 4 to 7 above are set out in the notice of the AGM dated April 28, 2026.
2
As more than 50% of the votes were cast in favour of each of the resolutions above, the resolutions numbered 1 to 7 were duly passed as ordinary resolutions of the Company by way of poll at the AGM. Dr. Wentao Zhang, Dr. Zhongping Lin, Ms. Zhuan Yin, Mr. Hao Wu, Mr. Erh Fei Liu and Dr. Jingsong Wang attended the AGM in person or by electronic means while Dr. Song Li and Mr. Yifan Li were unable to attend the AGM due to other business commitments. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, June 2, 2026
As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors. *
For identification purpose only
3
(3) PROPOSED GRANTING Of ANNUAL MANDATE UNDER THE 2018 SHARE INCENTIVE PLAN (4) PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026 AND (5) NOTICE OF ANNUAL GENERAL MEETING
A notice convening the Annual General Meeting of Frontage Holdings Corporation to be held at Building 2, No. 1227 Zhangheng Road, Zhangjiang Hi-Tech Park, Shanghai, China on Tuesday, June 2, 2026 at 10:00 a.m. is set out on pages 20 to 25 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of The Stock Exchange of Hong Kong Limited and the Company. Whether or not you are able to attend the Annual General Meeting in person, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the Annual General Meeting (i.e. no later than 10:00 a.m. on Sunday, May 31, 2026 (Hong Kong time)) or any adjournment of such meeting (as the case may be). Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the Annual General Meeting if they so wish. If you attend and vote at the Annual General Meeting, the authority of your proxy will be revoked. *
For identification purposes only
April 28, 2026
CONTENTS Page Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1
Letter from the Board 1.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4
Proposed Re-election of Retiring Directors . . . . . . . . . . . . . . . . . . . . . . . .
5
Proposed Granting of General Mandate to Repurchase Shares . . . . . . . . .
6
Proposed Granting of General Mandate to Issue Shares . . . . . . . . . . . . . .
7
Proposed Granting of Annual Mandate under the 2018 Share Incentive Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7
Proposed Re-appointment of Auditor for 2026 . . . . . . . . . . . . . . . . . . . . . .
9
Closure of Register of Members . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9
Annual General Meeting and Proxy Arrangement . . . . . . . . . . . . . . . . . . .
9
Voting by way of Poll . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10
- Responsibility Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10
- Recommendation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11
Appendix I
Details of the Retiring Directors Proposed to be Re-elected at the Annual General Meeting . . . . . . . . . . .
12
Explanatory Statement on the Repurchase Mandate . . . . .
17
Notice of Annual General Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20
Appendix II
–
–
–i–
DEFINITIONS In this circular, unless the context otherwise requires, the following expressions shall have the following meanings: “2015 Share Incentive Plan”
the pre-IPO share incentive plan approved by Frontage Labs in 2015 and assumed by the Company on April 17, 2018
“2018 Share Incentive Plan”
the post-IPO share incentive plan approved by the Company on May 11, 2019
“Annual General Meeting”
the annual general meeting of the Company to be held at Building 2, No. 1227 Zhangheng Road, Zhangjiang Hi-Tech Park, Shanghai, China on Tuesday, June 2, 2026 at 10:00 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 20 to 25 of this circular, or any adjournment thereof
“Articles of Association”
the articles of association of the Company, as amended from time to time
“Audit and Risk Management Committee”
the audit and risk management committee of the Board
“Award(s)”
options, RSUs and any other type of share incentive award under the 2018 Share Incentive Plan
“Board”
the board of Directors
“CG Code”
the Corporate Governance Code as set out in the Listing Rules
“Companies Law”
the Companies Law Chapter 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands as amended, supplemented or otherwise modified from time to time
“Company”
Frontage Holdings Corporation, a company incorporated on April 16, 2018 under the laws of the Cayman Islands with limited liability, and the Shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”
the director(s) of the Company from time to time
–1–
DEFINITIONS “Frontage Labs”
Frontage Laboratories, Inc., a company incorporated under the laws of Pennsylvania, United States on April 21, 2004 and the wholly-owned subsidiary of the Company
“Group”
the Company and its subsidiaries
“Hangzhou Tigermed”
Hangzhou Tigermed Consulting Co., Ltd., a company established in the PRC on December 15, 2004 with its shares being listed on ChiNext market of the Shenzhen Stock Exchange with stock code 300347 and on the Main Board of the Hong Kong Stock Exchange with stock code 3347, which is one of the controlling shareholders of the Company
“HK$”
Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”
the Hong Kong Special Administrative Region of the People’s Republic of China
“Hongkong Tigermed”
Hongkong Tigermed Co., Limited, a company incorporated under the laws of Hong Kong with limited liability on September 14, 2011 and which is a whollyowned subsidiary of Hangzhou Tigermed and one of the controlling shareholders of the Company
“Issuance Mandate”
a general and unconditional mandate proposed to be granted to the Directors to exercise the power of the Company to allot, issue or otherwise deal with additional Shares of not exceeding 20% of the total number of the Shares in issue (excluding any treasury shares) as at the date of passing of relevant resolution at the Annual General Meeting
“Latest Practicable Date”
April 22, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular
“Listing Rules”
the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Nomination Committee”
the nomination committee of the Board
–2–
DEFINITIONS “PRC” or “China”
the People’s Republic of China, but for the purposes of this circular only, except where the context requires, references to the PRC or China exclude Hong Kong, Macau and Taiwan
“Remuneration Committee”
the remuneration committee of the Board
“Repurchase Mandate”
a general and unconditional mandate proposed to be granted to the Directors to exercise the power of the Company to repurchase Shares of not exceeding 10% of the total number of the Shares in issue (excluding any treasury shares) as at the date of passing the relevant resolution at the Annual General Meeting
“RMB”
Renminbi, the lawful currency of the PRC
“RSUs”
a restricted share unit, being a contingent right to receive Shares pursuant to the 2018 Share Incentive Plan
“SFO”
the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
“Share(s)”
ordinary share(s) of US$0.00001 each in the issued capital of the Company
“Shareholder(s)”
holder(s) of the issued Share(s)
“Stock Exchange” or “Hong Kong Stock Exchange”
The Stock Exchange of Hong Kong Limited
“Takeovers Code”
The Codes on Takeovers and Mergers and Share Buybacks issued by the Securities and Futures Commission of Hong Kong, as amended from time to time
“United States”
the United States of America
“US$”
Dollars, the lawful currency of the United States
“%”
per cent
–3–
LETTER FROM THE BOARD
FRONTAGE HOLDINGS CORPORATION 方達控股公司* (Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1521) Executive Directors: Dr. Song Li (Chairman) Dr. Wentao Zhang Dr. Zhongping Lin
Registered Office: Conyers Trust Company (Cayman) Limited Cricket Square, Hutchins Drive P.O. Box 2681 Grand Cayman, KY1-1111 Cayman Islands
Non-executive Directors: Ms. Zhuan Yin Mr. Hao Wu
Principal Place of Business in Hong Kong: Room 1920, 19/F Lee Garden One 33 Hysan Avenue Causeway Bay, Hong Kong
Independent Non-executive Directors: Mr. Yifan Li Mr. Erh Fei Liu Dr. Jingsong Wang
April 28, 2026 To the Shareholders Dear Sir/Madam,
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND ISSUE SHARES (3) PROPOSED GRANTING OF ANNUAL MANDATE UNDER THE 2018 SHARE INCENTIVE PLAN (4) PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026 AND (5) NOTICE OF ANNUAL GENERAL MEETING 1.
INTRODUCTION
The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the Annual General Meeting to be held on Tuesday, June 2, 2026.
–4–
LETTER FROM THE BOARD 2.
PROPOSED RE-ELECTION OF RETIRING DIRECTORS
Pursuant to Article 84(1) of the Articles of Association, at each annual general meeting, one-third of the Directors for the time being (or, if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. Pursuant to Article 84(2) of the Articles of Association, a retiring Director shall be eligible for re-election and shall continue to act as a Director throughout the meeting at which he retires and any Director appointed by the Board pursuant to Article 83(3) shall not be taken into account in determining which particular Directors or the number of Directors who are to retire by rotation. The Directors to retire by rotation shall include (so far as necessary to ascertain the number of directors to retire by rotation) any Director who wishes to retire and not to offer himself for re-election. Any further Directors so to retire shall be those of the other Directors subject to retirement by rotation who have been longest in office since their last re-election or appointment and so that as between persons who became or were last re-elected Directors on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot. Accordingly, pursuant to Article 84 of the Articles of Association, Dr. Song Li, Mr. Yifan Li, and Mr. Erh Fei Liu will hold office until the Annual General Meeting and, being eligible, offer themselves for re-election at the Annual General Meeting. The Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the Directors, the qualifications, skills and experience, time commitment and contribution of the retiring Directors with reference to the nomination principles and criteria set out in the Company’s Board Diversity Policy and Director Nomination Policy as well as the Company’s corporate strategy, and the independence of all independent non-executive Directors. The Nomination Committee has recommended to the Board on the re-election of each of Dr. Song Li as Executive Director, Mr. Yifan Li and Mr. Erh Fei Liu as Independent Non-executive Directors, at the Annual General Meeting. As a good corporate governance practice, each of the retiring Directors abstained from voting at the relevant Board meeting on the respective propositions of their recommendations for re-election by the Shareholders at the Annual General Meeting. Each of the independent non-executive Directors, Mr. Yifan Li and Mr. Erh Fei Liu, has provided valuable contributions to the Company and has demonstrated their ability to exercise independent judgment and provide a balanced and objective view in relation to the Company’s affairs. Both of them have also confirmed that they will continue to devote sufficient time for the discharge of their functions and responsibilities as independent non-executive Directors. Each of Mr. Yifan Li and Mr. Erh Fei Liu currently does not hold seven or more listed company directorships in Hong Kong. With their relevant background and experience, Mr. Yifan Li and Mr. Erh Fei Liu are fully aware of the responsibilities and expected time involvements in the Company. Based on the foregoing, the Board believes that the positions of Mr. Yifan Li and Mr. Erh Fei Liu outside the Company will not affect them in maintaining their current roles in, and their functions and responsibilities for, the Company.
–5–
LETTER FROM THE BOARD In proposing each of Mr. Yifan Li and Mr. Erh Fei Liu to be re-elected as an independent non-executive Director at the Annual General Meeting, the Board has considered, among others, the valuable business experience, knowledge and professionalism of Mr. Yifan Li and Mr. Erh Fei Liu, as further described in the details of the respective Director in Appendix I to this circular, and the requirements as set out in Code Provision B.3.4 of the CG Code. With their unique background, the Board considers that each of Mr. Yifan Li and Mr. Erh Fei Liu is a highly valued and respected member of the Board, and can contribute to the diversity of the Board, in particular, with their strong and diversified educational background and professional experience in their expertise, including their in-depth knowledge in commercial and general management, professional accounting and auditing, international experience, investment strategies and connections in various industries. Accordingly, the Nomination Committee has recommended to the Board on the re-election of all the retiring Directors, including the aforesaid independent non-executive Directors who are due to retire at the Annual General Meeting. The Company considers that the retiring independent non-executive Directors are independent in accordance with the independence guidelines set out in the Listing Rules and will continue to bring valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning and diversity. The biographical details of the retiring Directors offering themselves for re-election at the Annual General Meeting are set out in Appendix I to this circular. The procedures and process for the nomination of Directors are set out in the section headed “Corporate Governance Report” in the annual report of the Company for the year ended December 31, 2025. 3.
PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES
At the annual general meeting of the Company held on May 28, 2025, a general mandate was granted to the Directors to repurchase Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. In order to give the Company the flexibility to repurchase Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Repurchase Mandate to the Directors to exercise the power of the Company to repurchase Shares of not exceeding 10% of the total number of Shares in issue (excluding any treasury shares) as at the date of passing of the proposed ordinary resolution numbered 4 in the notice of the Annual General Meeting as set out on pages 20 to 25 of this circular (i.e. a total of 203,448,891 Shares, based on 2,034,488,910 Shares in issue (excluding Shares repurchased by the Company but not yet cancelled) as at the Latest Practicable Date and assuming that the total number of Shares in issue will remain unchanged on the date of the Annual General Meeting). An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the ordinary resolution in relation to the granting of the Repurchase Mandate is set out in Appendix II to this circular.
–6–
LETTER FROM THE BOARD 4.
PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES
At the annual general meeting of the Company held on May 28, 2025, a general mandate was granted to the Directors to issue Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. In order to give the Company the flexibility to issue Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Issuance Mandate to the Directors to exercise the power of the Company to allot, issue or otherwise deal with additional Shares not exceeding 20% of the total number of Shares in issue (excluding any treasury shares) as at the date of passing of the proposed ordinary resolution numbered 5 in the notice of the Annual General Meeting as set out on pages 20 to 25 of this circular (i.e. a total of 406,897,782 Shares, based on 2,034,488,910 Shares in issue (excluding Shares repurchased by the Company not yet cancelled) as at the Latest Practicable Date and assuming that the total number of Shares in issue will remain unchanged on the date of the Annual General Meeting. An ordinary resolution to extend the Issuance Mandate by adding the number of Shares repurchased by the Company pursuant to the Repurchase Mandate will also be proposed at the Annual General Meeting. 5.
PROPOSED GRANTING OF ANNUAL MANDATE UNDER THE 2018 SHARE INCENTIVE PLAN
Background of the 2018 Share Incentive Plan The 2018 Share Incentive Plan was approved and adopted by the Shareholders on May 11, 2019. Apart from the 2018 Share Incentive Plan, the other share option schemes currently in force include the 2015 Share Incentive Plan and the pre-IPO share incentive plan approved by Frontage Labs in 2008 and assumed by the Company on April 17, 2018. The purpose of the 2018 Share Incentive Plan is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate skilled and experienced personnel who are expected to make important contributions to the Group. In particular, the 2018 Share Incentive Plan aims to motivate personnel to strive for the future development and expansion of the Group by providing them with the opportunity to acquire equity interests in the Company. Please refer to the prospectus of the Company dated May 17, 2019 for further details on the 2018 Share Incentive Plan. 2018 Share Incentive Plan Pursuant to the 2018 Share Incentive Plan, its “Scheme Mandate Limit”, being the total number of Shares in respect of which Awards may be granted pursuant to the 2018 Share Incentive Plan and any other equity-based incentive schemes of the Company, is 10% of the Shares in issue on the Listing Date, which is equal to 200,764,091. Pursuant to the 2018 Share Incentive Plan, the Scheme Mandate Limit may be renewed subject to prior approval of the shareholders of the Company. As of the Latest Practicable Date, the Scheme Mandate Limit has never been renewed and the number of shares of the Company in respect of which Awards may be granted under the 2018 Share Incentive Plan was 85,823,591, assuming that no further awards will be granted under any other equity-based incentive schemes of the Company. –7–
LETTER FROM THE BOARD Pursuant to the 2018 Share Incentive Plan, if the Company proposes to grant Awards under the 2018 Share Incentive Plan during the period between one annual general meeting and the subsequent annual general meeting of the Company which may be satisfied by the Company allotting and issuing new Shares upon the vesting of the Awards, the Company shall, at the Annual General Meeting, propose for the Shareholders to consider and, if thought fit, approve an ordinary resolution granting a mandate authorizing the Board to grant Awards pursuant to the 2018 Share Incentive Plan during the Applicable Period and that the Board shall have the power to allot, issue and deal with Shares in respect of Awards granted during the Applicable Period as and when the Awards vest, provided that the number of awarded shares available for grant under the 2018 Share Incentive Plan during the Applicable Period shall not exceed 85,823,591 Shares, being 4.21% of the total number of Shares in issue (excluding any treasury shares) as at the Latest Practicable Date, pursuant to paragraph 8.4 of the 2018 Share Incentive Plan (the “Annual Mandate”). The “Applicable Period” during which the Annual Mandate will be effective is from the period from the passing of the ordinary resolution granting the mandate until the earliest of (a) the conclusion of the next annual general meeting of the Company; (b) the end of the period within which the Company is required by any applicable laws or by the bye-laws of the Company to hold the next annual general meeting of the Company; and (c) the variation or revocation of such mandate by an ordinary resolution of the Shareholders in a general meeting. Proposed Granting of the Annual Mandate As at the Latest Practicable Date, 91,990,000 Awards have been granted under the 2018 Share Incentive Plan. For details, please refer to the Company’s announcements dated October 7, 2022, October 11, 2022, December 20, 2023 and October 30, 2024. The Directors are of the view that in order to provide incentives and rewards to the eligible participants for their contribution or potential contribution to the Group by granting share options to them, the Annual Mandate shall be approved to allow the Board to grant Awards under the 2018 Share Incentive Plan during the Applicable Period. The Directors further consider that the granting of the Annual Mandate is in the interest of the Group and Shareholders as a whole as it enables the Company to reward appropriately and motivate the eligible participants. At the Annual General Meeting, an ordinary resolution will be proposed to the Shareholders to approve the Annual Mandate so as to allow the Company to grant further Awards under the 2018 Share Incentive Plan for up to 85,823,591 Shares. The Scheme Mandate Limit, being the total number of Shares in respect of which Awards may be granted under the 2018 Share Incentive Plan and any other equity-based incentive schemes of the Company and as originally approved by the then shareholders on May 11, 2019, remains unchanged and in effect. Conditions of the Granting of the Annual Mandate The Annual Mandate is conditional upon the Shareholders passing the relevant ordinary resolution at the Annual General Meeting.
–8–
LETTER FROM THE BOARD 6.
PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026
At the Annual General Meeting, an ordinary resolution will be proposed to the Shareholders to consider and approve the re-appointment of BDO Limited as the auditor of the Company for a term until the conclusion of the next annual general meeting of the Company, and to authorise the Board to fix their remuneration. The estimated audit fee payable to BDO Limited for the audit of the consolidated financial statements of the Company and its subsidiaries for the financial year ending December 31, 2026 is expected to be RMB2.4 million. The estimated audit fee has been determined after due consideration and arm’s length negotiations between the Company and BDO Limited, taking into account, among other things, the size, nature and complexity of the Group’s business operations, the expected scope of the audit (covering the consolidated financial statements prepared in accordance with International Financial Reporting Standards), the audit timetable, and the level and mix of professional staff to be deployed. The estimated audit fee also assumes that there will be no material change in the Group’s operations, accounting policies or regulatory environment during the financial year, and that the Company will provide timely and adequate assistance and information as reasonably required for the purposes of the audit. Unless there is a material change in the basis or assumptions set out above, the final audit fee should not deviate materially from the estimated amount initially disclosed. In the event of any material change, the Company will make further disclosure as appropriate. 7.
CLOSURE OF REGISTER OF MEMBERS
For determining the entitlement to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from Wednesday, May 27, 2026 to Tuesday, June 2, 2026, both dates inclusive, during which period no transfer of Shares will be registered. The record date for determining the entitlement of the shareholders to attend and vote at the meeting will be Tuesday, June 2, 2026. In order to eligible to attend and vote at the Annual General Meeting, all share transfer forms accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong Hong Kong, for registration not later than 4:30 p.m. on Tuesday, May 26, 2026. 8.
ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT The notice of the Annual General Meeting is set out on pages 20 to 25 of this circular.
A form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.frontagelab.com). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and
–9–
LETTER FROM THE BOARD deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority at the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible but in any event not less than 48 hours before the time appointed for the Annual General Meeting (i.e. no later than 10:00 a.m. on Sunday, May 31, 2026 (Hong Kong time)) or the adjourned meeting (as the case may be). Completion and delivery of the form of proxy will not preclude you from attending and voting at the Annual General Meeting if you so wish. If you attend and vote at the Annual General Meeting, the authority of your proxy will be revoked. 9.
VOTING BY WAY OF POLL
Pursuant to Rule 13.39(4) of the Listing Rules and article 66 of the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll, except where the chairman of the meeting may in good faith allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Accordingly, each of the resolutions set out in the notice of the Annual General Meeting will be taken by way of poll. To the best of the knowledge, information and belief of the Directors, none of the Shareholders are required to abstain from voting on any of the resolutions to be proposed at the Annual General Meeting. The Company will announce the results of the poll after the Annual General Meeting in the manner prescribed under Rule 13.39(5) of the Listing Rules. 10. RESPONSIBILITY STATEMENT This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading. 11.
GENERAL INFORMATION
Your attention is drawn to the additional information set out in Appendix I (Details of the Retiring Directors Proposed to be Re-elected at the Annual General Meeting) and Appendix II (Explanatory Statement on the Repurchase Mandate) to this circular.
– 10 –
LETTER FROM THE BOARD 12. RECOMMENDATION The Directors consider that the proposed re-election of retiring Directors, granting of the Repurchase Mandate and the Issuance Mandate and the extension of the Issuance Mandate by adding to it the number of Shares repurchased pursuant to the Repurchase Mandate, granting of the Annual Mandate under the 2018 Share Incentive Plan and the Proposed Re-appointment of Auditor for 2026 are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favor of the relevant resolutions to be proposed at the Annual General Meeting. Yours faithfully, On behalf of the Board Frontage Holdings Corporation Dr. Song Li Chairman
– 11 –
APPENDIX I
DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING
The following are the details of the Directors who will retire, and, being eligible, offer themselves for re-election at the Annual General Meeting. EXECUTIVE DIRECTOR (1)
Dr. Song Li
Dr. Song Li (“Dr. Li”), aged 68, was appointed as a Director and designated as an executive Director and Chairman on February 10, 2021. He is also a member of the Remuneration Committee and Nomination Committee. Dr. Li ceased to be the Chief Executive Officer of the Company on January 3, 2023. In 2001, Dr. Li founded Frontage Labs and has been the chief executive officer of Frontage Labs ever since and remains a driving force behind the Group’s strategic, technical and commercial success. His visionary leadership of Frontage Labs has earned him widespread respect in the industry and within the Group. Prior to joining the Group, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During that period of time, he led numerous projects related to the development of pharmaceutical products. Dr. Li was formerly a director in the second session and the third session of the board of directors of Hangzhou Tigermed, a company listed on the Shenzhen Stock Exchange under stock code 300347 and on the Stock Exchange under stock code 3347, from August 2014 to April 2018. Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Dr. Li has been the recipient of numerous awards, most recently the Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, the Ernst & Young Entrepreneur of the Year Award, the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the Asian American Business Development Center. Dr. Li received his PhD degree in analytical chemistry from McGill University, Canada in 1992 and a Bachelor of Science in chemistry from Zhengzhou University, China. The Company has entered into a director appointment letter with Dr. Li relating to his service as a director for a term of three years commencing from February 10, 2024, pursuant to which he will not be entitled to any Director’s remuneration. Dr. Li’s appointment to the Board is subject to retirement by rotation and re-election at annual general meetings pursuant to the articles of association of the Company.
– 12 –
APPENDIX I
DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING
As at the Latest Practicable Date, Dr. Li had interests in 177,541,320 Shares, representing approximately 8.71% of the issued Shares within the meaning of Part XV of the SFO. He is the beneficial owner of 40,733,050 Shares and is the founder and a trustee of each of The Linna Li GST Exempt Trust, The Wendy Li GST Exempt Trust and The Yue Monica Li GST Exempt Trust, which hold 45,600,090 Shares, 45,602,090 Shares and 45,606,090 Shares, respectively. Save as disclosed above, as at the Latest Practicable Date, Dr. Li (i) did not have any interests in Shares within the meaning of Part XV of the SFO; (ii) did not hold any other position with the Company and other members of the Group; (iii) did not hold any directorship in the last three years prior to the Latest Practicable Date in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) did not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company. Save as disclosed above, there is no other information in relation to Dr. Li required to be disclosed pursuant to any of the requirements of Rules 13.51(2) of the Listing Rules, nor are there other matters concerning Dr. Li that need to be brought to the attention of the Shareholders. INDEPENDENT NON-EXECUTIVE DIRECTORS (2)
Mr. Yifan Li
Mr. Yifan Li (“Mr. Li”), aged 58, was appointed as an independent non-executive Director on April 17, 2018. He is the chairman of the Audit and Risk Management Committee and a member of each of the Remuneration Committee and Nomination Committee. Mr. Li has extensive experience in corporate financial management. His experience spans across various industries such as automotive, insurance, port operations, environmental services, online financing and real estate development and management in both the United States and China. Mr. Li was the chief financial officer of Human Horizons Group Inc. (“Human Horizons”) from April 2021 to March 2022. He then served as the chief financial and investment advisor of Human Horizons until December 2023. Mr. Li had held the role of the vice president of Zhejiang Geely Holding Group (“Geely”), responsible for the strategic investments and new business from October 2013 to April 2021. Prior to joining Geely, he had held the role of chief financial officer in China Zenix Auto International Limited (stock code: ZXAIY) from December 2010 to February 2014, which is a company listed on the New York Stock Exchange. Mr. Li was also a director of Zhejiang Qianjiang Motorcycle Co., Ltd. (stock code: 000913) from November 2016 to April 2018 and an independent non-executive Director of Zhejiang Tiantie Industry Co., Ltd. (stock code: 300587) from December 2017 to April 2021, both listed on the Shenzhen Stock Exchange, an independent director of Heilongjiang
– 13 –
APPENDIX I
DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING
Interchina Water Treatment Co., Ltd. (stock code: 600187) from May 2015 to April 2021 and Shanghai International Port Group Co., Ltd. (stock code: 600018) from September 2015 to September 2021, both listed on the Shanghai Stock Exchange and an independent nonexecutive director of ZhongAn Online P & C Insurance Co., Ltd. (stock code: 6060) from December 2016 to July 2021, a company listed on the Hong Kong Stock Exchange. Mr. Li received his MBA from the University of Chicago Booth School of Business, United States, in June 2000, his Master of Science in Accounting from University of Texas at Dallas, United States, in May 1994, and his Bachelor of Economics in World Economy from Fudan University, China, in July 1989. Mr. Li has been an independent non-executive director of Everest Medicines Limited (stock code: 1952) since September 2020 and Xinyuan Property Management Service (Cayman) Ltd. (stock code: 1895) since September 2019 (which are companies listed on the Hong Kong Stock Exchange), Shanghai Jinqiao Export Processing Zone Development Co., Ltd. (stock codes: 600639 (A shares), 900911 (B shares)) since June 2019 (which is a company listed on the Shanghai Stock Exchange), 36Kr Holdings Inc. (stock code: KRKR) since November 2019 (which is a company listed on NASDAQ), Sunlands Technology Group (stock code: STG) since July 2019 until May 2024, Qudian Inc. (stock code: QD) since October 2017 and Xinyuan Real Estate Co., Ltd. (stock code: XIN) since February 2017, which are companies listed on the New York Stock Exchange. Mr. Li entered into a service contract with the Company for a term of three years, commencing from March 29, 2024, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Under the letter of appointment, Mr. Li is entitled to a director’s fee of RMB310,000 per annum in respect of his service as an independent non-executive Director. Mr. Li’s annual remuneration as independent nonexecutive Director is determined by the Board based on the recommendation from the Remuneration Committee with reference to the Company’s performance, his duties and responsibilities with the Company and prevailing market conditions. Save as disclosed above, as at the Latest Practicable Date, Mr. Li (i) did not have any interests in Shares within the meaning of Part XV of the SFO; (ii) did not hold any other position with the Company and other members of the Group; (iii) did not hold any directorship in the last three years prior to the Latest Practicable Date in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) did not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company. Save as disclosed above, there is no other information in relation to Mr. Li required to be disclosed pursuant to any of the requirements of Rules 13.51(2) of the Listing Rules, nor are there other matters concerning Mr. Li that need to be brought to the attention of the Shareholders.
– 14 –
APPENDIX I
(3)
DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING
Mr. Erh Fei Liu
Mr. Erh Fei Liu (“Mr. Liu”), aged 67, was appointed as an independent non-executive Director on April 17, 2018. He is a member of each of the Audit and Risk Management Committee and Nomination Committee. Mr. Liu is currently a founding partner and chief executive officer of Asian Investment Capital. He was a co-founder of Cindat Capital Management Limited (“Cindat”), a global real estate investment platform. Prior to founding Cindat, he was an investment banker. From December 1999 to July 2012, he was the Managing Director of Merrill Lynch, based in Hong Kong. He was awarded the Asian Banker Skills-based Achievements Award in investment banking in 2006 by The Asian Banker. From 1992 to 1994, he worked at Goldman Sachs Group, Inc. as the head of investment banking for China. From May 1987 to March 1990, he worked as an associate at Goldman Sachs Group, Inc’s New York and Tokyo offices. Mr. Liu graduated from Harvard Business School, United States, in June 1987 with a master’s degree in business administration, from Brandeis University, United States, in May 1984 with a Bachelor of Arts degree in economics and from the Beijing Foreign Studies University, China, in 1981 with a Bachelor of Arts degree in economics. Mr. Liu has been an independent non-executive director of J&T Global Express, Limited since October 2023 (which is listed on the Hong Kong Stock Exchange with stock code 1519). Mr. Liu was appointed as an independent non-executive director of Shandong Weigao Blood Purification Products Co Ltd. since May 19, 2025 (which is listed on the Shanghai Stock Exchange, stock code: 603014). Mr. Liu was an independent non-executive director of Qingling Motors Company Limited from May 2015 to June 2024 (which is listed on the Hong Kong Stock Exchange with stock code 1122), 21Vianet Group, Inc. from May 2015 to July 2024 (which is listed on NASDAQ with stock code VNET), Fortunet e-Commerce Group Limited (now known as Changyou Alliance Group Limited) from March 2015 to April 2017 (which is listed on the Hong Kong Stock Exchange with stock code 1039 and Jiangxi Copper Company Limited from July 2016 to October 2022 (which is listed on the Hong Kong Stock Exchange with stock code 0358 and listed on the Shanghai Stock Exchange with Stock code 600362).
– 15 –
APPENDIX I
DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING
Mr. Liu entered into a service contract with the Company for a term of three years, commencing from March 29, 2024, subject to retirement by rotation and re-election at annual general meetings pursuant to the Articles of Association. Under the letter of appointment, Mr. Liu is entitled to a director’s fee of RMB310,000 per annum in respect of his service as an independent non-executive Director. Mr. Liu’s annual remuneration as independent nonexecutive Director is determined by the Board based on the recommendation from the Remuneration Committee with reference to the Company’s performance, his duties and responsibilities with the Company and prevailing market conditions. Save as disclosed above, as at the Latest Practicable Date, Mr. Liu (i) did not have any interests in Shares within the meaning of Part XV of the SFO; (ii) did not hold any other position with the Company and other members of the Group; (iii) did not hold any directorship in the last three years prior to the Latest Practicable Date in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) did not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company. Save as disclosed above, there is no other information in relation to Mr. Liu required to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor are there other matters concerning Mr. Liu that need to be brought to the attention of the Shareholders.
– 16 –
APPENDIX II
EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE
The following serves as an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the Annual General Meeting in relation to the granting of the Repurchase Mandate. 1.
SHARE CAPITAL
As at the Latest Practicable Date, the issued share capital of the Company comprised 2,038,024,910 Shares and the total number of Shares repurchased by the Company but not yet cancelled was 3,536,000 Shares. Subject to the passing of the ordinary resolution set out in resolution no. 4 of the notice of the Annual General Meeting in respect of the granting of the Repurchase Mandate and on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting, i.e. being 2,034,488,910 Shares, the Directors would be authorized under the Repurchase Mandate to repurchase, during the period in which the Repurchase Mandate remains in force, a total of 203,448,891 Shares, representing 10% of the total number of Shares in issue (excluding any treasury shares) as at the date of the Annual General Meeting. 2.
REASONS FOR SHARE REPURCHASES
The Directors believe that the granting of the Repurchase Mandate is in the best interests of the Company and the Shareholders as a whole. Repurchases of Shares may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such a repurchase will benefit the Company and the Shareholders. 3.
FUNDING OF REPURCHASES
Share repurchases pursuant to the Repurchase Mandate would be funded out of funds legally available for such purposes in accordance with the Company’s memorandum of association, Articles of Association, the laws of the Cayman Islands and/or any other applicable laws, as the case may be. Subject to the foregoing, any repurchases by the Company may be made out of profits of the Company, out of the Company’s share premium account, out of proceeds of a new issue of Shares made for the purpose of the repurchase or, if authorized by the Articles of Association and subject to the Companies Law, out of capital. Any amount of premium payable on the purchase over the par value of the Shares to be repurchased must be paid out of profits of the Company or from sums standing to the credit of the Company’s share premium account or, if authorized by the Articles of Association and subject to the Companies Law, out of capital.
– 17 –
APPENDIX II
EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE
IMPACT OF REPURCHASES
There might be a material adverse impact on the working capital and/or gearing position of the Company (as compared with the position disclosed in the audited consolidated financial statements contained in the annual report of the Company for the year ended December 31, 2025) in the event that the Repurchase Mandate was to be carried out in full at any time during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company. 5.
MARKET PRICES OF SHARES
The highest and lowest prices per Share at which Shares have traded on the Stock Exchange in each of the twelve months preceding and up to and including the Latest Practicable Date were as follows: Month
Highest HK$
Lowest HK$
2025 April May June July August September October November December
1.300 1.240 1.380 1.870 1.640 1.500 1.330 1.200 1.070
1.010 1.070 1.050 1.050 1.310 1.230 1.080 1.010 0.950
2026 January February March April (up to the Latest Practicable Date)
1.100 1.160 1.160 1.100
0.900 1.000 1.050 0.950
MARKET PRICES OF SHARES
To the best of their knowledge and having made all reasonable enquiries, none of the Directors nor any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company in the event that the granting of the Repurchase Mandate is approved by the Shareholders.
– 18 –
APPENDIX II
EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE
The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any Shares to the Company, or that they have undertaken not to sell any Shares held by them to the Company in the event that the granting of the Repurchase Mandate is approved by the Shareholders. The Directors will exercise the power of the Company to make repurchases of Shares pursuant to the Repurchase Mandate in accordance with the Articles of Association, the Listing Rules and the applicable laws of the Cayman Islands. In addition, the Company has confirmed that neither the Explanatory Statement nor the proposed share repurchase has any unusual features. 7.
TAKEOVERS CODE
If as a result of a repurchase of Shares pursuant to the Repurchase Mandate, a Shareholder’s proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder’s interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code. To the best knowledge of the Company, as at the Latest Practicable Date, the controlling shareholders (as defined in the Listing Rules) of the Company are Hangzhou Tigermed and Hongkong Tigermed (collectively, the “Controlling Shareholders”), were interested in 1,314,504,090 Shares, representing approximately 64.50% of the issued share capital of the Company. In the event that the Directors exercise the proposed Repurchase Mandate in full, the shareholding of the Controlling Shareholders would be increased to approximately 71.67% of the issued share capital of the Company. The Directors consider that such increase in shareholding would not give rise to an obligation to make a mandatory offer under Rules 26 and 32 of the Takeovers Code. 8.
REPURCHASE OF SHARES MADE BY THE COMPANY
The Company has not repurchased any of its Shares (whether on the Stock Exchange or otherwise) in the six months preceding the Latest Practicable Date.
– 19 –
NOTICE OF ANNUAL GENERAL MEETING
FRONTAGE HOLDINGS CORPORATION 方達控股公司* (Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1521) NOTICE IS HEREBY GIVEN that the annual general meeting of Frontage Holdings Corporation (the “Company”) will be held at Building 2, No. 1227 Zhangheng Road, Zhangjiang Hi-Tech Park, Shanghai, China on Tuesday, June 2, 2026 at 10:00 a.m. to consider and if thought fit, transact the following resolutions as ordinary resolutions of the Company: 1.
To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors (the “Directors”) and auditor of the Company for the year ended December 31, 2025.
(a)
To re-elect Dr. Song Li as an Executive Director;
(b)
To re-elect Mr. Yifan Li as an Independent Non-executive Director;
(c)
To re-elect Mr. Erh Fei Liu as an Independent Non-executive Director; and
(d)
To authorize the board of Directors (the “Board”) to fix the respective Directors’ remuneration.
To re-appoint BDO Limited as the Company’s auditor and to authorize the Board to fix their remuneration.
As special business, to consider and, if thought fit, pass the following resolution, with or without amendments, as an ordinary resolution: “THAT: (a)
subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as defined in paragraph (c) below) of all the powers of the Company to repurchase the issued shares of the Company (excluding any treasury shares) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) or any other stock exchange on which the shares in the capital of the Company may be listed and recognized by the Securities and Futures Commission of Hong Kong and the Stock Exchange for such purpose, and subject to and in accordance with all applicable laws and the requirements of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) or any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved; – 20 –
NOTICE OF ANNUAL GENERAL MEETING (b)
the total number of shares of the Company which may be repurchased or agreed to be repurchased by the Company pursuant to the approval in paragraph (a) above during the Relevant Period shall not exceed 10% of the total number of the issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and
(c)
for the purposes of this resolution: “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of: (i)
the conclusion of the next annual general meeting of the Company;
(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.” 5.
As special business, to consider and, if thought fit, pass the following resolution, with or without amendments, as an ordinary resolution: “THAT: (a)
subject to paragraph (c) below, pursuant to the Listing Rules, the exercise by the Directors during the Relevant Period (as defined in paragraph (d) below) of all the powers of the Company to allot, issue and deal with additional shares in the share capital of the Company, and to make or grant any offers, agreements, options and awards which would or might require the exercise of such powers, be and is hereby generally and unconditionally approved;
(b)
the approval in paragraph (a) above shall authorize the Directors to make or grant any offers, agreements, options and awards during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;
– 21 –
NOTICE OF ANNUAL GENERAL MEETING (c)
the aggregate number of shares allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to: (i)
a Rights Issue (as defined in paragraph (d) below);
(ii) any issue of shares under a share scheme of the Company; (iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company and other relevant regulations in force from time to time; or (iv) any issue of shares in the Company upon the exercise of rights of subscription or conversion under the terms of any securities of the Company which carry the rights to subscribe for or are convertible into shares of the Company shall not exceed 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and (d)
for the purposes of this resolution: “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of: (i)
the conclusion of the next annual general meeting of the Company;
(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting. “Rights Issue” means an offer of shares in the Company or offer or issue of warrants, options or other securities giving rights to subscribe for shares open for a period fixed by the Directors to holders of shares in the Company on the register on a fixed record date in proportion to their then holdings of such shares (subject to such exclusions or other arrangements as the Directors may deem necessary for expedient in relation to fractional entitlements, or having – 22 –
NOTICE OF ANNUAL GENERAL MEETING regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, or any recognized regulatory body or any stock exchange in any territory applicable to the Company).” 6.
As special business, to consider and, if thought fit, pass the following resolution, with or without amendments, as an ordinary resolution: “THAT conditional upon the passing of the resolutions nos. 4 and 5 above, the unconditional general mandate referred to in the resolution no. 5 above be and is hereby extended by the addition to the aggregate number of shares which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to such general mandate of the number of shares repurchased by the Company pursuant to the mandate granted under the resolution no. 4 above, provided that such amount shall not exceed 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.”
Consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “THAT: (a)
the Board is authorized to grant Awards (as defined in paragraph (b) below) pursuant to the share incentive scheme adopted by the Company on May 11, 2019 (the “2018 Share Incentive Plan”) during the Applicable Period (as defined in paragraph (b) below) in respect of a maximum number of 85,823,591 shares in the capital of the Company and that the Board shall have the power to allot, issue and deal with Shares in respect of which Awards are granted during the Applicable Period as and when the Awards vest, provided that the total number of Shares in respect of which Awards granted and to be granted pursuant to the 2018 Share Incentive Plan and any other equity-based incentive schemes of the Company shall not exceed 200,764,091;
– 23 –
NOTICE OF ANNUAL GENERAL MEETING (b)
for the purposes of this resolution: “Applicable Period” means the period from the passing of the ordinary resolution granting the mandate until the earliest of: (i)
the conclusion of the next annual general meeting of the Company;
(ii) the end of the period within which the Company is required by any applicable laws or by the by-laws of the Company to hold the next annual general meeting of the Company; and (iii) the variation or revocation of such mandate by an ordinary resolution of the shareholders of the Company in a general meeting. “Awards” means options, RSUs and any other type of share incentive award under the 2018 Share Incentive Plan. “RSU” means a restricted share unit, being a contingent right to receive Shares pursuant to the 2018 Share Incentive Plan.” By order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, April 28, 2026 Notes: 1.
All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
Any shareholder of the Company entitled to attend and vote at the above meeting is entitled to appoint a proxy to attend and vote instead of him/her. A member who is the holder of two or more shares may appoint more than one proxy to represent him/her to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him/her.
In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for the holding of the annual general meeting of the Company (i.e. no later than 10:00 a.m. on Sunday, May 31, 2026 (Hong Kong time)) or any adjourned meeting (as the case may be). Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
– 24 –
NOTICE OF ANNUAL GENERAL MEETING 4.
For the purpose of determining the entitlement of shareholders to attend and vote at the above meeting, the register of members of the Company will be closed from Wednesday, May 27, 2026 to Tuesday, June 2, 2026, both dates inclusive, during which period no transfer of shares will be registered. The record date for determining the entitlement of the shareholders to attend and vote at the meeting will be Tuesday, June 2, 2026. In order to be eligible to attend and vote at the meeting, all share transfer forms accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Tuesday, May 26, 2026. In the event that the Annual General Meeting is adjourned to a date later than June 2, 2026 because of bad weather or other reasons, the book closure period and record date for determination of entitlement to attend and vote at the above meeting will remain the same as stated above.
Where there are joint holders of any shares carrying voting rights, any one of such joint holders may vote, either in person or by proxy, in respect of such Share as if he/she were solely entitled thereto, but if more than one of such joint holders are present at any meeting the vote of the most senior holder who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names of the joint holders appear in the register of members of the Company in respect of the joint holding.
A circular containing resolutions nos. 2 and 4 to 7 set out in the above notice will be sent to all shareholders of the Company together with the annual report of the Company for the year ended December 31, 2025 upon request of the shareholders.
In the case of any inconsistency between the Chinese translation and the English text hereof, the English text shall prevail.
As at the date of this notice, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors. *
For identification purposes only
– 25 –
NOTICE IS HEREBY GIVEN that the annual general meeting of Frontage Holdings Corporation (the “Company”) will be held at Building 2, No. 1227 Zhangheng Road, Zhangjiang Hi-Tech Park, Shanghai, China on Tuesday, June 2, 2026 at 10:00 a.m. to consider and if thought fit, transact the following resolutions as ordinary resolutions of the Company: 1.
To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors (the “Directors”) and auditor of the Company for the year ended December 31, 2025.
(a)
To re-elect Dr. Song Li as an Executive Director;
(b)
To re-elect Mr. Yifan Li as an Independent Non-executive Director;
(c)
To re-elect Mr. Erh Fei Liu as an Independent Non-executive Director; and
(d)
To authorize the board of Directors (the “Board”) to fix the respective Directors’ remuneration.
To re-appoint BDO Limited as the Company’s auditor and to authorize the Board to fix their remuneration.
As special business, to consider and, if thought fit, pass the following resolution, with or without amendments, as an ordinary resolution: “THAT: (a)
subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as defined in paragraph (c) below) of all the powers of the Company to repurchase the issued shares of the Company (excluding any treasury shares) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) or any other stock exchange on which the shares in the capital of the Company may be listed and recognized by the Securities and Futures Commission of Hong Kong and the Stock Exchange for such purpose, and subject to and in accordance with all applicable laws and the requirements of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) or any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved; –1–
(b)
the total number of shares of the Company which may be repurchased or agreed to be repurchased by the Company pursuant to the approval in paragraph (a) above during the Relevant Period shall not exceed 10% of the total number of the issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and
(c)
for the purposes of this resolution: “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of: (i)
the conclusion of the next annual general meeting of the Company;
(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.” 5.
As special business, to consider and, if thought fit, pass the following resolution, with or without amendments, as an ordinary resolution: “THAT: (a)
subject to paragraph (c) below, pursuant to the Listing Rules, the exercise by the Directors during the Relevant Period (as defined in paragraph (d) below) of all the powers of the Company to allot, issue and deal with additional shares in the share capital of the Company, and to make or grant any offers, agreements, options and awards which would or might require the exercise of such powers, be and is hereby generally and unconditionally approved;
(b)
the approval in paragraph (a) above shall authorize the Directors to make or grant any offers, agreements, options and awards during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;
–2–
(c)
the aggregate number of shares allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to: (i)
a Rights Issue (as defined in paragraph (d) below);
(ii) any issue of shares under a share scheme of the Company; (iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company and other relevant regulations in force from time to time; or (iv) any issue of shares in the Company upon the exercise of rights of subscription or conversion under the terms of any securities of the Company which carry the rights to subscribe for or are convertible into shares of the Company shall not exceed 20% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and (d)
for the purposes of this resolution: “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of: (i)
the conclusion of the next annual general meeting of the Company;
(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting. “Rights Issue” means an offer of shares in the Company or offer or issue of warrants, options or other securities giving rights to subscribe for shares open for a period fixed by the Directors to holders of shares in the Company on the register on a fixed record date in proportion to their then holdings of such shares (subject to such exclusions or other arrangements as the Directors may deem necessary for expedient in relation to fractional entitlements, or having –3–
regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, or any recognized regulatory body or any stock exchange in any territory applicable to the Company).” 6.
As special business, to consider and, if thought fit, pass the following resolution, with or without amendments, as an ordinary resolution: “THAT conditional upon the passing of the resolutions nos. 4 and 5 above, the unconditional general mandate referred to in the resolution no. 5 above be and is hereby extended by the addition to the aggregate number of shares which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the Directors pursuant to such general mandate of the number of shares repurchased by the Company pursuant to the mandate granted under the resolution no. 4 above, provided that such amount shall not exceed 10% of the total number of issued shares of the Company (excluding any treasury shares) as at the date of passing of this resolution.”
Consider and, if thought fit, pass the following resolution as an ordinary resolution of the Company: “THAT: (a)
the Board is authorized to grant Awards (as defined in paragraph (b) below) pursuant to the share incentive scheme adopted by the Company on May 11, 2019 (the “2018 Share Incentive Plan”) during the Applicable Period (as defined in paragraph (b) below) in respect of a maximum number of 85,823,591 shares in the capital of the Company and that the Board shall have the power to allot, issue and deal with Shares in respect of which Awards are granted during the Applicable Period as and when the Awards vest, provided that the total number of Shares in respect of which Awards granted and to be granted pursuant to the 2018 Share Incentive Plan and any other equity-based incentive schemes of the Company shall not exceed 200,764,091;
–4–
(b)
for the purposes of this resolution: “Applicable Period” means the period from the passing of the ordinary resolution granting the mandate until the earliest of: (i)
the conclusion of the next annual general meeting of the Company;
(ii) the end of the period within which the Company is required by any applicable laws or by the by-laws of the Company to hold the next annual general meeting of the Company; and (iii) the variation or revocation of such mandate by an ordinary resolution of the shareholders of the Company in a general meeting. “Awards” means options, RSUs and any other type of share incentive award under the 2018 Share Incentive Plan. “RSU” means a restricted share unit, being a contingent right to receive Shares pursuant to the 2018 Share Incentive Plan.” By order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, April 28, 2026 Notes: 1.
All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
Any shareholder of the Company entitled to attend and vote at the above meeting is entitled to appoint a proxy to attend and vote instead of him/her. A member who is the holder of two or more shares may appoint more than one proxy to represent him/her to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him/her.
In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for the holding of the annual general meeting of the Company (i.e. no later than 10:00 a.m. on Sunday, May 31, 2026 (Hong Kong time)) or any adjourned meeting (as the case may be). Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
–5–
For the purpose of determining the entitlement of shareholders to attend and vote at the above meeting, the register of members of the Company will be closed from Wednesday, May 27, 2026 to Tuesday, June 2, 2026, both dates inclusive, during which period no transfer of shares will be registered. The record date for determining the entitlement of the shareholders to attend and vote at the meeting will be Tuesday, June 2, 2026. In order to be eligible to attend and vote at the meeting, all share transfer forms accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Tuesday, May 26, 2026. In the event that the Annual General Meeting is adjourned to a date later than June 2, 2026 because of bad weather or other reasons, the book closure period and record date for determination of entitlement to attend and vote at the above meeting will remain the same as stated above.
Where there are joint holders of any shares carrying voting rights, any one of such joint holders may vote, either in person or by proxy, in respect of such Share as if he/she were solely entitled thereto, but if more than one of such joint holders are present at any meeting the vote of the most senior holder who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names of the joint holders appear in the register of members of the Company in respect of the joint holding.
A circular containing resolutions nos. 2 and 4 to 7 set out in the above notice will be sent to all shareholders of the Company together with the annual report of the Company for the year ended December 31, 2025 upon request of the shareholders.
In the case of any inconsistency between the Chinese translation and the English text hereof, the English text shall prevail.
As at the date of this notice, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors. *
For identification purposes only
–6–
28 April 2026 Dear Registered Shareholders, Frontage Holdings Corporation (the “Company”) – Notice of publication of (i) 2025 Annual Report and (ii) Circular in relation to (1) proposed re-election of retiring Directors; (2) proposed granting of general mandates to repurchase shares and issue shares; (3) proposed granting of annual mandate under the 2018 share incentive plan; (4) proposed re-appointment of auditor for 2026; and (5) notice of annual general meeting, and (iii) Form of proxy of the Company (collectively the “Current Corporate Communication”) The English and Chinese versions of the Company’s Current Corporate Communications are now available on the Company’s website at www.frontagelab.com and the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications (Note). If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communication is enclosed. If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited (the “Branch Share Registrar”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to [email protected]. The Company will promptly upon your request send the Current Corporate Communications to you in printed form free of charge. It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the above-mentioned address by post or by email to [email protected]. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications (“Notice of Publication”) and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form. Should you have any queries relating to this notification, please call the Branch Share Registrar’s telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays). By order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Note:
Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications. Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.
各位登記股東: 方達控股公司(「本公司」) – (i) 2025年度報告及(ii) 有關(1)建議重選退任董事;(2)建議授出購回股份及發行股份的一般授權;(3) 建議授出2018年股份激勵計劃下的年度授權;(4) 建議續聘2026 年度核數師;及 (5) 股東週年大會通告之通函,以及(iii)代表委任表格(統稱「本次公司通訊」)之登載通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.frontagelab.com)及香港聯合交易所有限公司(「聯交所」)之網站(www.hkexnews.hk)(「網站 版本」)。我們建議閣下閱覽本公司本次及日後公司通訊(附註)的網站版本。如閣下已選擇收取公司通訊的印刷本,隨函附上本次公司通訊。 如閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本,及欲索取本次公司通訊及日後公司通訊的印刷本,請填妥及簽署隨附之回條,並以已預付 郵費的郵寄標籤寄回本公司之香港股份過戶登記分處(「股份過戶登記分處」)卓佳證券登記有限公司(地址為香港夏慤道16號遠東金融中心17樓)(如在香港投寄 毋須貼上郵票),或電郵至 [email protected]。本公司會因應閣下之要求立即寄上本次公司通訊的印刷本,費用全免。 登記股東有責任提供有效的電子郵件地址。如閣下尚未提供閣下之電子郵件地址予本公司,或需更新閣下之電子郵件地址,本公司建議閣下填妥及簽署隨附 之回條,並按上述地址以郵寄方式交回本公司的股份過戶登記分處或以電郵方式發送至[email protected]。如果本公司沒有收到閣下的有效電子郵件地址,直至股 份過戶登記分處收到閣下有效的電子郵件地址前, 閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採 取行動的公司通訊。本公司只能以印刷本方式向閣下發送登載通知及可供採取行動的公司通訊之印刷本予閣下。 倘
閣下對本通知有任何查詢,請於辦公時間星期一至星期五(公眾假期除外)上午9時至下午6時,致電股份過戶登記分處熱線(852) 2980 1333。 承董事會命 方達控股公司
主席 李松博士 2026年4月28日
附註:
公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於 (a) 董事會報告及公司年度帳目連同 核數師報告以及財務摘要報告(如適用); (b) 中期報告及中期摘要報告(如適用); (c) 會議通告; (d) 上市文件; (e) 通函; (f) 代表委任表格; 及 (g)可 供採取行動的公司通訊。 可供採取行動的公司通訊是指任何涉及要求股東指示其擬如何行使其有關股東權利的公司通訊。
- For identification purposes only
- 僅供識別
Registered Shareholder’s information (English name and address) 登記股東資料(英文姓名及地址)
REPLY FORM 回條 To: Frontage Holdings Corporation (the “Company”) (Stock Code: 1521) (Incorporated in the Cayman Islands with limited liability) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre 16 Harcourt Road, Hong Kong Part A 甲部
致:
方達控股公司 (「本公司」)(股份代號:1521)
(於開曼群島註冊成立之有限公司) 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓
I/We would like to receive the Current Corporate Communication and all future Corporate Communications in printed form in the manner indicated below: 本人╱我們現欲以下列方式收取本次公司通訊及將來所有公司通訊之印刷本:
(Please mark “✓” in ONLY ONE of the following boxes 請從下列選擇中,僅在其中一個空格內劃上「✓」號) I/We would like to receive a printed copy in the English language only; OR 本人╱我們現欲收取一份英文印刷本;或 I/We would like to receive a printed copy in the Chinese language only; OR 本人╱我們現欲收取一份中文印刷本;或 I/We would like to receive a printed copy in both the English language and the Chinese language. 本人╱我們現欲收取英文和中文各一份印刷本。 Part B 乙部
I/We would like to receive the notices of publication of all future Corporate Communications and Actionable Corporate Communications in electronic form via the email address below: 本人╱我們現欲以以下電子郵件地址以電子方式收取本公司日後所有公司通訊的登載通知及可供採取行動的公司通訊:
(Please provide the email address in English BLOCK LETTERS)
(請以英文正楷填寫電子郵件地址) Name(s) of Shareholder(s): 股東姓名: Address: 地址:
28 April 2026 Dear Non-Registered Shareholders, Frontage Holdings Corporation (the “Company”) – Notice of publication of (i) 2025 Annual Report, and (ii) Circular in relation to (1) proposed re-election of retiring Directors; (2) proposed granting of general mandates to repurchase shares and issue shares; (3) proposed granting of annual mandate under the 2018 share incentive plan; (4) proposed re-appointment of auditor for 2026; and (5) notice of annual general meeting (collectively the “Current Corporate Communication”) The English and Chinese versions of the Company’s Current Corporate Communications are available on the Company’s website at www.frontagelab.com and the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the Website Version of Current Corporate Communication. If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Request Form and return it to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited (“Branch Share Registrar”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to [email protected]. The Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge. As a non-registered shareholder, if you wish to receive Corporate Communications of the Company in electronic form, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares in the Company are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries. Please contact your Intermediaries for the detailed procedure. If the Company does not receive your functional email address from the Intermediaries, until such time that the functional email address is provided to the Intermediaries, you will be unable to receive any notices of publication of the Website Version of Corporate Communications (“Notice of Publication”) by email; and the Company would only be able to send you the Notice of Publication in printed form. Should you have any queries relating to this notification, please call the Branch Share Registrar’s telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays). By order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Notes:
Non-Registered Holder means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications of the Company. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; and (e) a circular.
各位非登記股東: 方達控股公司(「本公司」) – (i) 2025年度報告,以及(ii) 有關(1)建議重選退任董事;(2)建議授出購回股份及發行股份的一般授權;(3) 建議授出2018年股份激勵計劃下的年度授權;(4) 建議續聘 2026年度核數師;及 (5) 股東週年大會通告之通函(統稱「本次公司通訊」)之登載通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.frontagelab.com)及香港聯合交易所有限公司(「聯交所」)之網站(www.hkexnews.hk) (「網站 版本」)。本公司建議閣下閱覽本公司本次公司通訊的網站版本。 如閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本,及欲索取本次及日後公司通訊的印刷本,請填妥及簽署隨附之申請表格,並以已預付郵費 的郵寄標籤寄回本公司之香港股份過戶登記分處(「股份過戶登記分處」)卓佳證券登記有限公司(地址為香港夏慤道16號遠東金融中心17樓)(如在香港投寄毋須 貼上郵票),或電郵至 [email protected]。本公司會因應閣下之要求立即寄上本次公司通訊的印刷本,費用全免。 作為非登記股東,如閣下欲以電子方式收取本公司的公司通訊, 閣下應聯絡代閣下持有股份的銀行、經紀人、託管人、代理人或香港中央結算(代理人)有限 公司(統稱「中介機構」),並向閣下的中介機構提供閣下的電子郵件地址。請聯絡閣下的中介機構以了解詳細程序。如果本公司沒有從中介機構收到閣下 的有效電子郵件地址,直至中介機構收到閣下有效的電子郵件地址前,本公司將無法透過電子郵件方式發送公司通訊網站版本的登載通知(「登載通知」),而本 公司只能發送登載通知之印刷本予閣下。 倘
閣下對本通知有任何查詢,請於辦公時間星期一至星期五(公眾假期除外)上午9時至下午6時,致電股份過戶登記分處熱線(852) 2980 1333。 承董事會命 方達控股公司
主席 李松博士 2026年4月28日
附註:
非登記股東指其股份存放於中央結算及交收系統(中央結算及交收系統)的有關人士或公司,而彼等已透過香港中央結算有限公司不時通知本公司,彼等 擬收取本公司之公司通訊。 公司通訊包括本公司發出或將予發出以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於 (a) 董事會報告及公司年度帳目連同 核數師報告以及財務摘要報告(如適用); (b) 中期報告及中期摘要報告(如適用); (c) 會議通告; (d) 上市文件;及 (e) 通函。
- For identification purposes only
- 僅供識別
Non-registered shareholder’s information (English name and address) 非登記股東資料(英文姓名及地址)
REQUEST FORM 申請表格 To: Frontage Holdings Corporation (the “Company”) (Stock Code: 1521) (Incorporated in the Cayman Islands with limited liability) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre 16 Harcourt Road, Hong Kong
致:
方達控股公司 (「本公司」)(股份代號:1521)
(於開曼群島註冊成立之有限公司) 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓
REMINDER 提示 As a non-registered shareholder(1), if you wish to receive Corporate Communications(2) pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries. 作為非登記股東(1) ,如有意根據《上市規則》收取公司通訊(2) , 閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算(代理人)有限公司(統稱「中介公 司」),並向閣下的中介公司提供閣下的電子郵件地址。 I/We would like to receive the Current Corporate Communication and all future Corporate Communications of the Company in the manner as indicated below: 本人╱我們現在希望以下列方式收取本公司本次及日後所有公司通訊: (Please mark a “✓” in ONLY ONE of the following boxes) (請從下列選擇中,僅在其中一個空格內劃上「✓」號) to receive a printed copy in the English language only; OR 僅收取所有日後公司通訊的英文印刷本;或 to receive a printed copy in the Chinese language only; OR 僅收取所有日後公司通訊的中文印刷本;或 to receive a printed copy in both the English language and the Chinese language. 同時收取所有日後公司通訊的英文及中文印刷本。 Name(s) of Shareholder(s): 股東姓名: Address: 地址:
April 28, 2026 Dear Shareholder(s), Frontage Holdings Corporation (the “Company”) – Notice of Publication of 2025 Environmental, Social and Governance Report of the Company (the “2025 ESG Report”) The English and Chinese versions of the 2025 ESG Report are available on the Company ’ s website at www.frontagelab.com and the Hong Kong Exchanges and Clearing Limited’s website at www.hkexnews.hk (the “HKEX website”). You may visit our website by clicking “Financial Reports” under the section headed “Investor Relations” or the HKEX website to view and/or download the 2025 ESG Report. If you wish to request printed version(s) of the 2025 ESG Report, please send a letter stating your request with signature by mail to the Company’s Hong Kong share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. Yours faithfully, Frontage Holdings Corporation
各位股東: 方達控股公司(「本公司」) - 本公司2025年環境、社會及管治報告(「2025年環境、社會及管治報告」)之刊發通知 2025年環境、社會及管治報告的中英文版本已登載於本公司網站 www.frontagelab.com 及香港聯合交易所有限公 司的網站 www.hkexnews.hk(「香港交易所網站」)。閣下可瀏覽本公司網站並於「投資者關係」項下點擊「財務報 告」或於香港交易所網站閱覽及 ╱ 或下載2025年環境、社會及管治報告。 倘閣下欲要求索取2025年環境、社會及管治報告之印刷本,請寄回已簽署書面要求至本公司香港證券登記處, 卓佳證券登記有限公司,地址為香港夏愨道16號遠東金融中心17樓。 方達控股公司 * 謹啟 二零二六年四月二十八日 *
僅供識別
This announcement is made by Frontage Holdings Corporation (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). In addition, this announcement is made by the Company with a view to ensuring that all the shareholders of the Company have equal and timely access to the information of the Company, in light of the announcement by its controlling shareholder, Hangzhou Tigermed Consulting Co., Ltd. (a company listed on the Main Board of the Hong Kong Stock Exchange with stock code: 3347 and on ChiNext market of the Shenzhen Stock Exchange with stock code: 300347), of its unaudited first quarter results of 2026 for the three months ended March 31, 2026 on the Hong Kong Stock Exchange on April 28, 2026. The board (the “Board”) of directors of the Company wishes to inform the shareholders of the Company and potential investors of the following unaudited consolidated financial information of the Group, which were prepared in accordance with the International Financial Reporting Standards based on its unaudited consolidated management accounts: For the three months ended March 31, 2026, the Group recorded a net profit of approximately US$2.9 million as compared to a net loss of approximately US$0.9 million for the same period in 2025, on revenue of approximately US$67.9 million, which represented an increase of 18.9% as compared to approximately US$57.1 million for the same period in 2025. After excluding share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, and expenses in relation to mergers and acquisitions, the adjusted net profit of the Group was approximately US$5.0 million, which represented an increase of 212.5% as compared to approximately US$1.6 million for the same period in 2025.
1
The net profit for the Group, including a significant increase in adjusted net profit during the first quarter of 2026 compared to the same period last year, was primarily attributable to several factors including: (1) the Group’s year-on-year revenue growth driven by the recovery in market demand, with economies of scale gradually materializing; (2) the continuous and in-depth implementation of lean operation initiatives, which significantly improved operating efficiency and drove a year-on-year increase in both the overall net profit margin and adjusted net profit margin; and (3) the consolidation of Teddy Clinical Research Laboratory (Shanghai) Ltd. (“Teddy Lab”) following the completion of its acquisition on March 3, 2026, which also contributed incremental revenue and net profit for the current period. As at March 31, 2026, the unaudited consolidated net assets of the Group were approximately US$351.8 million, compared to approximately US$334.6 million as at December 31, 2025. Shareholders and potential investors of the Company should note that the information contained in this announcement is unaudited and has not been reviewed by the Company’s auditors or the audit committee of the board of directors of the Company and may be subject to possible adjustments. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, April 28, 2026
As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive Directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive Directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors.
- For identification purpose only
2
News
/ Frontage Promotes Dr. Xiaonan Tang to Senior Vice President, Bioanalytical Services

March 31, 2026
Frontage Promotes Dr. Xiaonan Tang to Senior Vice President, Bioanalytical Services
EXTON, Pa., March 31, 2026 – Frontage Holdings Corporation announces the promotion of Dr. Xiaonan Tang to Senior Vice President, Bioanalytical Services, effective March 2026. In this role, Dr. Tang will continue to lead the bioanalytical operations, with a focus on mass spectrometry-based platforms, further strengthening scientific excellence, operational efficiency, regulatory compliance, and innovation across Frontage’s service platform.
Dr. Tang has been with Frontage since 2008, joining as a laboratory scientist and progressing through a series of leadership roles with increasing responsibility. Over nearly two decades, he has established himself as a highly effective leader with strong managerial and interpersonal skills. He has played a key role in advancing Frontage’s bioanalytical capabilities, including driving the implementation of paperless bioanalytical workflows and modernizing laboratory operations. Under his leadership, the Mass Spectrometry Services team has consistently delivered strong performance and remains a key contributor to the Company’s continued growth. Dr. Tang completed his postdoctoral research training at the University of Chicago and holds a Ph.D. in Physical Chemistry from the University of California, Davis.
“We are very pleased to recognize Xiaonan’s outstanding contributions and leadership with this well-deserved promotion,” said Dr. John Lin, Co-CEO of Frontage. “His ability to combine scientific expertise with operational excellence has been instrumental in strengthening our bioanalytical services. I am confident that in his new role, Xiaonan will continue to drive innovation, enhance our capabilities, and support Frontage’s long-term strategic growth.”
“I am honored to take on this new role at Frontage,” said Dr. Tang. “Having grown with the Company over the years, I am proud of what our team has accomplished. I look forward to continuing to advance our bioanalytical capabilities, foster innovation, and deliver high-quality solutions to support our clients’ drug development programs.”
About Frontage
Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), is a US based global CRO/CDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.
SOURCE Frontage Laboratories, Inc.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
Name
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
Notifications
News
/ Frontage Promotes Dr. Xin (James) Huang to Senior Vice President, Corporate QA & IT

March 31, 2026
Frontage Promotes Dr. Xin (James) Huang to Senior Vice President, Corporate QA & IT
EXTON, Pa., March 31, 2026 – Frontage Holdings Corporation announces the promotion of Dr. Xin (James) Huang to Senior Vice President, Corporate Quality Assurance & Information Technology. In this expanded leadership role, James will continue to report to Dr. John Lin, Co-Chief Executive Officer and lead the Company’s global quality, compliance, and IT governance strategies, further strengthening Frontage’s commitment to regulatory excellence, operational efficiency, and digital transformation.
James has over 30 years of experience in quality assurance, regulatory compliance, and IT governance within the life sciences industry. Prior to joining Frontage, he held leadership roles at MDS, Deloitte, Almac Group, and Nestlé Health Science, driving global quality and digital transformation initiatives. Since joining Frontage, James has played a critical role in advancing Frontage’s quality and digital capabilities, including supporting AI implementation in laboratory systems, leading multiple successful FDA inspections with no findings, overseeing the transition from Salesforce to NetSuite, and driving the launch of Frontage’s AI applications such as chatbot – ALEX, lead management, etc. James holds a PhD in Computer System Control & Automation from McGill University, Montréal, Quebec, Canada, and is an active contributor to industry organizations such as ISPE and DIA.
Dr. John Lin, Co-CEO at Frontage said: “James’s deep expertise in quality and compliance, combined with his vision for digital transformation, has played a critical role in strengthening our global quality systems and ensuring the highest standards across our operations. We are confident that James will continue to drive excellence and innovation in his expanded role.”
Dr. James Huang said, “I am truly honored to be promoted to Senior Vice President of Frontage Lab Global QA and IT Compliance and sincerely grateful for the trust placed in me. I remain committed to advancing quality, integrity, and innovation across our organization.”
About Frontage
Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), is a US based global CRO/CDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.
SOURCE Frontage Laboratories, Inc.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
Notifications
FINANCIAL HIGHLIGHTS 2025 US$ million
2024 US$ million
Change
Revenue
256.7
254.9
0.7%
Gross Profit Gross Profit Margin
69.2 27.0%
69.8 27.4%
(0.9)%
EBITDA EBITDA Margin
54.0 21.1%
50.0 19.6%
8.0%
Adjusted EBITDA Adjusted EBITDA Margin
55.8 21.7%
54.0 21.2%
3.3%
Net Profit Net Profit Margin
6.8 2.6%
0.6 0.2%
1,033.3%
Adjusted Net Profit Adjusted Net Profit Margin
15.7 6.1%
13.2 5.2%
18.9%
US$
US$
Earnings per share
– Basic – Diluted
0.0034 0.0033
0.0004 0.0004
750.0% 725.0%
Adjusted Earnings per share
– Basic – Diluted
0.0078 0.0078
0.0066 0.0066
18.2% 18.2%
The Board does not recommend any payment of final dividend for the Reporting Period.
1
(1)
Calculation of adjusted EBITDA is modified and calculated as EBITDA for the Reporting Period, excluding the share-based compensation expenses, gain or loss arising from financial assets/liabilities measured as fair value through profit or loss, goodwill impairment and expenses in relation to mergers and acquisitions to better reflect the Company’s current business and operations.
(2)
Calculation of adjusted net profit is modified and calculated as net profit for the Reporting Period, excluding the share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, gain or loss arising from financial assets/ liabilities measured as fair value through profit or loss, goodwill impairment and expenses in relation to mergers and acquisitions to better reflect the Company’s current business and operations.
Non-IFRS Measures To supplement the Group’s consolidated financial statements which are presented in accordance with the IFRSs, the Company has provided adjusted net profit, adjusted net profit margin and adjusted basic and diluted earnings per share (excluding the share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, gain or loss arising from financial assets/liabilities measured as fair value through profit or loss, goodwill impairment and expenses in relation to mergers and acquisitions) as additional financial measures, which are not required by, or presented in accordance with, the IFRSs. The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, noncash and/or non-operating items that the Group does not consider indicative of the performance of the Group’s business. However, the presentation of these non-IFRSs financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. The adjusted results should not be viewed on a stand-alone basis or as a substitute for results under IFRSs. The Board of the Company is pleased to announce the consolidated annual results of the Group for the Reporting Period together with comparative figures for the corresponding period in 2024 as set out below:
2
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the year ended December 31, 2025 2025 US$ ’000
2024 US$ ’000
256,691 (187,492)
254,907 (185,096)
69,199 2,777 1,518 (4,300)
69,811 4,300 (195) (5,592)
8
(1,959) (1,491) (1) – (7,655) (39,230) 282 (7,553)
(929) – (120) 314 (8,489) (47,050) 258 (9,564)
9 10
11,587 (4,825)
2,744 (2,125)
Profit for the year
6,762
619
Other comprehensive income Items that may be reclassified subsequently to profit or loss: Exchange differences arising from translation of foreign operations Share of other comprehensive income of associates
4,797 155
(5,749) (98)
4,952
(5,847)
11,714
(5,228)
NOTES 4
Revenue Cost of services Gross profit Other income Other gains and losses, net Research and development expenses (Impairment losses)/reversal of recognized on – trade receivables – goodwill – unbilled revenue – others Selling and marketing expenses Administrative expenses Share of profit of an associate Finance costs
6 7
Profit before tax Income tax expense
Total comprehensive income for the year
3
NOTES Profit/(loss) for the year attributable to: Owners of the Company Non-controlling interests
Total comprehensive income for the year attributable to: Owners of the Company Non-controlling interests
2025 US$ ’000
2024 US$ ’000
6,793 (31)
791 (172)
6,762
619
11,718 (4)
(5,031) (197)
11,714
(5,228)
US$
US$
0.0034
0.0004
0.0033
0.0004
11
Earnings per share – Basic – Diluted
4
CONSOLIDATED STATEMENT OF FINANCIAL POSITION As at December 31, 2025 2025 US$ ’000
2024 US$ ’000
123,331 45,253 187,658 23,205 7,184 10,598
126,423 54,253 187,014 29,984 6,747 7,451
4,813 – 816
2,995 300 693
402,858
415,860
2,979 72,206 20,125 2,845 3,017 695 36,299
2,876 69,091 18,889 – 2,401 385 44,091
138,166
137,733
18,596 27,795 47,497 887 210 8,511
19,294 30,336 51,228 573 210 9,899
103,496
111,540
Net Current Assets
34,670
26,193
Total Assets less Current Liabilities
437,528
442,053
NOTES Non-current Assets Property, plant and equipment Right-of-use assets Goodwill Intangible assets Interest in an associate Deferred tax assets Financial assets at fair value through profit or loss (“FVTPL”) Restricted bank deposits Other long-term deposits
Current Assets Inventories Trade and other receivables and prepayments Unbilled revenue Structured deposits Income tax recoverable Restricted bank deposits Cash and cash equivalents
14
12 13 14 14
Current Liabilities Trade and other payables Advances from customers Bank borrowings Income tax payable Amounts due to shareholders Lease liabilities
15 16 17
5
2025 US$ ’000
2024 US$ ’000
28,181 1,936 15,939 43,426
44,442 1,998 12,548 48,796
89,482
107,784
348,046
334,269
20 (313) 347,079
20 (313) 333,298
Equity attributable to owners of the Company Non-controlling interests
346,786 1,260
333,005 1,264
Total Equity
348,046
334,269
NOTES Non-current Liabilities Bank borrowings Deferred government grant Deferred tax liabilities Lease liabilities
17
Net Assets Capital and Reserves Share capital Treasury shares Reserves
18 19
6
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS For the year ended December 31, 2025 1.
GENERAL INFORMATION Frontage Holdings Corporation (the “Company”) was incorporated in the Cayman Islands as an exempted company with limited liability on April 16, 2018 under the Company Law of the Cayman Islands, and its shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since May 30, 2019 ( “ Listing Date ” ). The immediate holding company of the Company is Hongkong Tigermed Co., Limited (“Hongkong Tigermed”), a company incorporated under the laws of Hong Kong with limited liability. The ultimate holding company of the Company is Hangzhou Tigermed Consulting Co., Ltd. (“Hangzhou Tigermed”), a company established in Hangzhou, the PRC and whose shares have been listed on the ChiNext market of the Shenzhen Stock Exchange and the Main Board of The Stock Exchange. The Company is a holding company. The principal activities of the Company and its subsidiaries (collectively referred to as the “Group”) are to provide laboratory and related services to pharmaceutical and agrochemical companies. The registered office of the Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111 Cayman Islands. The principal place of business in the United States of America (the “USA”) and Hong Kong is 700 Pennsylvania Drive, Exton, PA 19341, USA and Room 1920, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, respectively. The functional currency of the Company and the operating subsidiaries incorporated in the USA is US dollars (“US$”). The functional currency of the PRC operating subsidiaries is Renminbi (“RMB”). The functional currency of the operating subsidiaries incorporated in Canada is Canadian dollars (“CAD”). The functional currency of the operating subsidiary incorporated in Italy is Euro (“EUR”). The reporting currency used for the presentation of the consolidated financial statements is US$, which is the same as the functional currency of the Company.
APPLICATION OF NEW AND AMENDMENTS TO IFRS ACCOUNTING STANDARDS Adoption of amendments to IFRS Accounting Standards – effective January 1, 2025 In the current year, the Group has applied the following amendments to IFRS Accounting Standards issued by the International Accounting Standards Board (the “IASB”) for the first time, which are mandatorily effective for the annual period beginning on or after January 1, 2025 for the preparation of the consolidated financial statements: Amendments to IAS 21
Lack of Exchangeability
The amendments specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity’s financial performance, financial position and cash flows. The amendments did not have a material impact on the Group’s financial statements.
7
MATERIAL ACCOUNTING POLICY INFORMATION The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards issued by the IASB. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) and by the Hong Kong Companies Ordinance. The consolidated financial statements have been prepared on historical cost basis except for certain financial instrument that is measured at fair value at the end of each reporting period, as explained in the accounting policies set out below. Historical cost is generally based on the fair value of the consideration given in exchange for services.
REVENUE The Group’s revenue streams are categorized as follows: –
Drug Discovery Unit, consisting of medicinal chemistry, pharmacology, and efficacy & absorption, distribution, metabolism, and excretion (“ADME”) screening;
–
Drug Development Unit, comprising drug metabolism and pharmacokinetics ( “ DMPK ” ), safety and toxicology, early phase clinical services, as well as a suite of bioequivalence and related services such as pharmacology, medical writing and regulatory support;
–
Pharmaceutical Product Development Unit, encompassing intermediate and active pharmaceutical ingredient ( “ API ” ) synthesis, process and formulation development, and clinical trial material manufacturing;
–
Laboratory Testing Unit is to offer extensive laboratory testing support to clients worldwide involved in drug development. Their services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, chemistry, manufacturing and controls ( “ CMC ” ) analytical testing, and central laboratory services.
The Group had two main divisions: Global Drug Discovery & Development Services and Global Laboratory Services. The Global Drug Discovery & Development Services division aims to provide comprehensive services in the drug discovery and development process. It includes three subunits: (i) the Drug Discovery Unit, (ii) the Drug Development Unit, and (iii) the Pharmaceutical Product Development Unit. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. The consolidation of services allows the Group to respond to client needs more effectively and provide tailored solutions of exceptional quality. By aligning and streamlining operations, the Group can optimize synergies, allocate resources efficiently, and foster innovation and growth across all business units. This strategic realignment sets the foundation for the Group to achieve its goals and sustain growth in the global drug discovery and development services industry.
8
An analysis of the Group’s revenue is as follows:
– Drug discovery – Drug development – Pharmaceutical product development – Laboratory testing
2025 US$ ’000
2024 US$ ’000
25,841 83,989 10,579 136,282
31,225 81,868 9,272 132,542
256,691
254,907
All revenue of the Group listed above are recognized over time as the Group’s performance does not create an asset with an alternative future use since the Group cannot redirect the asset for use on another customer, and the contract terms specify the Group has an enforceable right to payment for performance completed to date. Transaction Price Allocated to Future Performance Obligations IFRS 15 requires that the Group to disclose the aggregate amount of transaction price that is allocated to each performance obligation that has not yet been satisfied as at year-end. The guidance provides certain practical expedients that limit this requirement and, therefore, for the vast majority of contracts, the Group does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which revenue is recognized at the amount to which the Group has the right to invoice for services performed. For the service contracts for which the Group does not recognize revenue at the amount to which the Group has the right to invoice for services performed, management has assessed whether there are any contracts with an original expected length greater than one year. While contracts do occasionally extend beyond one year, the timing of the services performed is contingent upon when the customer provides items for testing, and is not subject to a contractual term. Accordingly, for these contracts management is unable to determine whether the original contract term will exceed one year and has not disclosed the related unsatisfied performance obligations. 5.
SEGMENT INFORMATION Operating segments are determined based on the Group’s internal reports which are submitted to chief executive officer, being the chief operating decision maker (“CODM”) of the Group, for the purpose of performance assessment and resources allocation. This is also the basis upon which the Group is organized and managed. The Group’s consolidated revenue and results are primarily attributable to the markets in the USA, Canada and Europe (together as “North America and Europe”) and the PRC and all of the Group’s consolidated assets and liabilities are either located in North America and Europe or the PRC. No segment assets and liabilities are presented as they were not regularly provided to the CODM for the purpose of performance assessment and resources allocation.
9
The following are the Group’s reportable segments under IFRS 8 “Operating Segments ”: –
North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe;
–
PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC.
Segment revenues and results The following is an analysis of the Group’s revenue by reportable segments.
For the year ended December 31, 2025
Revenue – Drug discovery – Drug development – Pharmaceutical product development – Laboratory testing
Cost of services Other income Other gains and losses, net Research and development expenses Impairment losses recognized on trade receivables, goodwill, unbilled revenue and others Selling and marketing expenses Administrative expenses Share of profit of associates Finance costs Profit before tax
10
North America and Europe US$ ’000
PRC US$ ’000
Total US$ ’000
12,628 65,627 7,071 112,327
13,213 18,362 3,508 23,955
25,841 83,989 10,579 136,282
197,653
59,038
256,691
(141,378) 1,119 711 –
(46,114) 1,658 807 (4,300)
(187,492) 2,777 1,518 (4,300)
(3,293) (5,610) (31,706) – (6,057)
(158) (2,045) (7,524) 282 (1,496)
(3,451) (7,655) (39,230) 282 (7,553)
11,439
148
11,587
For the year ended December 31, 2024
Revenue – Drug discovery – Drug development – Pharmaceutical product development – Laboratory testing
Cost of services Other income Other gains and losses, net Research and development expenses Impairment losses recognized on trade receivables, unbilled revenue and others Selling and marketing expenses Administrative expenses Share of profit of associates Finance costs Profit before tax
North America and Europe US$ ’000
PRC US$ ’000
Total US$ ’000
18,581 66,680 6,168 106,782
12,644 15,188 3,104 25,760
31,225 81,868 9,272 132,542
198,211
56,696
254,907
(140,155) 1,187 749 –
(44,941) 3,113 (944) (5,592)
(185,096) 4,300 (195) (5,592)
(690) (6,494) (38,251) – (7,743)
(45) (1,995) (8,799) 258 (1,821)
(735) (8,489) (47,050) 258 (9,564)
6,814
(4,070)
2,744
The material accounting policies of reportable segments are the same as the Group’s material accounting policies. Other segment information Amounts included in the measure of segment profit or loss:
For the year ended December 31, 2025
Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortization of intangible assets Interest income Gain on disposal of property, plant and equipment Income tax (expense)/credit
11
North America and Europe US$ ’000
PRC US$ ’000
Total US$ ’000
(10,934) (6,156) (6,988) 163 113 (5,370)
(7,808) (2,560) (449) 126 212 545
(18,742) (8,716) (7,437) 289 325 (4,825)
For the year ended December 31, 2024
Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortization of intangible assets Interest income Gain on disposal of property, plant and equipment Income tax (expense)/credit
North America and Europe US$ ’000
PRC US$ ’000
Total US$ ’000
(10,247) (6,418) (8,443) 340 2 (3,652)
(8,421) (3,764) (379) 472 130 1,527
(18,668) (10,182) (8,822) 812 132 (2,125)
Geographical information The Group’s operations and non-current assets are located in North America and Europe, and the PRC. An analysis of the Group’s revenue from external customers, analyzed by the customer’s respective country/ region of operation, is presented below:
Revenue from external customers – USA and Canada – PRC – Rest of the world
2025 US$ ’000
2024 US$ ’000
195,215 46,312 15,164
188,187 45,197 21,523
256,691
254,907
Information about the Group’s non-current assets by geographical location of the assets are presented below:
Non-current assets excluding financial assets and deferred tax assets – North America and Europe – PRC
2025 US$ ’000
2024 US$ ’000
313,015 73,616
322,395 82,026
386,631
404,421
Information about major customers No customers contributed more than 10% of the Group revenue during the year ended December 31, 2025 and 2024.
12
OTHER INCOME
Interest income Government grants related to income Income from rendering service
289 1,601 887
812 658 2,830
2,777
4,300
2025 US$ ’000
2024 US$ ’000
789 – 1,725 325 (1,321)
1,270 (159) (488) 132 (950)
1,518
(195)
2025 US$ ’000
2024 US$ ’000
2,989 4,564
3,119 6,445
7,553
9,564
2025 US$ ’000
2024 US$ ’000
107,136 2,017 7,002
114,566 3,144 7,817
116,155
125,527
547
281
FINANCE COSTS
Interest expense on lease liabilities Interest expense on bank borrowings
2024 US$ ’000
OTHER GAINS AND LOSSES, NET
Net foreign exchange gain Fair value change on financial liabilities measured at FVTPL Fair value change on financial assets measured at FVTPL Gain on disposal of property, plant and equipment Others
2025 US$ ’000
PROFIT BEFORE TAX Profit before tax has been arrived at after charging:
Staff costs (including directors’ emoluments): – Salaries and other benefits – Share-based payment expense – Retirement benefit scheme contributions
Auditors’ remuneration
13
INCOME TAX EXPENSE
Current tax: – PRC Enterprise Income Tax (“EIT”) – US Federal Tax – US State Tax – Canada Corporate Tax Under-provision of EIT, US Federal Tax and US State Tax in prior year
Deferred tax: – Current year Total income tax expense
2025 US$ ’000
2024 US$ ’000
979 800 1,479 971
811 2,359 531 288
317
129
4,546
4,118
279
(1,993)
4,825
2,125
The group entities incorporated in the USA are subject to Federal and State Income taxes, and the effective weighted average income tax rate is 26.41% for the year ended December 31, 2025 (2024: 24.66%). The Tax Cuts and Jobs Act (the “2017 Tax Act”) was signed into law on December 22, 2017. The 2017 Tax Act includes a tax on the mandatory deemed repatriation of accumulated previously untaxed foreign earnings (the “Transition Tax”). The USA group entities are subject to Transition Tax for the years ended December 31, 2025 and December 31, 2024, which is included in the Federal tax expense above. BRI Biopharmaceutical Research, Inc. (“BRI”), a wholly owned subsidiary of the Group, as a non-Canadiancontrolled private corporation (“CCPC”) and engaged in active business in British Columbia, Canada, has been subject a flat tax rate of 27%. Nucro-Technics, Inc. (“Nucro”), a wholly owned subsidiary of the Group, as a non-CCPC and engaged in active business in Ontario, Canada, has been subject an effective corporate tax rate of 26.5%. Under the law of the PRC on Enterprise Income Tax (the “EIT Law”) and Implementation Regulation of the EIT Law, the EIT rate of the PRC subsidiaries is 25% unless subject to tax exemption set out below. Frontage Laboratories (Shanghai) Co., Ltd. (“Frontage Shanghai”), a wholly owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in November 2020 and renewed its status in November 2023, and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2023.
14
Acme Biopharma Co. (Shanghai) Ltd. ( “Acme Shanghai”), a wholly owned subsidiary of the Group in the PRC, was accredited as an “Advanced Technology Enterprise” in December 2022 and renewed its status in December 2025, and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2025. Wuhan Heyan Biomedical Technology Co., Ltd. (“Heyan Biotech”), a 70% owned subsidiary of the Group in the PRC, was accredited as a “High and New Technology Enterprise” in December 2020 and renewed its status in October 2023, and therefore is entitled to a preferential tax rate of 15% for a three-year period commencing from the beginning of 2023. The group entities incorporated in Hong Kong are subject to Hong Kong profits tax at a rate of 16.5% on the estimated assessable profits for the years ended December 31, 2025 and 2024. On March 21, 2018, the Hong Kong Legislative Council passed the Inland Revenue (Amendment) (No. 7) Bill 2017 (the “Bill”) which introduces the two-tiered profits tax rates regime. The Bill was signed into law on March 28, 2018 and was gazette on the following day. Under the two-tiered profits tax rates regime, the first HK$2,000,000 of profits of qualifying corporations will be taxed at 8.25%, and profits above HK$2,000,000 will be taxed at 16.5%. The two-tiered profits tax rates regime is applicable to the Group’s Hong Kong subsidiaries with estimated assessable profits for its annual reporting periods ending on or after April 1, 2018. The group entities incorporated in the Cayman Islands are not subject to income or capital gains tax under the law of the Cayman Islands. No provision for Italy income tax has been made as the Group did not generate any assessable profits in Italy during the years ended December 31, 2025 and 2024. 11.
EARNINGS PER SHARE The calculation of the basic and diluted earnings per share attribute to owners of the Company is based on the following data:
Earnings: Earnings for the purpose of calculating basic and diluted earnings per share
2025 US$ ’000
2024 US$ ’000
6,793
791
2025
2024
2,027,056,628
2,026,464,720
50,755 679,309
794,758 4,151,393
2,027,786,692
2,031,410,871
Number of Shares:
Weighted average number of ordinary shares for the purpose of calculating basic earnings per share Effect of dilutive potential ordinary shares: Share options Share awards Weighted average number of ordinary shares for the purpose of calculating diluted earnings per share
Note: (i)
The weighted average number of ordinary shares shown above has been adjusted for issue of new shares and treasury shares.
15
TRADE AND OTHER RECEIVABLES AND PREPAYMENTS 2025 US$ ’000
2024 US$ ’000
65,882 2,053 (5,402)
63,448 425 (4,045)
62,533
59,828
1,996 (37)
2,570 (37)
1,959
2,533
Notes receivable – third parties
102
88
Prepayments – third parties – related parties
6,018 287
3,755 39
6,305
3,794
1,307
2,848
72,206
69,091
Trade receivables – third parties – related parties Less: loss allowance for trade receivables
Other receivables – third parties Less: loss allowance for other receivables
Value added tax recoverable
The Group allows a credit period ranging from 30 to 90 days to its customers. The following is an aging analysis of trade receivables (net of loss allowance), presented based on the invoice dates, at the end of the reporting period:
Within 90 days 91 to 180 days 181 days to 1 year Over 1 year
16
2025 US$ ’000
2024 US$ ’000
53,727 3,436 2,975 2,395
44,885 8,132 4,270 2,541
62,533
59,828
UNBILLED REVENUE
Unbilled revenue – third parties – related parties Less: loss allowance for unbilled revenue
2025 US$ ’000
2024 US$ ’000
17,286 3,662 (823)
18,604 1,072 (787)
20,125
18,889
Generally, significant payment terms are disclosed within the contents of a given contract and are in the form of either milestone payment terms representing a percentage of the total budgeted contract price or corresponding directly with the value to the customer of the Group’s performance. Revenues recognized in excess of billings are recognized as contract assets and disclosed in the consolidated statement of financial position as unbilled revenue. 14.
CASH AND CASH EQUIVALENTS/RESTRICTED BANK DEPOSITS Cash and cash equivalents comprise of cash held by the Group and short-term bank deposits with an original maturity of three months or less. The bank deposits carry interest at market rates which ranged from 0.02% to 3.5% per annum as at December 31, 2025 (2024: from 0.02% to 4.33% per annum). According to the lease agreement for the property at Secaucus, NJ, a cash deposit of US$300,000 was required as a guarantee over the property. As at December 31, 2025, a cash deposit of US$392,000 (2024: US$381,000) was required by Pennsylvania dept of environmental protection, Bureau of radiation protection in the USA for radiology license in the USA, and the amount is restricted. As at December 31, 2025, the remaining amount in the collateral account was US$392,000 (2024: US$381,000), which has been included in restricted bank deposits. As at December 31, 2025, certain bank deposits with balances of approximately RMB24,000 (equivalent to approximately US$3,000) (2024: RMB26,000 (equivalent to approximately US$4,000)), were pledged to secure bills payable and bank facilities granted to the Group.
17
TRADE AND OTHER PAYABLES
Trade payables – third parties – related parties
Other payables – third parties – related parties
Note payables Salary and bonus payables Other taxes payable
2025 US$ ’000
2024 US$ ’000
8,389 971
8,360 299
9,360
8,659
1,997 –
3,344 11
1,997
3,355
838 5,813 588
– 6,418 862
18,596
19,294
Payment terms with suppliers are mainly on credit ranging from 30 to 90 days from the invoice date. The following is an aging analysis of trade payables, presented based on invoice date, at the end of each reporting period:
Within 90 days 91 days to 1 year Over 1 year
2025 US$ ’000
2024 US$ ’000
9,360 – –
7,878 28 753
9,360
8,659
2025 US$ ’000
2024 US$ ’000
26,371 1,424
29,439 897
27,795
30,336
ADVANCES FROM CUSTOMERS
Advances from customers – third parties – related parties
Amounts received in accordance with contracted payment schedules but in excess of revenues earned are recognized as contract liabilities and disclosed in the consolidated statement of financial position as advances from customers. Changes in advances from customers primarily relate to the Group’s performance of services under the related contract Revenue of US$18,863,000 was recognized in 2025 (2024: US$20,295,000) that were included in the advances from customers at the beginning of the year.
18
BANK BORROWINGS Bank Loans 2025 US$ ’000
2024 US$ ’000
75,678
95,670
2025 US$ ’000
2024 US$ ’000
Within one year and shown under current liabilities More than one year, but not exceeding two years More than two years, but not exceeding five years
47,497 19,522 8,659
51,228 14,192 30,250
Less: Amounts shown under current liabilities
75,678 (47,497)
95,670 (51,228)
Amounts shown under non-current liabilities
28,181
44,442
2.65% – 6.09%
2.75% – 6.73%
Secured and unguaranteed bank loans
Loan interest at rate per annum in the range of Bank Facilities
The Group has aggregated banking facilities of RMB622,174,000 (equivalent to US$88,518,000) (2024: RMB510,000,000 (equivalent to US$70,948,000)), of which RMB211,061,000 (equivalent to approximately US$30,028,000) (2024: RMB177,344,000 (equivalent to approximately US$24,670,000)) was utilized as borrowings as at December 31, 2025. On May 31, 2022, Frontage Labs, one of the subsidiaries of the Company, entered into a three-year committed senior secured revolving credit agreement with a bank. On July 28, 2023 the bank has agreed to extend to Frontage Labs a revolving line of credit in the maximum principal amount of US$54,000,000 and extend the maturity date to four years from the loan commencement date. As at December 31, 2025, US$20,500,000 (2024: US$35,000,000) of the facility were utilized as borrowings. Frontage Labs is obligated to grant to the bank security interest in and to the collateral of some of its designated subsidiaries in the U.S. On July 22, 2022, Frontage Labs entered into a credit agreement with a bank under which the bank has agreed to provide Frontage Labs a non-revolving term loan facility in an aggregate principal amount of US$49,000,000. As at December 31, 2025, US$25,150,000 (2024: US$36,000,000) of the facility were utilized as borrowings. The Company, as the guarantor, is obligated to guarantee for the liabilities, obligations and the full satisfaction of Frontage Labs under this facility. This facility is collateralized by Frontage Labs’ assets in some of its designated subsidiaries in the U.S. The Group had aggregated revolving banking facilities of RMB362,275,000 (equivalent to approximately US$51,541,000) (2024: RMB304,436,000 (equivalent to approximately US$42,351,000)) and US$33,500,000 (2024: US$19,000,000) which were unutilized as at December 31, 2025.
19
SHARE CAPITAL Number of shares
Amount US$
Ordinary shares of US$0.00001 each Authorized: As at January 1, 2024, December 31, 2024, January 1, 2025 and December 31, 2025
5,000,000,000
50,000
Amount US$
Shown in the consolidated financial statements as US$ ’000
Number of shares Issued and Fully Paid: As at January 1, 2024 Exercise of share options (note (a)) Cancellation of shares (note (b))
2,062,645,910 36,179,000 (63,100,000)
20,628 362 (631)
21 – (1)
As at December 31, 2024, January 1, 2025 and December 31, 2025
2,035,724,910
20,359
20
Notes:
(a)
During the year ended December 31, 2025, no (2024: 36,179,000) share options was exercised, with a deduction from equity-settled share based compensation reserve of US$nil (2024: US$2,312,000) and an increase of US$nil (2024: US$9,530,000) in share premium.
(b)
During the year ended December 31, 2024, the Company cancelled 63,100,000 shares with a deduction from the treasury shares of US$15,122,000, including a reduction of US$1,000 in share capital, and US$15,121,000 in share premium. The Company did not cancel any shares during the year ended December 31, 2025.
TREASURY SHARES 2025 Number of Cost of shares acquisition US$ ’000
2024 Number of Cost of shares acquisition US$ ’000
At beginning of year Repurchase of shares Cancellation of shares Vesting of share awards
12,084,002 – – (4,087,564)
313 – – –
28,741,064 50,788,000 (63,100,000) (4,345,062)
4,232 11,203 (15,122) –
At end of year
7,996,438
313
12,084,002
313
20
EVENT AFTER THE REPORTING PERIOD On October 10, 2025, Frontage Shanghai, a wholly-owned subsidiary of the Company (as purchaser), Hangzhou Tigermed (as vendor in respect of Sale Shares I) and Jiaxing Xinge, a wholly-owned subsidiary of Hangzhou Tigermed (as vendor in respect of Sale Shares II), entered into the Share Transfer Agreement, pursuant to which Frontage Shanghai has conditionally agreed to acquire, and each of Hangzhou Tigermed and Jiaxing Xinge has conditionally agreed to sell the sale Shares, representing the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd. (the “Target Company”) upon completion of the repurchase and capital reduction, at the total cash consideration of RMB270,000,000 (equivalent to US$38,413,000). The acquisition was completed on March 3, 2026. Immediately following the completion of acquisition, the Target Company has become a wholly-owned subsidiary of the Company and the financial results of the Target Company and its subsidiaries will be consolidated into the financial statements of the Group. For details of the acquisition, please refer to the announcement of the Company dated October 10, 2025,January 7, 2026 and March 3, 2026 and the circular of the Company dated December 15, 2025. Given the completion was close to the date of this announcement, it is not practicable to provide an estimate of financial effect of the above acquisition until the Group has a detailed review.
21
MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS REVIEW Overview Frontage is a globally integrated, science-driven CRO delivering high-quality research and development services to the pharmaceutical, biotechnology, chemical, and life sciences industries. With a commitment to scientific excellence and customer-centric solutions, Frontage offers comprehensive services from drug discovery to clinical trials. Our services are designed to help biopharmaceutical companies accelerate their product development and achieve their goals with efficiency and precision. Additionally, we support academic institutions and start-up companies in discovering and developing new therapeutics for human health. In 2025, the biopharmaceutical industry navigated a complex operating environment. Geopolitical tensions, pricing pressures, evolving regulatory expectations, and heightened scrutiny from sponsors and governments, each factor influenced development strategies and commercialization plans. In 2025, Frontage continued to enhance its research and development capabilities. With its two core service divisions, Global Drug Discovery & Development Services and Global Laboratory Services, Frontage has refined its operational structure to offer more comprehensive and integrated solutions. The Global Drug Discovery & Development Services division continued to expand and strengthen its offerings in discovery chemistry, biology, pharmacology, DMPK, Safety & Toxicology, CMC & Contract Research, Development, and Manufacturing Organization (“CRDMO”) services, and the Global Laboratory Services continued to enhance its technical capabilities, expand service capacity across bioanalysis, central lab services, genomics, biologics, and biomarker diagnostics. Artificial intelligence ( “AI”) is becoming increasingly important across all aspects of society including the biopharmaceutical industry. In response, Frontage established a dedicated AI applications team to enhance both commercial and laboratory operations. By supporting key activities such as client engagement, quotation process, project management, as well as quality control (“QC”) and quality assurance (“QA”) reportings, this AI initiative has greatly improved operational visibility and established a strong foundation for Frontage to compete with industry peers in an increasingly AI-driven future. Overall, the Group’s revenue increased by 0.7% from approximately US$254.9 million for the year ended December 31, 2024 to approximately US$256.7 million for the year ended December 31, 2025. Additionally, the Group’s contract future revenue, which represents future service revenues from work not yet completed or performed under all signed contracts or customer’s purchase orders in effect at that time, achieved approximately US$433.7 million as at December 31, 2025, representing an increase of 11.0% compared to approximately US$390.6 million as at December 31, 2024.
22
ENHANCED CAPABILITIES AND EXPERTISE We firmly believe that aspiring to excel in the CRO industry requires a steadfast commitment to continuously enhancing our service capabilities, regardless of macro-environmental fluctuations. During the Reporting Period, we continued to enhance our capabilities and expertise in each of our service unit through organic growth and strategic acquisitions in order to provide more comprehensive and high-quality services for our customers on a global scale. North America and Europe The CRO services market size was valued at US$92.27 billion in 2025, with the North American market holding a dominating market share of 50.10%.1 Europe is expected to be the second-largest region in the market with a value of US$25.77 billion in 2026 and is estimated to hold a CAGR of 8.3% during the forecast period.2 Headquartered in Exton, Pennsylvania with a presence in Europe, Frontage continues to strengthen its presence in these two key markets. Through the delivery of comprehensive and integrated “one-stop shop” solutions, Frontage has achieved strong market recognition and consistently provided high-value services that address the evolving needs of clients in North America and Europe. In May 2025, we officially opened a new 46,300-square-foot CRDMO facility, in Exton, Pennsylvania. This state-of-the-art facility features nine (9) Good Manufacturing Practice (“GMP”) suites including two (2) high-potent suites, two (2) aseptic suites, and five (5) non-sterile suites, supporting manufacturing for injectables, tablets, capsules, creams, gels, ointments, ophthalmic and nasal preparations. This new facility also houses two (2) formulation development labs, and three (3) analytical labs including a micro lab. This new site had completed GMP facility validation in October 2025, and has been fully operational with ongoing Clinical Phase III, Process Performance Qualification (“PPQ”) batches and small-scale commercial manufacturing. This expansion significantly enhances Frontage’s manufacturing capabilities and strengthens our position as a full-service drug development partner. In parallel, we also completed the relocation of our chemistry services from the site in Palo Alto, California to Exton, Pennsylvania as part of our ongoing efforts to optimize operational efficiency and resource allocation across the organization.
1 2
https://www.fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-100864 https://www.fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-100864
23
In 2025, we established a dedicated AI applications team to enhance both commercial and laboratory operations, supporting client interactions, Requests for Information ( “ RFIs ” ), lead management, quotations, improvement of the QC and QA reportings, and project timeline management, laying the foundation for future AI-driven analytics and operational efficiencies. Frontage’s two core business divisions: Global Drug Discovery & Development Services and Global Laboratory Services have further integrated resources across the United States, Canada, and Europe in 2025. These coordinated efforts supported stable and sustained progress across the North American and European markets and positioned the Company for continued momentum during the Reporting Period. •
Global Drug Discovery & Development Services During the Reporting Period, our Global Drug Discovery & Development Services division continued to expand and strengthen our offerings in discovery chemistry, biology, pharmacology and DMPK services, including IND-enabling studies and C-14 radiolabeled human absorption, metabolism and excretion studies. During the Reporting Period, we continued to enhance our Product Development and Manufacturing ( “ PDM ” ) capabilities through targeted investments in industry-leading equipment for mixing and filling operations, supporting expanded product manufacturing activities. We leveraged our established analytical laboratories to provide comprehensive testing services, including extractables and leachables, nitrosamine analysis, and specialized in-vitro analytical techniques, strengthening our integrated CMC support offering. During the Reporting Period, we established manufacturing capabilities to support Phase III clinical trial materials, with a focus on sterile ophthalmic injections and oral solid dosage forms. These capabilities are intended to support late-stage development programs and advance client projects toward New Drug Application (“ NDA ” ) submission, further reinforcing Frontage’s position as an end-to-end partner across the clinical development and regulatory lifecycle. We have also established an approximately 800-square-foot manufacturing laboratory at our headquarter in Exton, Pennsylvania to support U.S.-based demand for active pharmaceutical ingredients ( “ APIs ” ) production. This new laboratory is currently undergoing GMP certification and is expected to be operational in early Q2 of 2026. During the Reporting Period, our Chicago, Illinois site successfully launched new service platforms, including mass radiolabeled balance studies for multiple species, enhanced analytical methods for radioactive compounds, and specialized dietary study capabilities, along with upgraded data management systems to improve study efficiency and regulatory compliance. At our Concord, Ohio site, we established comprehensive electrophysiology laboratory capabilities with validated assays for safety pharmacology testing and expanded genetic toxicology offerings with new validated assays and enhanced our non-human primate capabilities through specialized equipment and colony establishment.
24
•
Global Laboratory Services During the Reporting Period, the Global Laboratory Services continued to enhance its technical capabilities, expand service capacity across bioanalysis, central lab services, genomics, biologics, and biomarker diagnostics. During the Reporting Period, the Global Laboratory Services advanced its laboratory digital transformation by implementing a fully paperless ecosystem, leveraging tools such as IDBS ELN, Integrated Electronic Binder System (“IEBS”), Watson LIMS, and StudyDoc automated reporting tool, and establishes a strong foundation for AI-driven applications. This digital framework strengthens compliance through robust audit trails and version control, accelerates reporting timelines, and enables seamless global collaboration with sponsors. During the Reporting Period, the Global Laboratory Services built organoid research platforms to offer comprehensive organoid-based services to pharmaceutical companies, academic institutions, and hospitals. These services include the commercialization of organoid models and biobanks for drug screening, bioanalytical assays, and detailed organoid characterization using techniques such as immunohistochemistry ( “ IHC ” ), immunofluorescence (IF), flow cytometry, RNA sequencing ( “RNA-Seq ”), whole exome sequencing (“WES”), and single-cell RNA sequencing (“scRNA-seq”). During the Reporting Period, Frontage Europe, S.r.l. located in Milan, Italy expanded its capabilities to include biologics bioassay and biomarker services and also expanded our central lab services capabilities in the third quarter of 2025, and successfully achieved GLP and GCP certifications in 2025. Alongside our expanded and enhanced services, 2025 was marked by exceptional performances in quality and regulatory compliance across our operations in North America and Europe. Our facilities across the United States, Canada, and Europe (Italy) all successfully completed regulatory inspections by U.S. FDA, U.S. Drug Enforcement Administration (“DEA”), and other government authorities. We also achieved recertification of the ISO/IEC Information Security Management System across multiple sites and successfully obtained EU-US Data Privacy Framework certifications, reinforcing our commitment to operational integrity, data security, and regulatory excellence.
25
China China’s role in the global biopharmaceutical sector has grown significantly in recent years. It is the world’s largest supplier of APIs. In the first quarter of 2025 alone, Chinese companies accounted for 32% of global biotech licensing deal value versus 21% in both 2023 and 2024, according to a July report from New York investment firm, Jefferies Group LLC.3 While geopolitical uncertainty and evolving cross-border regulatory policies continue to shape how companies collaborate globally, China remains an important driver of innovation, manufacturing capacity, and deal activity in the biopharmaceutical industry. Frontage has been actively operating in China for more than two decades, building strong and unparalleled local presence and experience. In 2025, our operations in China demonstrated significant progress across multiple service lines while maintaining comprehensive capabilities spanning drug discovery, preclinical research, and clinical development. •
Global Drug Discovery & Development Services During the Reporting Period, we continued to strengthen our established capabilities across chemistry, DMPK, pharmacology, CMC, and Safety & Toxicology. To support nucleic acid-based drug discovery, we launched new chemistry services for oligonucleotides and further expanded our services in vitro and in vivo platforms for siRNA and other oligonucleotide modalities. During the Reporting Period, we conducted non-human primate (“NHP”) studies for in vivo CAR-T programs. In addition, we developed and manufactured placebo formulations for Traditional Chinese Medicines (“TCM”). During the Reporting Period, we expanded our CMC capabilities to include comprehensive ophthalmic GMP manufacturing for both liquid and suspension products. The new production lines incorporate advanced technologies including high-shear mixing systems, blow-fill-seal capabilities, and integrated quality control systems. Our CMC group achieved key regulatory milestones, receiving the China Manufacturing License in July 2025, and obtained CNAS certification issued in August 2025.
3
https://www.ddw-online.com/is-china-the-next-global-biopharma-powerhouse-38210-202510/
26
The Chemistry team introduced advanced continuous flow platforms to support specialized process development, enhancing our capabilities in complex chemical synthesis. In parallel, the Process Scale-Up Hub in Wuhan underwent major expansion, more than doubling its laboratory space and increasing capacity with new kilo-scale facilities and upgraded purification capabilities. During the Reporting Period, the Clinical Services expanded capabilities in complex formulation products, gaining extensive experience across diverse dosage forms including advanced delivery systems and biosimilars. The Clinical Services unit successfully managed multicenter bioequivalence studies in both healthy volunteers and patient populations across various therapeutic areas, demonstrating our capability to handle sophisticated clinical programs. •
Global Laboratory Services During the Reporting Period, the Global Laboratory Services advanced its bioanalytical capabilities by developing an integrated platform that combines small molecule and large molecule analysis within a unified workflow. This integrated system enhances operational efficiency and accelerates timelines for pharmacokinetic, immunogenicity, and biomarker studies across diverse therapeutic modalities including antibody-drug conjugates, peptide-drug conjugates, and mRNA vaccines. During the Reporting Period, the Global Laboratory Services launched a real-time quality control dashboard to track assay performance metrics and turnaround times. This tool enables early identification of potential issues, improves data quality oversight, and has increased overall operational efficiency by 25%. During the Reporting Period, to support the growing demand for biomarker discovery and validation in precision medicine, the Global Laboratory Services implemented the Alamar NULISA HT-Argo platform. This high-throughput technology expands our biomarker assay capabilities and enables more comprehensive biomarker profiling to meet growing project demand in 2025.
27
THE GROUP’S FACILITIES As of December 31, 2025, the Group had thirteen (13) facilities in North America and Europe, consisting of: •
four (4) facilities in Exton, PA, USA;
•
two (2) facilities in Hayward, CA, USA;
•
one (1) facility in Secaucus, NJ, USA;
•
one (1) facility in Concord, OH, USA;
•
one (1) facility in Deerfield, FL, USA;
•
one (1) facility in Chicago, IL, USA;
•
one (1) facility in Vancouver, Canada;
•
one (1) facility in Toronto, Canada; and
•
one (1) facility in Milan, Italy.
In addition, as of December 31, 2025, the Group had ten (10) facilities in China, consisting of: •
four (4) facilities in Shanghai;
•
three (3) facilities in Suzhou, Jiangsu Province;
•
one (1) facility in Zhengzhou, Henan Province; and
•
two (2) facilities in Wuhan, Hubei Province.
QUALITY ASSURANCE The Group’s quality compliance programs are managed by a dedicated group responsible for quality compliance. Our independent quality units have overseen and also implemented the quality management systems, including global computer system validation. Within each regulated business segment, we have established quality assurance units responsible for risk-based internal audit programs to manage regulatory requirements and customer expectations. The quality assurance units operate independently from those individuals that direct and conduct studies, manufacturing or analytical testing. Our quality assurance team works closely with study teams to ensure compliance with protocols, Standard Operating Procedures (“SOPs”) and regulatory guidelines to ultimately protect research subject safety as well as the integrity and validity of study data. Our quality assurance team also provides services including regulatory training, internal system audits, SOP oversight, hosting of client audits and regulatory inspections, as well as performs third party audits of critical vendors and investigative sites on behalf of our customers.
28
Virtually all facets of the Group’s service offerings are subject to quality programs and procedures, including accuracy and reproducibility of tests, turnaround time, customer service, and data integrity. This includes licensing, credentialing, training and competency of professional and technical staff, and internal auditing. In addition to the Group’s internal quality programs, our laboratories, facilities, and processes are subject to on-site regulatory agency inspections and accreditation evaluations, as applicable, by local or national government agencies, and inspections and audits by customers and vendors. During the Reporting Period, our facilities in the U.S. and Canada were inspected by the FDA, DEA (Drug Enforcement Administration), CNSC (Canadian Nuclear Safety Commission; for radiation safety), PHAC (Public Health Agency of Canada; for biosafety), Clinical Laboratory Improvement Amendments/The College of American Pathologists (CLIA/CAP), DOH (Department of Health), AAALAC and USDA (United States Department of Agriculture) and none of the inspections resulted in any materially adverse issues being identified. Our facilities in China were also inspected by the NMPA and none of the inspections resulted in any materially adverse issues being identified. Frontage Labs has deployed ZenQMS solution to manage all quality system, SOP, Training, Quality Assurance KPI to ensure all business operations operate under the same quality and compliance standards. INFORMATION TECHNOLOGY The Group has implemented a wide area network (SDWAN) to connect all sites in North America and Europe into a unified network. Frontage Lab China established its own separate SDWAN network, distinct from the global Frontage SDWAN in order to comply with data security and privacy regulations in both China and the United States, including GDPR (General Data Protection Regulation). During the Reporting Period, Frontage successfully obtained ISO 27001 certification for data security. Additionally, Frontage has deployed the NetSuite and Salesforce systems for project management, providing comprehensive transparency in financial reporting, cost control, procurement, and risk monitoring. Animal Welfare We focus on animal welfare issues in our business operations and are committed to following strict procedures in upholding animal rights. According to the Guide of the Care and Use of Laboratory Animals and all relevant laws and regulations, we implement our SOPs and quality animal care program to treat animals humanely. As responsible researchers, we have established plans and procedures on the living environment, animal facility control, back-up veterinary care plan, transferal, and termination/euthanasia procedures. We regularly monitor animal conditions and assess the adequacy of our existing protocols, as well as keeping abreast of recent scientific developments in this area. Training and education are also provided to the responsible people for carrying out their duties. During the Reporting Period, we did not receive any non-compliance reports from the USDA and FDA.
29
Business Development Our global business development team supports global commercial activities by creating relationships with prospective customers and growing relationships with our existing customers. We rely heavily on our past project performance, experienced teams, and new capabilities, in securing and developing new business opportunities. Our business development representatives collaborate closely with our seasoned scientific experts and operational leaders from the beginning of the sales process to ensure proposals meet customers’ needs in a strategic and solution-based manner. Our business development personnel work with our clients throughout the life of the project by partnering with project managers and strategic alliance executives to optimize timely completion of the projects and foster long-term relationships with the customers. The specific role of the business development team is to grow the business across all service areas across the entire continuum of drug development. Our global business development team is strategically located across the United States, China, and Canada and is responsible for managing all accounts within their geographical territory. In addition to significant client engagement and key account development experience, many of our project managers possess advanced scientific and technical degrees to support our customers’ complex product development endeavors and challenges within various market segments (global biopharmaceutical, small and mid-sized pharmaceutical and biotechnology companies, and academic and government institutions). This enhances our ability to meet client needs by offering customized solutions across our entire portfolio ranging from discovery services to late phase clinical trial management specifically through the application of central laboratory and early phase clinical services. Marketing The marketing team is focused on building global brand awareness, trust and driving deeper client engagement through demand generation initiatives. The marketing team leverages several key channels to include digital marketing, conferences and events, and high-profile publications. Potential customers are directed to our website where they can access a wide range of scientific content including whitepapers, video material, webinars, case studies, scientific posters, and other resources. Our core marketing initiatives focus on driving long-term client engagement and stimulating demand for our entire services portfolio. We believe that our ability to provide comprehensive solutions addressing all aspects of our customers’ research and development needs are increasingly attractive. As a result, we continue to market our ability to provide clients with scientific expertise, complex solutions that meet high quality standards.
30
SIGNIFICANT INVESTMENTS HELD, MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES Acquisitions of Teddy Labs In October 2025, Frontage Shanghai, a wholly-owned subsidiary of the Company, entered into a share transfer agreement (the “Share Transfer Agreement”) with Hangzhou Tigermed and Jiaxing Xinge to acquire 45,169,326 shares representing 100% of the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd. (“Teddy Lab”) at the total consideration of RMB270 million upon completion of a repurchase and capital reduction by the Teddy Lab (the “Acquisition”). The Acquisition constitutes (i) a major transaction under Chapter 14 of the Listing Rules as the highest applicable percentage ratio exceeds 25% but is less than 100%; and (ii) a connected transaction under Chapter 14A of the Listing Rules as Hangzhou Tigermed is the controlling shareholder of the Company and the highest applicable percentage ratio exceeds 5%, and was subject to the reporting, disclosure and shareholder approval requirements under the Listing Rules. For details, please refer to the announcement of the Company dated October 10, 2025 and the circular of the Company dated December 15, 2025. Save as disclosed above, there were no significant investments held, no material acquisitions or disposals of subsidiaries, affiliates and joint ventures of the Company during the year ended December 31, 2025. Events After the Reporting Period On January 7, 2026, an extraordinary general meeting of the Company was held at which the independent shareholders approved the Share Transfer Agreement and the Acquisition. On March 3, 2026, all the conditions precedent as set out in the Share Transfer Agreement have been satisfied and the Acquisition was completed. Following the completion, Teddy Lab has become a wholly-owned subsidiary of the Company and the financial results of Teddy Lab and its subsidiaries will be consolidated into the financial statements of the Group. Save as disclosed above, the Board is not aware of any significant events affecting the Group, which have occurred subsequent to December 31, 2025 and up to the date of this announcement. Prospects Looking ahead, Frontage is well positioned to navigate a dynamic global biopharmaceutical landscape. We provide comprehensive, integrated “one-stop-shop” solutions across North America, Europe, and China, supported by decades of experience in biopharmaceutical development. We are strategically focused on expanding our capacity to meet rising study volumes and the increasing complexity of therapeutic programs. At the same time, we are also investing in digital transformation initiatives, including AI, to strengthen data consistency and drive operational efficiency.
31
As we move into 2026, Frontage is committed to driving innovation and quality, leveraging advanced technologies like AI, and building the capabilities and expertise to continue to meet the evolving needs of the biopharmaceutical industry. FINANCIAL REVIEW Revenue The revenue of the Group increased by 0.7% from approximately US$254.9 million for the year ended December 31, 2024 to approximately US$256.7 million for the year ended December 31, 2025. Revenue from operations in North America and Europe decreased by 0.3% from approximately US$198.2 million for the year ended December 31, 2024 to approximately US$197.7 million for the year ended December 31, 2025. Excluding the impact of currency translation, the revenue from operations in China increased by 4.4% from approximately RMB403.5 million (equivalent to approximately US$56.7 million) for the year ended December 31, 2024 to approximately RMB421.2 million (equivalent to approximately US$59.0 million) for the year ended December 31, 2025. The slightly decrease in revenue from operations in North America and Europe was mainly attributable to the decline in revenue generated from drug discovery businesses. This decline was negatively affected by the pharmaceutical and biotechnology companies remained focused on optimizing research and development portfolios and exercising prudent control over development spending. However, it was partially offset by the fairly strong demand for laboratory testing services. The growth of revenue from operations in China was mainly attributable to improvement of capacity utilization and marketing efforts made by the Group.
32
The following table sets forth a breakdown of our revenue by type of service during the Reporting Period: For the year ended December 31, 2025 2024 US$ ’000 US$ ’000 Drug discovery Drug development Pharmaceutical product development Laboratory testing
25,841 83,989 10,579 136,282
31,225 81,868 9,272 132,542
256,691
254,907
An analysis of the Group’s revenue from external customers, analyzed by the customer ’s respective country/region of operation, is presented below: For the year ended December 31, 2025 2024 US$ ’000 % US$ ’000
%
Revenue – USA and Canada – China – Rest of the world(Note)
195,215 46,312 15,164
76.1 18.0 5.9
188,187 45,197 21,523
73.9 17.7 8.4
Total
256,691
100.0
254,907
100.0
Note: Rest of the world primarily includes Europe, India, Japan, South Korea and Australia.
Top 5 customers’ revenue increased by 15.3% from approximately US$37.2 million for the year ended December 31, 2024 to approximately US$42.9 million for the year ended December 31, 2025, accounting for 16.7% of total revenue for the year ended December 31, 2025 as compared to 14.6% for the year ended December 31, 2024. Top 10 customers’ revenue increased by 8.8% from approximately US$52.5 million for the year ended December 31, 2024 to approximately US$57.1 million for the year ended December 31, 2025, accounting for 22.3% of total revenue for the year ended December 31, 2025, as compared to 20.6% for the year ended December 31, 2024.
33
Cost of Services The cost of services of the Group increased by 1.3% from approximately US$185.1 million for the year ended December 31, 2024 to approximately US$187.5 million for the year ended December 31, 2025. The increase in the cost of services was in line with the increased revenue. The cost of services of the Group consists of direct labor costs, cost of raw materials and overhead. Direct labor costs primarily consist of salaries, bonuses and social security costs for the employees in the Group’s business units. Cost of raw materials primarily consists of costs incurred for the purchase of raw materials used in rendering of our services. Overheads primarily consist of depreciation charges of the facilities and equipment used in rendering the Group’s services, utilities and maintenance. Gross Profit and Gross Profit Margin The gross profit of the Group decreased by 0.9% from approximately US$69.8 million for the year ended December 31, 2024 to approximately US$69.2 million for the year ended December 31, 2025. The Group’s gross profit margin decreased from approximately 27.4% for the year ended December 31, 2024 to approximately 27.0% for the year ended December 31, 2025. In particular, gross profit margin in North America and Europe decreased from approximately 29.3% for the year ended December 31, 2024 to approximately 28.5% for the year ended December 31, 2025, which was primarily due to the decline in revenue generated from drug discovery business. Gross profit margin in China increased from approximately 20.7% for the year ended December 31, 2024 to approximately 21.9% for the year ended December 31, 2025, mainly due to the decrease of cost driven by the improvement in capacity utilization. Other Income The Group’s other income decreased by 34.9% from approximately US$4.3 million for the year ended December 31, 2024 to approximately US$2.8 million for the year ended December 31, 2025, primarily due to a decreased income from rendering service. Other Gains and Losses, Net The Group’s net other gains and losses changed from approximately US$0.2 million of loss for the year ended December 31, 2024 to approximately US$1.5 million of gain for the year ended December 31, 2025, primarily due to the gain from fair value change on financial assets measured at FVTPL. Selling and Marketing Expenses Selling and marketing expenses of the Group decreased by 9.4% from approximately US$8.5 million for the year ended December 31, 2024 to approximately US$7.7 million for the year ended December 31, 2025, as a result of cost driven by the improvement in efficiency.
34
Administrative Expenses The Group’s administrative expenses decreased by 16.8% from approximately US$47.1 million for the year ended December 31, 2024 to approximately US$39.2 million for the year ended December 31, 2025. Excluding share-based compensation expense and amortization of intangible assets acquired from mergers and acquisitions and expenses in relation to mergers and acquisitions, the Group’s administrative expenses decreased by 14.2% from approximately US$35.1 million for the year ended December 31, 2024 to approximately US$30.1 million for the year ended December 31, 2025, primarily due to the decrease in labor cost and improvement of efficiency. Research and Development Expenses Our research and development activities mainly focused on (i) developing technologies and methodologies to continue to enhance our services; and (ii) improving the quality and efficiency of our services. The Group’s research and development expenses decreased by 23.2% from approximately US$5.6 million for the year ended December 31, 2024 to approximately US$4.3 million for the year ended December 31, 2025, primarily due to the implementation of cost reduction and efficiency improvement measures to enhance research and development efficiency and reduce costs. Finance Costs The Group’s finance costs decreased by 20.8% from approximately US$9.6 million for the year ended December 31, 2024 to approximately US$7.6 million for the year ended December 31, 2025, primarily due to the repayment of bank borrowings. Income Tax Expense The income tax expense of the Group increased by 128.6% from approximately US$2.1 million for the year ended December 31, 2024 to approximately US$4.8 million for the year ended December 31, 2025, primarily due to an increase in pretax income. Net Profit and Net Profit Margin The Group recorded net profit of approximately US$6.8 million for the year ended December 31, 2025, as compared to net profit of approximately US$0.6 million for the year ended December 31, 2024. The Group recorded net profit margin of 2.6% for the year ended December 31, 2025, as compared to net profit margin of 0.2% for the year ended December 31, 2024. The higher net profit and net profit margin compared to the year ended December 31, 2024 was mainly attributable to the implementation of cost reduction and efficiency improvement measures to enhance efficiency.
35
Adjusted Net Profit The following table presents a reconciliation of adjusted net profit to the net profit for the periods, the most directly comparable IFRS measure, for each of the periods indicated: For the year ended ended December 31, 2025 2024 US$ ’000 US$ ’000 Net Profit
6,762
619
Add: Share – based compensation expense Amortization of acquired intangible assets from mergers and acquisitions Loss arising from financial liabilities measured as fair value through profit or loss (Gain)/Loss arising on financial assets measured as fair value through profit or loss Goodwill impairment Expenses in relation to mergers and acquisitions
2,017
3,144
7,150
8,581
–
159
(1,725) 1,491 3
488 – 252
Adjusted Net Profit
15,698
13,243
Adjusted Net Profit Margin
6.1%
5.2%
The adjusted net profit of the Group increased by 18.9% from approximately US$13.2 million for the year ended December 31, 2024 to approximately US$15.7 million for the year ended December 31, 2025. The adjusted net profit margin of the Group for the year ended December 31, 2025 was 6.1%, compared to 5.2% for the year ended December 31, 2024. The higher adjusted net profit and adjusted net profit margin of the Group for the year ended December 31, 2025 was primarily due to a higher net profit and net profit margin as discussed above.
36
EBITDA The EBITDA4 of the Group increased by 8.0% from approximately US$50.0 million for the year ended December 31, 2024 to approximately US$54.0 million for the year ended December 31, 2025. The EBITDA margin of the Group for the year ended December 31, 2025 was 21.1%, compared to 19.6% for the year ended December 31, 2024. The increase of EBITDA is in line with the net profit which had been discussed above. Adjusted EBITDA The adjusted EBITDA5 of the Group increased by 3.3% from approximately US$54.0 million for the year ended December 31, 2024 to approximately US$55.8 million for the year ended December 31, 2025. The adjusted EBITDA margin of the Group increased from 21.2% for the year ended December 31, 2024 to 21.7% for the year ended December 31, 2025. The increase of adjusted EBITDA is in line with the EBITDA which had been discussed above. Basic and Diluted Earnings Per Share The basic earnings per share of the Group increased from US$0.0004 for the year ended December 31, 2024 to US$0.0034 for the year ended December 31, 2025. The diluted earnings per share of the Group increased from US$0.0004 for the year ended December 31, 2024 to US$0.0033 for the year ended December 31, 2025. The increase in the basic and diluted earnings per share was primarily due to the increase in the net profit as discussed above. The adjusted basic earnings per share for the year ended December 31, 2025 amounted to US$0.0078, representing an increase of 18.2% as compared with that of US$0.0066 for the year ended December 31, 2024. The adjusted diluted earnings per share of the Group for the year ended December 31, 2025 amounted to US$0.0078 when compared with that of US$0.0066 for the year ended December 31, 2024. The increase in both the adjusted basic and the adjusted diluted earnings per share was primarily due to the increase in the adjusted net profit as discussed above.
4
5
EBITDA represents net profit before (i) interest expenses; (ii) income tax expenses; and (iii) amortization and depreciation. Calculation of adjusted EBITDA is modified and calculated as EBITDA for the Reporting Period, excluding the share-based compensation expenses, gain or loss arising from financial liabilities measured as fair value through profit or loss, gain or loss arising from financial assets measured as fair value through profit or loss, goodwill impairment and expenses in relation to mergers and acquisitions to better reflect the Company ’s current business and operations.
37
Non-IFRS Measures To supplement the Group’s consolidated financial statements which are presented in accordance with the IFRS, the Company has provided adjusted net profit, adjusted net profit margin, and adjusted basic and diluted earnings per share (excluding the share-based compensation expenses, amortization of acquired intangible assets from mergers and acquisitions, gain or loss arising from financial liabilities measured as fair value through profit or loss, gain or loss arising from financial assets measured as fair value through profit or loss, goodwill impairment and expenses in relation to mergers and acquisitions) as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that the adjusted financial measures are useful for understanding and assessing underlying business performance and operating trends, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non – operating items that the Group does not consider indicative of the performance of the Group’s business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. The adjusted results should not be viewed on a stand-alone basis or as a substitute for results under IFRS. Right-of-Use Assets The Group recorded approximately US$45.3 million right-of-use assets as at December 31, 2025, which decreased by 16.6% from approximately US$54.3 million as at December 31, 2024. The decrease was mainly due to the depreciation charges of existing leases. Intangible Assets The Group recorded approximately US$23.2 million intangible assets as at December 31, 2025, which decreased by 22.7% from approximately US$30.0 million as at December 31, 2024. The decrease was mainly due to the amortization. Trade and Other Receivables and Prepayment The trade and other receivables and prepayment of the Group increased by 4.5% from approximately US$69.1 million as at December 31, 2024 to approximately US$72.2 million as at December 31, 2025. Such change is within the normal fluctuation range of the Group’s business development. Trade and Other Payables The trade and other payables of the Group decreased by 3.6% from approximately US$19.3 million as at December 31, 2024 to approximately US$18.6 million as at December 31, 2025, primarily due to the payments for other payables. Advances from Customers The Group has recorded a decrease of 8.3% in advance from customers, which were converted to revenue during the Reporting Period.
38
Liquidity and Capital Resources The Group’s bank balances and cash amounted to approximately US$36.3 million in total as at December 31, 2025, as compared to approximately US$44.1 million as at December 31, 2024, as a result of payments for purchase of property, plant and equipment and repayment of bank borrowings, plus cash inflow from operating activities. The cash and cash equivalents held by the Company are composed of RMB, HK$, CAD, EUR and US$. Currently, the Group follows a set of funding and treasury policies to manage its capital resources and prevent risks involved. The following table sets forth a condensed summary of the Group’s consolidated statements of cash flows for the periods indicated and analysis of balances of cash and cash equivalents for the periods indicated: For the year ended December 31, 2025 2024 US$ ’000 US$ ’000 Net cash generated from operating activities Net cash used in investing activities Net cash used in financing activities
43,926 (13,846) (37,362)
40,638 (41,482) (10,217)
Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the period Effect of exchange rate changes
(7,282) 44,091 (510)
(11,061) 53,186 1,966
Cash and cash equivalents at the end of the period
36,299
44,091
Capital Expenditures Our principal capital expenditures relate primarily to purchases of property, plant and equipment, and intangible assets relation to the expansion and enhancement of our facilities and purchases of equipment and intangible assets used in providing our services. Approximately US$11.7 million of capital expenditures were incurred for the year ended December 31, 2025, which decreased by 54.8% when compared to approximately US$25.9 million for the year ended December 31, 2024, primarily due to the decreased expenditures for enhancement of facilities.
39
Indebtedness
Borrowings The Group had total bank borrowings of US$75.7 million as at December 31, 2025 compared to US$95.7 million as at December 31, 2024. On December 31, 2025, the effective interest rate of the Group’s bank borrowings ranged from 2.65% to 6.09%. US$ borrowings amounted to US$45.7 million and RMB borrowings amounted to RMB211.1 million (equivalent to US$30.0 million).
Lease Liabilities The Group leased some of our equipment and facilities under lease agreements with lease terms of three to twenty-five years and right-of-use assets agreements. The Group recorded approximately US$51.9 million lease liabilities as at December 31, 2025, compared to approximately US$58.7 million as at December 31, 2024 due to the payments for existing leases.
Contingent Liabilities and Guarantees As at December 31, 2025, the Group did not have any material contingent liabilities or guarantees.
Currency Risk The functional currency of the Company and the operating subsidiaries incorporated in the USA is US$. The functional currency of the PRC operating subsidiaries is RMB. The functional currency of the operating subsidiary incorporated in Canada is CAD. The functional currency of the operating subsidiary incorporated in Italy is EUR. Particularly, the PRC operating subsidiaries have foreign currency sales and purchases, which expose the Group to foreign currency risk. The PRC operating subsidiaries are mainly exposed to foreign currencies of US$ and EUR. The Group does not use any derivative contracts to hedge against its exposure to currency risk. The Group seeks to limit its exposure to foreign currency risk by closely monitoring and minimizing its net foreign currency position.
Gearing Ratio The gearing ratio is calculated using interest-bearing borrowings less cash and cash equivalents and structured deposits divided by total equity and multiplied by 100%. The gearing ratios were 25.4% and 33.0% as at December 31, 2025 and December 31, 2024, respectively. The decrease in the Company’s gearing ratio was primarily due to the repayment of bank borrowings.
40
EMPLOYEES AND REMUNERATION POLICY As at December 31, 2025, the Group had a total of 1,523 employees, of whom 845 were located in North America and Europe and 678 were located in China; 1,321 were scientific and technical support staff and 202 were sales, general & administrative staff. Approximately 85% of employees hold a bachelor’s degree or above, and we have 535 employees that hold an advanced degree (a master’s level degree or higher such as Ph.D, M.D. or other doctorate level degrees). The staff costs, including Directors’ emoluments but excluding any contributions to retirement benefit scheme contributions and share-based compensation expenses, were approximately US$107.1 million for the year ended December 31, 2025, as compared to approximately US$114.6 million for the year ended December 31, 2024. The remuneration packages of employees generally include salary and bonus elements. In general, the Group determines the remuneration packages based on the qualifications, position and performance of its employees. The Group also makes contributions to pension schemes, social insurance funds, including basic pension insurance, medical insurance, unemployment insurance, childbirth insurance, work-related injury insurance funds, and housing reserve fund as applicable to the countries where the Group operates. As at the date of this announcement, the Group has adopted the Pre-IPO Share Incentive Plans, the 2018 Share Incentive Plan and the 2021 Share Award Scheme to provide incentives or rewards to eligible participants for their contribution or potential contribution to the Group. In addition, the Group has training systems, including orientation and on-the-job training for all staff, to accelerate the learning progress and improve the knowledge and skill levels of its workforce. The Group also has a training program for senior management that focuses on management skills, conflict resolution and effective communication skills and sessions on how to recruit and retain talent. The orientation process covers corporate culture and policies, work ethics, introduction to the drugs development process, quality management and occupational safety. The periodic on-the-job training covers certain technical aspects of the Group’s services, environmental, health and safety management systems and mandatory training required by applicable laws and regulations. FINAL DIVIDEND The Board does not recommend any payment of a final dividend for the Reporting Period (2024: Nil). ANNUAL GENERAL MEETING The Annual General Meeting (“AGM”) of the Company will be held on Tuesday, June 2, 2026 and the notice of the AGM will be published in accordance with the Articles of Association and the Listing Rules and dispatched to the Shareholders in due course upon request of the Shareholders.
41
CLOSURE OF REGISTER OF MEMBERS For determining the entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Wednesday, May 27, 2026 to Tuesday, June 2, 2026, both dates inclusive, during which period no transfer of Shares will be registered. The record date will be Tuesday, June 2, 2026. In order to be eligible to attend and vote at the AGM, all share transfer forms accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Tuesday, May 26, 2026. PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company’s listed securities (whether on the Stock Exchange or otherwise) for the year ended December 31, 2025 (including sale of treasury shares (as defined under the Listing Rules)). As at December 31, 2025, the Company did not hold any treasury shares (as defined under the Listing Rules). MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS The Company has adopted the Model Code as its code of conduct regarding securities transactions by the Directors. Having made specific enquiries with all the Directors, all the Directors confirmed that they had complied with the required standard of dealings as set out in the Model Code during the Reporting Period.
42
CORPORATE GOVERNANCE CODE During the Reporting Period, the Company has followed the principles and complied with the code provisions set out in the Part 2 of the CG Code effective until June 30, 2025 which are applicable to the Company’s corporate governance report and annual report for the year ended December 31, 2025. The amendments to the CG Code effective July 1, 2025 will apply to the corporate governance reports and annual report of the Company for the financial years commencing on or after July 1, 2025. The principles and code provisions set out in this announcement refer to the CG Code prior to the revision, not the revised CG Code. REVIEW OF ANNUAL RESULTS BY THE AUDIT AND RISK MANAGEMENT COMMITTEE The Audit and Risk Management Committee has reviewed, together with the Company ’ s management, the accounting principles and policies, internal controls, risk management and financial reporting adopted by the Group, and the audited consolidated financial statements of the Group for the Reporting Period. The Audit and Risk Management Committee is satisfied that the audited consolidated financial statements of the Group for the Reporting Period were prepared in accordance with the applicable accounting standards and fairly present the Group’s financial position and results for the Reporting Period. SCOPE OF WORK OF BDO LIMITED The figures in respect of the Group’s consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the Reporting Period as set out in the preliminary announcement have been compared by the Group’s auditor, BDO Limited, to the amounts set out in the Group ’ s audited consolidated financial statements for the Reporting Period and the amounts were found to be in agreement. The work performed by BDO Limited in this respect did not constitute an audit, review or other assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by BDO Limited on this announcement. PUBLICATION OF THE 2025 ANNUAL RESULTS ANNOUNCEMENT AND 2025 ANNUAL REPORT This annual results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.frontagelab.com). The annual report of the Company for the Reporting Period containing all the information required under the Listing Rules will be published on the aforesaid websites of the Stock Exchange and the Company and will be dispatched to the Shareholders upon request of the Shareholders.
43
DEFINITIONS “2008 Share Incentive Plan”
the pre-IPO share incentive plan approved by Frontage Labs in 2008 and assumed by the Company on April 17, 2018
“2015 Share Incentive Plan”
the pre-IPO share incentive plan approved by Frontage Labs in 2015 and assumed by the Company on April 17, 2018
“2017 Tax Act” or “Transition Tax”
The Tax Cuts and Jobs Act was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes reduce tax rates and modify policies, credits and deductions for businesses. The 2017 Tax Act also transitions the U.S. international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which could result in subjecting certain earnings of Frontage Shanghai to U.S. taxation. These changes are effective beginning in 2018. The 2017 Tax Act also includes a tax on the mandatory deemed repatriation of accumulated previously untaxed foreign earnings of Frontage Shanghai (the “Transition Tax”)
“2018 Share Incentive Plan”
the post-IPO share incentive plan adopted by the Company on May 11, 2019
“2021 Share Award Scheme”
the “2021 Share Award Scheme” constituted by the rules adopted on January 22, 2021, in its present form or as amended from time to time in accordance with the provisions therein
“Articles of Association”
the articles of association of the Company, as amended from time to time
“Audit and Risk Management Committee”
the audit and risk management committee of the Board
“Award Participants”
the selected participants who were awarded the Awarded Shares under the 2021 Share Award Scheme
“Awarded Shares”
the 22,950,500 Shares granted by the Company to the Award Participants pursuant to the terms of the 2021 Share Award Scheme
“Board of Directors” or “Board”
the board of directors of the Company from time to time
“BRI”
BRI Biopharmaceutical Research Inc., a company incorporated under the laws of Canada on February 18, 2003, and a subsidiary of the Company
“CAD”
Canadian Dollars, the lawful currency of Canada
44
“CG Code”
the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
“CMC”
stands for Chemistry, Manufacturing and Controls. The Group’s portfolio of CMC services spans from drug discovery to the post-approval phase, including lead compound quantification and analytical testing for the discovery phase, formulation development, Good Laboratory Practice toxicology batch studies, release and product testing, stability testing, Clinical Trial Materials and Good Manufacturing Practice manufacturing, extractability and leachability studies and commercial product release following approval of an application
“CODM”
the chief operating decision maker of the Group
“Company”
Frontage Holdings Corporation, a company incorporated under the laws of the Cayman Islands with limited liability on April 16, 2018
“Controlling Shareholder(s)”
has the meaning given to it under the Listing Rules and unless the context requires otherwise, refers to Hangzhou Tigermed and Hongkong Tigermed
“CRO”
Contract research organization
“Director(s)”
the director(s) of the Company from time to time
“DMPK”
Drug Metabolism and Pharmacokinetics, refers to studies designed to determine the absorption and distribution of an administered drug, the rate at which a drug takes effect, the duration a drug maintains its effects and what happens to the drug after being metabolized by the body
“EIT”
PRC Enterprise Income Tax
“EIT Law”
Enterprise Income Tax Law of the PRC
“FDA”
the U.S. Food and Drug Administration
“Frontage Labs”
Frontage Laboratories, Inc., a company incorporated under the laws of Pennsylvania, United States on April 21, 2004 and the wholly-owned subsidiary of the Company
“Frontage Shanghai”
Frontage Laboratories (Shanghai) Co., Ltd., a company established in the PRC on August 2, 2005 and a subsidiary of the Company
45
“Frontage Suzhou”
Frontage Laboratories (Suzhou) Co, Ltd., a company established in the PRC on January 7, 2014, and a subsidiary of the Company
“GLP”
Good Laboratory Practice, a quality system of management controls for research laboratories and organizations to try to ensure the uniformity, consistency, reliability, reproducibility, quality and integrity of chemical and pharmaceuticals non-clinical safety tests
“Group”, “We”, “Our” or “Us”
the Company and its subsidiaries
“Hangzhou Tigermed”
Hangzhou Tigermed Consulting Co., Ltd., a company established in the PRC on December 15, 2004 with its shares being listed on ChiNext market of the Shenzhen Stock Exchange with stock code 300347 and on the Main Board of the Hong Kong Stock Exchange with stock code 3347, which is one of the controlling shareholders of the Company
“HK$” or “HKD”
Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”
the Hong Kong Special Administrative Region of the PRC
“Hongkong Tigermed”
Hongkong Tigermed Co., Limited, a company incorporated under the laws of Hong Kong with limited liability on September 14, 2011 and which is a wholly-owned subsidiary of Hangzhou Tigermed and one of the controlling shareholders of the Company
“IFRSs”
International Financial Reporting Standards
“IPO”
initial public offering
“Jiaxing Xinge”
Jiaxing Xinge Medical Consulting Co., Ltd.* (嘉興欣格醫藥科 技有限公司), a company established in the PRC with limited liability and a wholly-owned subsidiary of Hangzhou Tigermed
“Listing”
the listing of the Shares on the Main Board of the Stock Exchange
“Listing Date”
May 30, 2019, being on the date the Shares were listed on the Main Board
“Listing Rules”
the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Model Code”
the Model Code for Securities Transactions by Directors of Listed Issues contained in Appendix C3 to the Listing Rules
46
“PRC” or “China”
the People ’ s Republic of China, but for the purposes of this announcement only, except where the context requires, references to the PRC or China exclude Hong Kong, Macau and Taiwan
“Pre-IPO Share Incentive Plans”
the 2008 Share Incentive Plan and the 2015 Share Incentive Plan
“Reporting Period”
the year ended December 31, 2025
“RMB”
Renminbi, the lawful currency of the PRC
“Share(s)”
ordinary shares(s) with nominal value US$0.00001 each in the issued share capital of the Company
“Shareholder(s)”
holder(s) of Shares
“Stock Exchange” or “Hong Kong Stock Exchange”
The Stock Exchange of Hong Kong Limited
In this announcement, the terms “associate ”, “connected person ”, “controlling shareholder ” and “subsidiary ” shall have the meanings given to such terms in the Listing Rules, unless the context otherwise requires. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, March 30, 2026
As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive Directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive Directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors. *
For identification purpose only
47
The board of directors (the “Board”) of Frontage Holdings Corporation (the “Company”) hereby announces that a meeting of the Board will be held on Monday, March 30, 2026 for the purposes of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and considering the recommendation of a final dividend, if any. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, March 17, 2026
As at the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.
- For identification purpose only
News
/ Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities

March 4, 2026
Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities
EXTON, Pa., March 4, 2026 — Frontage Laboratories, Inc. (“Frontage”), a leading global CRO/CDMO, today announced the completion of the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. (“Teddy Lab”), a leading clinical research laboratory service provider in China. The acquisition aims to enhance Frontage’s global laboratory service capabilities and further strengthen its presence in China and the Asia-Pacific region.
Teddy Lab is a recognized clinical research laboratory with extensive experience supporting more than 1,500 clinical trials across multiple therapeutic areas. The company is known for its GCP-compliant operations and internationally accredited laboratory services. Teddy Lab operates under CAP-accredited and NGSP Level 1 certified quality systems, as well as qualification as a Class II Unsealed Radioactive Material Workplace, providing pharmaceutical and biotechnology partners with reliable, audit-ready laboratory services that meet global regulatory standards. Its strong track record includes supporting regulatory inspections and contributing to the successful marketing approval of 50 new drugs.
As a result of the transaction, Frontage has expanded its central laboratory footprint in China, which it expects to leverage in supporting the increasing demand for both domestic China and multi-regional clinical trials (MRCT). By integrating Teddy Lab’s central laboratory expertise with Frontage’s comprehensive service platform – including bioanalytical, DMPK, safety and toxicology, CMC, and clinical trial support – Frontage hopes to further solidify its position as a trusted partner in the clinical research industry.
The acquisition further supports our role as a “one-stop shop” in delivering high-quality drug development services to pharmaceutical companies, biotechnology firms, contract research organizations, and research institutions worldwide. We anticipate that our continued investment in expanding our global infrastructure and scientific capabilities will help us meet the evolving needs of the life sciences industry.
About Frontage
Frontage Laboratories, Inc., a wholly owned subsidiary of Frontage Holdings Corporation (HKEX: 1521.HK), is a US based global CRO/CDMO offering end-to-end integrated product development services from drug discovery through late-phase clinical trials and manufacturing. With over 25 years of experience, Frontage supports pharmaceutical and biotech companies with services including drug discovery, API synthesis, DMPK, safety and toxicology, formulation development, GMP manufacturing, analytical services, clinical trials, bioanalytical services and central lab operations.
SOURCE Frontage Laboratories, Inc.
X
Have a question? I am Alex, would you like a chat?
-
🗗︎ 🗖
X
X
Get notifications about our blog!
"*" indicates required fields
Phone
This field is for validation purposes and should be left unchanged.
First Name*
Last Name*
Company*
Email*
Address*
Street Address Address Line 2 City State / Province / Region CountryAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTürkiyeTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUS Minor Outlying IslandsUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe Country
CAPTCHA
Submit
HQ: 700 Pennsylvania Drive Exton PA 19341
Main Tel: 610.232.0100
Sales: 484.362.0997
Main Fax: 610.232.0101
© 2026 Frontage Labs. All Rights Reserved
|
Notifications
References are made to (i) the announcement of Frontage Holdings Corporation (the “Company”) dated October 10, 2025; (ii) the circular of the Company dated December 15, 2025 (the “ Circular” ) in relation to, among others, the Acquisition; and (iii) the announcement of the Company dated January 7, 2026 in relation to the poll results of the EGM held to approve the Acquisition. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular. COMPLETION OF THE ACQUISITION The Board is pleased to announce that all the conditions precedent as set out in the Share Transfer Agreement have been satisfied and the Completion took place on March 3, 2026 in accordance with the terms and conditions of the Share Transfer Agreement. Following the Completion, the Target Company has become a wholly-owned subsidiary of the Company and the financial results of the Target Company and its subsidiaries will be consolidated into the financial statements of the Group. By Order of the Board Frontage Holdings Corporation Dr. Song Li Chairman Hong Kong, March 3, 2026
As of the date of this announcement, the Board comprises Dr. Song Li, Dr. Wentao Zhang and Dr. Zhongping Lin as executive Directors; Ms. Zhuan Yin and Mr. Hao Wu as non-executive Directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive Directors.
- For identification purpose only
News
/ Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development

January 30, 2026
Frontage Laboratories Expands Early Phase Clinical Capabilities to Support Global Drug Development
EXTON, Pa., Jan. 30, 2026 — Frontage Laboratories, Inc. (“Frontage”), a global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the expansion of its early phase clinical research capabilities across the United States and China. This strategic growth enhances the company’s ability to support pharmaceutical and biotech partners with accelerated, high‑quality clinical development solutions.
Frontage’s US operations are anchored by a modern 160‑bed, 36,000‑sq‑ft Phase I clinical unit in Secaucus, New Jersey, designed to conduct large‑scale Phase I and Bioequivalence (BE) studies as well as radiolabeled human AME research. The company has further strengthened its C14‑hAME capabilities through a dedicated unit staffed by licensed radiation experts and supported by an onsite nuclear pharmacy for sterile and non‑sterile radiolabeled compounding. Frontage has successfully executed combined hAME and Absolute Bioavailability studies aligned with the FDA’s 2024 guidance.
In response to growing industry demand, Frontage is also expanding into Oncology Phase I trials through partnerships with regional hospitals and clinical networks, enabling patient‑based research across key cancer indications.
As the industry approaches a significant wave of patent expirations, Frontage’s multiple US clinical units are positioned to manage complex, high‑volume BE programs. Collaboration with Frontage China enables flexible Multi‑Regional Clinical Trial (MRCT) execution to support global program timelines.
These capabilities are integrated through Frontage’s “One‑Stop Shop” model, which combines Bioanalytical & Central Lab services, DMPK, and CMC—including drug product manufacturing in Pennsylvania—to reduce handoffs, accelerate timelines, and lower overall study costs.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.


